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Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and occurs as 
two major subtypes; embryonal (ERMS) and alveolar RMS (ARMS). Therapies of RMS 
typically combine surgical excision or local irradiation with chemotherapy. However, the 
survival rate for metastatic disease is approximately 40 % for ERMS and 10-30 % for ARMS. 
This highlights the need to evaluate novel therapeutic strategies that can improve the prognosis 
of these patients. 
Like many other cancers, RMS show aberrant hedgehog (HH) signaling activity. This implicates 
that RMS might be sensitive towards small molecule inhibitors directed against components of 
the HH pathway. Components of the canonical HH signaling cascade are the HH ligand, its 
receptor Patched (PTCH), the signaling partner of PTCH Smoothened (SMO) and the family of 
GLI transcription factors. An approved readout for active HH signaling is the transcriptional 
level of GLI1.  
Various drugs targeting the HH pathway have been developed and most of them inhibit the 
pathway at the level of SMO. In the first part of this thesis potential antitumoral effects of the 
SMO antagonists GDC-0449, LDE225, HhA and cyclopamine were compared using two ERMS 
(RD, RUCH-2) and two ARMS (RMS-13, Rh41) cell lines.  
The data strongly suggest that GLI1 transcription and thus HH pathway activity in the used RMS 
cell lines is regulated independently of SMO by a noncanonical mechanism. Nevertheless, some 
SMO antagonists (i.e. HhA and LDE225) exerted strong antitumoral properties that were not 
associated with GLI1 expression. Interestingly, the mode of action of these compounds differed 
remarkably from each other. In addition, the observed effects were concentration dependent and 
the responsiveness of the RMS cell lines was heterogeneous. Thus, LDE225 and HhA induced 
strong proapoptotic and antiproliferative effects in most of the RMS cell lines. Moreover, the 
analysis revealed that LDE225 can activate caspase 3, HhA can block AKT activity and both 
drugs can stimulate autophagy (measured by LC3-II levels). GDC-0449 was less effective 
compared to LDE225 and HhA. It also paradoxically induced proliferation of some cell lines. 
This was similar for cyclopamine that induced cellular proliferation, never repressed HH 
signaling activity, showed no proapoptotic effects and activated AKT in most of the cell lines. In 
conclusion the data suggest that LDE225 and HhA are probably the most potent SMO inhibitors 





Besides HH signaling activity, RMS often show activation of the PI3K/AKT/mTOR pathway. 
Moreover, both pathways can interact with each other in several types of cancer. Hence, in the 
second part of this thesis SMO antagonists were combined with PI3K/AKT/mTOR inhibitors to 
investigate potential cooperative antitumoral effects. In order to block PI3K/AKT/mTOR 
signaling the dual PI3K/mTOR inhibitor PI103, the specific PI3K inhibitor GDC-0941, the pure 
AKT inhibitor MK-2206 and the mTOR inhibitors everolimus and rapamycin were applied.  
The findings indicate that HH signaling in RMS cell lines is rather regulated in a noncanonical 
manner by the PI3K/AKT/mTOR pathway. Moreover, HhA was the most efficient SMO 
antagonist and showed several cooperative antitumoral effects upon combination with 
PI3K/AKT/mTOR inhibitors. The most promising combination was HhA plus GDC-0941 since 
this combination showed cooperative antiproliferative and proapoptotic effects in almost all cell 
lines. In addition, this combination was superior to single drug treatments in RMS bearing 
Ptch
+/–
 mice.  
Taken together, the findings indicate that inhibition of HH signaling by a SMO antagonist plus 
an inhibitor of the PI3K/AKT/mTOR pathway may be an efficient strategy in order to improve 







Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and represents 
the third most common extracranial solid childhood tumor after neuroblastoma and Wilms tumor 
(Kramer et al., 1983). It is a malignant tumor with a supposedly origin in the mesenchyme. 
Approximately 65 % of all cases are diagnosed in children who are younger than six years. 
Common primary tumor sites are the head and neck region, the genitourinary tract and the 
extremities (Dagher and Helman, 1999). 
RMS are subdivided by their histological features and genetic alterations into two major 
subtypes, the embryonal (ERMS) and the alveolar RMS (ARMS). ERMS is the more frequent 
subtype and accounts for two-thirds of cases. It predominantly occurs in infants and young 
children (Dagher and Helman, 1999; Merlino and Helman, 1999). This subtype is histologically 
characterized by spindle shaped cells with a stroma rich appearance. ERMS commonly show a 
loss of heterozygosity (LOH) at the 11p15.5 locus, harboring the insulin-like growth factor 2 
(IGF2). Due to loss of maternal and duplication of paternal chromosomal material this is 
commonly associated with overexpression of IGF2 (reviewed in (Merlino and Helman, 1999)). 
ARMS occur more frequently in adolescents and young adults. They show histological structures 
of small, densely packed cells lined up along spaces, which resembles pulmonary alveoli. ARMS 
can be further divided in fusion gene positive (75 %) and fusion gene negative (25 %) ARMS. 
Fusion gene positive ARMS harbor specific chromosomal translocations that lead to the fusion 
of the PAX3 or PAX7 gene with the forkhead transcription factor (FOXO1) (Dagher and Helman, 
1999). In contrast ERMS are always fusion gene negative. 
2.2 Therapies of RMS 
Therapies of RMS are typically multidisciplinary and combine complete surgical excision for 
some patients, local irradiation for most patients and chemotherapy for all patients (Hawkins et 
al., 2014). Chemotherapy of RMS frequently involves treatment with vincristine, actinomycin D, 
doxorubicin (DOX), cyclophosphamide, ifosfamide or etoposide (Dagher and Helman, 1999). 





vincristine, actinomycin D plus cyclophosphamide (VAC), which is the gold standard procedure 
also for patients with higher risk (Dagher and Helman, 1999; Hawkins et al., 2013). The five 
year overall survival for RMS patients is approximately 73 % for ERMS and 48 % for ARMS 
(Ognjanovic et al., 2009). Nevertheless, the survival rate for metastatic ERMS is only 40 % 
(Breneman et al., 2003). ARMS have a very poor prognosis when metastatic thus the survival 
rate is merely 10-30 % (De Giovanni et al., 2009). This data indicate that although the current 
therapy opportunities for nonmetastatic RMS achieve acceptable outcomes, the perspective for 
already metastasized RMS stays very poor. However, the traditional chemotherapy for treatment 
of RMS has reached a plateau of efficacy (Egas-Bejar and Huh, 2014), in which treatment 
failure, toxicity and late effects including the formation of secondary cancers remain substantial 
(Dickerman, 2007). This highlights the need to evaluate novel therapies that can improve the 
prognosis of these patients. Therefore the development of new, targeted therapeutic strategies 
have been gained great interest (Egas-Bejar and Huh, 2014). 
2.3 The hedgehog signaling pathway 
The hedgehog (HH) signaling pathway was initially discovered in 1980 as a regulatory pathway 
of embryonic patterning in Drosophila melanogaster (Nusslein-Volhard and Wieschaus, 1980). 
The name of the pathway is derived from the hedgehog like appearance of the Hh mutant fruit 
fly larvae.  
In mammals, HH signaling pathway also plays a substantial role in embryonic development, cell 
fate decisions and tissue growth. Moreover, it controls cell proliferation in many embryonic and 
adult tissues (reviewed in (Jiang and Hui, 2008)). HH signaling is generally quiescent in the 
adult organism except for its involvement in the regulation of cell differentiation, stem cell 
maintenance, tissue homeostasis and repair (reviewed in (Petrova and Joyner, 2014)). 
Furthermore novel findings linked the HH pathway also to the regulation of metabolic 
homeostasis (Teperino et al., 2014). 
2.3.1 Canonical HH signaling 
The major components of the canonical HH signaling cascade comprise the ligand HH, the 
transmembrane receptor Patched (PTCH), the transmembrane signal transducer Smoothened 
(SMO) and the family of glioma-associated oncogene (GLI) transcription factors. A very 




which are sonic hedgehog (SHH), desert hedgehog and indian hedgehog, each with distinct 
temporal and spatial expression patterns (Ryan and Chiang, 2012). In the absence of the ligand 
HH, PTCH inhibits SMO resulting in the formation of transcriptional repressor forms of GLI and 
thus inactivation of the pathway (Figure 1 A). HH pathway activation is induced by binding of 
HH to its receptor PTCH. Thereby HH inhibits PTCH. This suspends the inhibition of SMO 
(Figure 1 B). After a series of poorly understood events that include SMO trafficking to the 
primary cilia, SMO activates the GLI transcription factors GLI2 and GLI3. Consequently, 
activated GLI2 and GLI3 induce the expression of several downstream target genes. Besides 
PTCH, another negative regulator of the HH pathway is suppressor of fused (SUFU), which 
sequesters GLI transcription factors in the cytoplasm and thus represses their transcriptional 
activity (reviewed in (Robbins et al., 2012; Rohatgi and Scott, 2007)).  
 
Figure 1: Major components of canonical HH signaling. The four major components of canonical HH signaling 
are illustrated; the ligand hedgehog (HH), its transmembrane receptor Patched (PTCH), the transmembrane signal 
transducer Smoothened (SMO) and glioma-associated oncogene (GLI) transcription factors. (A) In the absence of 
the ligand HH, PTCH inhibits SMO. This keeps the pathway in its inactive state due to the cleavage of the GLIs into 
their repressor forms (GLIRep), which inhibits target gene expression. (B) Activation of the pathway is induced by 
binding of HH to its receptor PTCH, which suspends the inhibition of SMO. Subsequently SMO stabilizes the GLI 
activator forms (GLIAct), which translocate in the nucleus where they induce expression of HH target genes. 
Besides other targets, the HH signal triggers the expression of GLI1, which amplifies HH 
signaling. Another important downstream target of the pathway is PTCH, which in contrast to 
GLI1 generates a negative feedback loop to the canonical HH pathway. Together GLI1 and 













(reviewed in (Scales and de Sauvage, 2009)). Finally, also the expression of IGF2 can be 
triggered by the HH signal (Corcoran et al., 2008; Hahn et al., 2000). Gene expression analysis 
revealed that IGF2 is frequently overexpressed in RMS and plays also a key role in the 
formation, proliferation, growth and metastasis of RMS (reviewed in (Martins et al., 2011)). 
 
Nevertheless, the precise interplay of the pathway components is still poorly defined, e.g. how 
the signal is transduced between SMO and GLI proteins. Moreover, the mechanism how PTCH 
regulates SMO has still not been revealed (Jiang and Hui, 2008). However, a direct physical 
interaction of PTCH and SMO can be excluded (Denef et al., 2000; Taipale et al., 2002). SMO 
activity is therefore commonly thought to be regulated by endogenous small molecules. This 
hypothesis is supported by the discovery of various small molecule drugs that bind SMO and 
either activate or inhibit its function (Rohatgi and Scott, 2007). 
2.3.2 Canonical HH signaling in cancer 
HH signaling activation results in the expression of cell specific transcription factors which 
mediate different effects including developmental fate responses (McMahon et al., 2003), 
upregulation of N-myelocytomatosis oncogene (N-Myc) and D-type cyclins that cause 
proliferation (Duman-Scheel et al., 2002; Kenney et al., 2003; Kenney and Rowitch, 2000), 
stimulation of antiapoptotic proteins like B-cell lymphoma 2 (Bcl2), that mediate cell survival 
(Bigelow et al., 2004; Regl et al., 2004) and regulation of angiogenesis by vascular endothelial 
growth factor (Pola et al., 2001). Therefore, it is not surprising that dysregulation of HH 
signaling is relevant for tumor formation and progression of a multiplicity of cancers (Scales and 
de Sauvage, 2009).  
In several cancers a constitutive activation of HH signaling is observed. This can be mediated by 
ligand dependent activation due to the overexpression of the HH ligands (Oro et al., 1997) or by 
ligand independent activation, due to mutational inactivation of the tumor suppressors PTCH or 
SUFU (Goodrich et al., 1997; Hahn et al., 1996; Taylor et al., 2002), activating mutations of 
SMO (Lam et al., 1999) or overexpression of GLI transcription factors (Nilsson et al., 2000).  
Types of cancers which showed ligand dependent HH signaling activity (Figure 2 A) generally 
do not harbor driver mutations of PTCH or SMO and found e.g. in cancers of the breast, the 
gastrointestinal tract, the prostate as well as in hematological malignancies and gliomas (Beachy 
et al., 2004; Lindemann, 2008; Mukherjee et al., 2006; Ruiz i Altaba et al., 2007). Nevertheless, 




clear because of multiple influencing factors including the tumor stroma and interactions with 
other oncogenic pathways (reviewed in (Amakye et al., 2013)).  
Ligand independent pathway activation (Figure 2 B) due to mutations of HH pathway 
components have been associated with basal cell carcinoma (BCC) and medulloblastoma (MB) 
(Wicking et al., 1999). Indeed nearly all sporadic BCC are caused by inactivating mutations of 
PTCH (more than 90 %) or activating mutations in SMO and over 25 % of sporadic MB are 
related to mutations in either PTCH or SUFU (reviewed in (Scales and de Sauvage, 2009)). 
 
Figure 2: Aberrant activation of canonical HH signaling in cancer. Pathological activation of canonical HH 
signaling in cancer can be mediated by two key mechanisms. (A) Ligand dependent pathway activation is induced 
by overexpression of the HH ligand. (B) Ligand independent cancers can harbor inactivating mutations in PTCH 
(red flash), activating mutations in SMO (green flash) or overexpress the GLI transcription factors (GLIAct), resulting 
in HH pathway activation even in the absence of the ligand HH. 
2.3.3 Noncanonical HH signaling 
In the last years, numerous evidences indicated that components of the canonical HH pathway 
also modulate cellular processes independently of the canonical HH axis. For instance, in the 
absence of HH, PTCH seems to be involved in cell cycle regulation and induction of apoptosis 
autonomously of GLI (Barnes et al., 2001; Thibert et al., 2003). Moreover SMO has been 
implicated in cytoskeletal rearrangement in a GLI independent manner (reviewed in (Robbins et 
al., 2012)) and signaling of the second messenger Ca
2+
 (Belgacem and Borodinsky, 2011). Thus, 
noncanonical HH signaling can be described as signaling derived from PTCH or SMO but 



















On the other hand noncanonical HH signaling can also be defined by SMO independent 
activation of GLI transcription factors since in several cancers GLI transcription factors are 
regulated by multiple oncogenic pathways, such as the RAS/RAF/MEK pathway in pancreatic 
cancer and melanoma (Ji et al., 2007; Nolan-Stevaux et al., 2009; Stecca et al., 2007) and the 
phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway in 
glioblastoma and esophageal adenocarcinoma (EAC) (Filbin et al., 2013; Stecca et al., 2007; 
Wang et al., 2012). Moreover, GLI transcription factors are regulated through tumor suppressors 
like phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and transformation 
related protein 53 (p53) (reviewed in (Stecca and Ruiz, 2010)).  
2.4 HH signaling in RMS 
The initial link between HH signaling and cancer formation (e.g. RMS) was found in patients 
suffering from an inherited haploinsufficiency of PTCH (Gorlin syndrome or basal cell nevus 
syndrome) (Hahn et al., 1996; Johnson et al., 1996). Besides developmental defects, these 
patients show predisposition to BCC, MB and RMS (Gorlin, 1987; Hahn et al., 1999). This 
provided first evidence of an existing correlation between constitutive activated HH signaling 
and RMS. In addition, Ptch
+/–
 mice spontaneously develop RMS that resembles the embryonal 
subtype in humans. This is based on histological appearance and on overexpression of the global 
HH markers genes Gli1, Ptch as well as Igf2 (Hahn et al., 2000; Hahn et al., 1998), which is also 
highly expressed in human ERMS (Merlino and Helman, 1999). 
However, the role of PTCH mutations in sporadic human RMS is less clear, since several studies 
screening for PTCH or SMO mutations in human RMS generated conflicting outcomes. For 
instance in deoxyribonucleic acid (DNA) sequence analyses of 14 RMS no point mutation or 
deletion in the PTCH region and only one case of LOH at the PTCH locus was detected. This 
indicates that sporadic RMS cannot explicitly linked to HH pathway mutations (Calzada-Wack 
et al., 2002). On the other hand, in one-third of ERMS genomic imbalances including loss of the 
chromosomal region 9q22 (which includes the PTCH gene) or amplification of the GLI1 gene 
have been found (Bridge et al., 2000; Merlino and Helman, 1999). Moreover, several studies 
revealed that both ERMS and ARMS express elevated PTCH and GLI1 mRNA levels compared 
to the corresponding normal tissue (Tostar et al., 2006) and also display increased GLI1 protein 
levels (Ragazzini et al., 2004). Furthermore, ERMS and fusion gene negative ARMS are 
characterized by higher HH signaling activity as shown by GLI1 and PTCH expression when 




indicate that alteration in PTCH and GLI1 expression levels and consecutive overexpression of 
HH target genes might indeed play a role in sporadic RMS.  
Although the mechanisms responsible for HH pathway activation in RMS remain elusive (i.e. no 
clear evidence for activating mutations in the HH pathway have been identified) these findings 
strongly implicate that RMS might be sensitive towards a targeted therapy using small molecule 
HH inhibitors directed against components of the HH pathway. 
2.5 HH inhibitors - SMO antagonists 
In the last years several drugs targeting the HH pathway have been developed for the treatment 
of patients with diverse cancers. Thereby compound discovery has been predominantly focused 
on drugs that bind and block SMO in order to inhibit the HH signaling pathway (SMO 
antagonists or SMO inhibitors). The impact of many SMO antagonists have been already 
analyzed in phase I/II clinical trials with promising results for BCC and MB treatment (reviewed 
in (Amakye et al., 2013)). However, only a couple of RMS patients have been included in 
clinical trials testing the potential antitumor effects of SMO inhibitors. These studies were 
recently completed and the results are eagerly awaited (reviewed in (Amakye et al., 2013)).  
Although clinical trials using SMO antagonists provided promising results, in tumors with HH 
pathway activation downstream of SMO (e.g. due to loss of SUFU, amplification of GLI or 
noncanonical GLI signaling) these compounds are ineffective. Hence, inhibitors targeting GLI 
transcription factors have been established, but they have not advanced to clinical development 
so far (Amakye et al., 2013; Ng and Curran, 2011).  
2.5.1 Cyclopamine - a prototype of SMO inhibitors  
Cyclopamine - the first described small molecule inhibitor of the HH pathway (Cooper et al., 
1998) - is a natural alkaloid of the corn lily Veratrum californicum. It was identified as a 
teratogen responsible for developmental defects in lambs (e.g. cyclopia and holoprosencephaly) 
(Binns et al., 1968) due to inhibition of the HH signaling pathway by direct binding to SMO 
(Chen et al., 2002a). This binding stimulates the translocation of SMO to the primary cilium 
without activation of GLIs (Wang et al., 2009). The synthetically generated SMO antagonists 
SANT1 and SANT2 also bind to the cyclopamine binding pocket but in contrast to cyclopamine 





activation of SMO represents a multistep process, in which cyclopamine prevents its conversion 
from a ciliary inactive to a ciliary active conformation (Rohatgi et al., 2009). 
Since cyclopamine has poor oral solubility, limited potency, nonspecific toxicity and chemical 
instability it is not suitable as a therapeutic agent in humans (Lipinski et al., 2008). However, it 
has been widely used for in vitro and in vivo experiments to investigate the effects of HH 
pathway inhibition in several biological processes. In vitro studies reported that cyclopamine 
inhibits the proliferation of a variety of cancer cell lines e.g. from breast (Kubo et al., 2004), 
prostate (Sanchez et al., 2004), colorectal and pancreas tumors (Qualtrough et al., 2004; Thayer 
et al., 2003) as well as of MB cell lines (Berman et al., 2002; Sanchez and Ruiz i Altaba, 2005). 




 mouse model for MB 
(Sanchez and Ruiz i Altaba, 2005) and in xenograft models using e.g. prostate carcinoma cells 
(Karhadkar et al., 2004), glioblastoma cells (Clement et al., 2007), tumor cells of the digestive 
tract (Berman et al., 2003) and the pancreas (Feldmann et al., 2007; Thayer et al., 2003). 
Nevertheless, the evaluation of cyclopamine as an effective inhibitor of RMS revealed that it 
inhibited Hh signaling and proliferation of in vitro cultured primary RMS cells. Although Hh 
signaling was partially suppressed also in RMS in vivo, cyclopamine failed to inhibit the in vivo 
growth of RMS in Ptch
+/–
 mice and rather seemed to enhance the growth of the tumors (Ecke et 
al., 2008).  
2.5.2 GDC-0449, LDE225 and HhA - more potent derivatives 
A variety of orally bioavailable SMO antagonists with increased potency have been synthesized 
and many of them are structurally unrelated to cyclopamine. SMO inhibitors that are currently 
investigated in clinical trials in a range of advanced cancers are GDC-0449 (vismodegib; 
Curis/Roche), LDE225 (sonidegib; Novartis), BMS-833923 (Bristol-Myers Squibb), 
PF04449913 (Pfizer) and LY2940680 (Eli Lilly) (reviewed in (Amakye et al., 2013)). Several of 
these compounds have triggered tumor responses particularly in patients with BCC and MB, 
which harbor PTCH mutations, i.e. mutations upstream of SMO (Amakye et al., 2013; LoRusso 
et al., 2011; Rudin et al., 2009; Sekulic et al., 2012).  
GDC-0449 represents the frontrunner of SMO inhibitors used in the clinics and shows attractive 
preclinical pharmacokinetic and drug metabolism properties in rat, mouse, dog and monkey 
(Wong et al., 2009). GDC-0449 was approved in 2012 by the US Food and Drug Administration 
for the treatment of locally advanced BCC and metastatic BCC (Rudin, 2012) due to tumor 




reduced the numbers of new developing BCC and the size of existing BCC of Gorlin syndrome 
patients. This effect was associated with a 90 % decrease in HH signaling activity and reduced 
tumor proliferation, without affecting apoptosis rate (Tang et al., 2012). Tumor responses with 
GDC-0449 have also been observed in MB patients (Amakye et al., 2013) and in mouse MB 
allografts from Ptch
+/–
 mice (Robarge et al., 2009). Actually, GDC-0449 represents the most 
investigated SMO inhibitor in the clinics and is also used in clinical trials of advanced solid 
tumors including few cases of adult RMS patients, but currently with unclear outcome (Amakye 
et al., 2013). 
Another SMO inhibitor used in this thesis is LDE225, which is a potent and selective SMO 
antagonist from a novel structural class (Pan et al., 2010). Similarly to GDC-0449, LDE225 
shows antitumoral activity and suppression of HH signaling in MB and BCC patients (Amakye 
et al., 2013). LDE225 was approved in July 2015 by the US Food and Drug Administration for 
the treatment of locally advanced BCC. Moreover, LDE225 already passed a phase II clinical 
trials for children with MB or other solid tumors, including a few cases of RMS. Currently 
available preliminary data show that LDE225 is well tolerated by the patients and shows 
promising efficacy in MB patients (Amakye et al., 2013). Many preclinical studies using 
LDE225 have been published. These studies show that LDE225 reduces GLI1 and GLI2 protein 
levels in human renal cell carcinoma (RCC) cell lines and possesses antitumoral effects in RCC 
tumor xenografts (D'Amato et al., 2014). Furthermore, LDE225 efficiently inhibits GLI1 
expression and growth of human melanoma cell lines and blocks the growth of melanoma 
xenografts in vivo (Jalili et al., 2013). Tumors of different PTCH mutant MB xenograft models 
are also responsive to LDE225 treatment as well as osteosarcoma bearing mice (Kool et al., 
2014; Paget et al., 2012). 
HhA (HhAntag691) is a benzimidazole, which was identified by high-throughput cell based 
screenings of a collection of small molecules (Romer et al., 2004). HhA provides the most 




 mouse model of 
spontaneously developing MB (Romer et al., 2004). Oral delivery of HhA to this mouse model 
decreased the Gli1 expression and inhibited tumor growth by reducing cell proliferation and 
increasing apoptosis to the point of complete eradication of large MB (Romer et al., 2004). 
Preclinical studies with HhA predicted potential responses of BCC and HH pathway activated 
MB in the clinics. This led to the inclusion of MB patients in initial clinical trials (Ng and 
Curran, 2011). However, HhA subsequently was shown to have an inadequate hepatic clearance. 





2.5.3 Side effects and toxicities of SMO antagonists 
SMO inhibitors have been shown to be generally well tolerated as side effects are fairly modest 
in adult patients. Clinical data of GDC-0449 and LDE225 reported that the most common 
toxicities comprise taste alteration, nausea, anorexia, weight loss, alopecia, muscle spasms and 
fatigue (reviewed in (Amakye et al., 2013)). Although moderate, the chronic nature of the side 
effects of SMO inhibitors led to discontinuation of therapy in 50 % of patients in GDC-0449 
trials of BCC treatment. Since this cancer is not typically life threatening, probably much 
self-motivation is needed for compliance to SMO inhibitor therapy (Sekulic et al., 2012; Tang et 
al., 2012). Whereas SMO inhibitors may be a good treatment option in adults with HH 
associated cancers, this may be different in children. Thus, preclinical data described dramatic 
and permanent bone defects in young mice treated with HhA (Kimura et al., 2008). In addition, 
SMO inhibitors may affect the proper development of many other organs such as the brain. This 
would be especially deleterious in young patients and may hamper the application of these drugs 
in pediatric tumors such as RMS.  
2.5.4 Mechanisms of acquired resistance to SMO inhibitors 
Treatment with SMO inhibitors can lead to the occurrence of acquired tumor resistance caused 
by three different possible mechanisms: i) secondary mutation in SMO; ii) amplification of 
downstream HH target genes; and/or iii) compensatory upregulation of noncanonical HH 
signaling. 
In 2009, one report described a considerable response of a patient with a PTCH mutant MB after 
two months GDC-0449 treatment, which relapsed just one month later (Rudin et al., 2009). 
Subsequently, a secondary mutation in SMO D473H was identified in the tumor material as the 
reason of the acquired resistance (Yauch et al., 2009). Interestingly, the mutation did not affected 
HH signaling activity but impaired the binding of GDC-0449 to SMO and consequently the 
ability to suppress the pathway. This resulted in reactivation of HH signaling and restoration of 





 mice, which similarly responded to GDC-0449 treatment and relapsed later 
(Yauch et al., 2009). LDE225 treatment can also lead to secondary resistance mutations as 
described for MB of Ptch mouse models (Buonamici et al., 2010), but they differed from the 
mutations found in GDC-0449 resistant tumors. Indeed, several SMO inhibitors have variable 
potency in blocking the activity of different SMO mutational variants (Dijkgraaf et al., 2011; 




Smo D473H variants, whereas HhA was essentially equipotent against all Smo alleles (Dijkgraaf 
et al., 2011).  
Amplification of Gli2 as a further mechanism of resistance to SMO inhibition was initially 




 mice after treatment with GDC-0449 or LDE225, respectively 
(Buonamici et al., 2010; Dijkgraaf et al., 2011). It was associated with increased Gli2 mRNA 
expression, which mediated tumor growth in a Smo independent manner (Buonamici et al., 
2010). 
Finally, acquired resistance to treatment with SMO inhibitors can also depend on activation of 





cells. Although LDE225 inhibited Hh signaling and induced tumor regressions, resistance was 
observed during the course of treatment. LDE225 resistant tumors showed an increased PI3K 
signaling activity (Buonamici et al., 2010). However, the molecular effects that led to the 
compensatory adaptation due to activation of PI3K pathway are unknown, but interestingly 
upregulation of the PI3K pathway was also detected in tumors with and without Gli2 
amplification (Buonamici et al., 2010). 
Thus, targeted therapy with SMO antagonists combined with inhibitors of the PI3K/AKT/mTOR 
pathway might be an attractive treatment option for RMS of young children. The combination of 
these drugs could potentially help to avoid side effects of SMO inhibitors by lowering the doses 
of the SMO inhibitors in combination treatment and to specifically circumvent a possible 
induction of PI3K signaling.  
2.6 The PI3K/AKT/mTOR pathway  
The PI3K/AKT/mTOR signaling pathway is important in many aspects of growth and cell 
survival and regulates various cellular processes, such as proliferation, apoptosis, cytoskeletal 
rearrangement and metabolism. Under physiological conditions this pathway is activated by 
many extracellular stimuli e.g. insulin, growth factors and chemokines (Lim et al., 2015). The 
PI3K/AKT/mTOR signaling cascade is schematically illustrated in Figure 3.  
One of the main components displays PI3K, which is a heterodimeric lipid kinase consisting of a 
regulatory and a catalytic subunit that are encoded by different genes. Binding of certain ligands 
to receptor tyrosine kinases (RTK), such as the IGF1 and IGF2 receptor (IGF1R, IGF2R) or the 
epidermal growth factor receptor (EGFR), leads to autophosphorylation and activation of these 
receptors. Subsequently, the regulatory subunit of PI3K binds (together with or without adaptors) 





phosphorylates its substrate, phosphatidylinositol 4,5-bisphosphate (PIP2) to produce the second 
messenger phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 then distributes intracellular 
signaling by direct contact with pleckstrin homology (PH) domains of various signaling proteins 
such as e.g. phosphoinositide dependent kinase 1 (PDK1) and AKT (or protein kinase B, PKB) 
that are subsequently recruited to the inner side of the plasma membrane. PDK1 partially 
activates AKT by phosphorylation of threonine 308 (Figure 3) (reviewed in (Courtney et al., 
2010; Vivanco and Sawyers, 2002)).  
 
Figure 3: Schematic representation of the PI3K/AKT/mTOR signaling cascade. In response to extracellular 
stimuli, PI3K is activated by receptor tyrosine kinases (RTK) and phosphorylates PIP2 to generate PIP3. 
Consequently, AKT is activated by phosphorylation of threonine 308 and serine 473. Subsequently, AKT activates 
its downstream effectors. For a more detailed description please see the text. 
AKT is a serine/threonine kinase that controls many biological processes by phosphorylation of 
its targets. For instance, AKT stimulates cell survival by inhibiting the proapoptotic Bcl-2 family 
































also impairs negative regulation of the transcription factor nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB), thereby enhancing transcription of antiapoptotic and 
prosurvival genes. Moreover, phosphorylation of murine double minute 2 (MDM2) by AKT 
antagonizes p53 mediated apoptosis. Furthermore, negative regulation of FOXO by AKT leads 
to reduced synthesis of cell death promoting proteins. AKT also modulates proliferation by 
inhibition of glycogen synthase kinase 3 (GSK3), which prevents cyclin D1 degradation 
(reviewed in (Hennessy et al., 2005; Vivanco and Sawyers, 2002)). Inactivated GSK3 also 
blocks glycogen synthesis, which contributes to the stimulation of glycogen and protein 
synthesis and thus influences metabolism (Cohen and Frame, 2001). 
Importantly, AKT activates the mTOR-containing protein complex mTORC1, leading to 
increased protein synthesis by phosphorylation of ribosomal S6 protein (S6) and eukaryotic 
translation initiation factor 4E-binding protein 1 (4EBP1). Whereas mTORC1 transmits signals 
from PI3K/AKT cascade, the second mTOR complex mTORC2 contributes to complete AKT 
activation by phosphorylation on serine 473 (Sarbassov et al., 2005). The mTORC1 downstream 
target S6 kinase (S6K) blocks ligand mediated PI3K activation by inhibiting the adaptor protein 
insulin receptor substrate (IRS) and thereby negatively feeds back to diminish PI3K activation 
(Carracedo and Pandolfi, 2008). Moreover, the phosphatase PTEN antagonizes PI3K signaling 
by dephosphorylating of PIP3 to PIP2, hence acting as a tumor suppressor (reviewed in 
(Courtney et al., 2010; Vivanco and Sawyers, 2002)).  
2.6.1 PI3K/AKT/mTOR signaling in RMS 
The PI3K/AKT/mTOR pathway is dysregulated in a wide spectrum of human cancers including 
those of the breast, ovarian and prostate, glioblastoma, colorectal cancer (CRC), hematological 
malignancies as well as sarcomas (reviewed (Lim et al., 2015)). Several studies show that 
numerous components of the PI3K/AKT/mTOR pathway are affected in tumors by e.g. 
amplification, mutation and translocation. The constitutive activation of this pathway not only 
leads to cellular growth and survival but also to metastatic ability and to therapy resistance of the 
tumors (reviewed in (Courtney et al., 2010; Hennessy et al., 2005)). 
The PI3K/AKT/mTOR signaling pathway also plays a crucial role in RMS. Activation of the 
PI3K/AKT/mTOR pathway, demonstrated by AKT phosphorylation (pAKT), was observed in 
human RMS and high levels of activated AKT were related to poor overall and disease free 
survival in these patients (Petricoin et al., 2007). Moreover, tissue microarray analyses revealed 





related to enhanced expression of IGF pathway proteins including IGF1, IGF2, IGF binding 
proteins 2 (IGFBP2) and to expression of IGF1R and IGF2R (Makawita et al., 2009). 
Additionally, RMS show increased levels of EGFR and ErbB-2 without evidence of EGFR or 
ErbB-2 amplifications or mutations in the EGFR tyrosine kinase domain (Ganti et al., 2006). 
Hence PI3K/AKT/mTOR pathway activation in RMS could also be promoted by the expression 
of these stimuli. Moreover, RMS from Ptch
+/–
 mice show increased activity of Akt. Since these 
tumors show high Igf2 transcript levels (Kappler et al., 2003) activation of the PI3K/Akt/mTor 
pathway could be probably caused by stimulation of the Igf-1 receptor by its ligand Igf2. 
2.6.2 Inhibitors of the PI3K/AKT/mTOR pathway 
Aberrant activation of the PI3K/AKT/mTOR pathway not only contributes to the pathogenesis of 
various human malignancies, it is also frequently associated with the occurrence of resistance to 
anticancer therapies. Therefore targeted inhibition of this pathway might possess great 
therapeutic potential. Actually, various PI3K/AKT/mTOR inhibitors are under investigation in a 
wide spectrum of cancers in clinical trials (reviewed in (Courtney et al., 2010; Lim et al., 2015). 
Within this work the anticancer potential of the PI3K/AKT/mTOR inhibitors PI103, GDC-0941, 
MK-2206, everolimus and rapamycin were investigated. 
The small synthetic molecule PI103 acts as a dual PI3K/mTOR inhibitor by blocking all catalytic 
isoforms of PI3K. It concomitantly inhibits mTORC1 and mTORC2 because the catalytic subunit 
of PI3K and mTOR are structurally similar. Therefore dual PI3K/mTOR inhibitors are thought to 
completely turn off PI3K/AKT/mTOR signaling and prevent feedback activation usually 
detected with mTORC1 inhibitors (e.g. rapamycin, see below). However, dual PI3K/mTOR 
inhibitors also hold the disadvantage of greater toxicity (Courtney et al., 2010; Markman et al., 
2010). PI103 inhibits cellular proliferation and invasion of various human cancer cells in vitro 
and shows antitumoral effects against human tumor xenografts (Fan et al., 2006; Raynaud et al., 
2007). Nevertheless, due to its rapid metabolism, PI103 is not suitable for clinical application but 
it was seminal for the development of GDC-0941 (Raynaud et al., 2009). 
GDC-0941 represents a selective and orally bioavailable inhibitor of PI3K. It was developed by 
optimizations of PI103 and consequently showing promising pharmacokinetic and 
pharmaceutical properties. In contrast to PI103, GDC-0941 possesses almost no inhibitory effect 
on mTOR (Raynaud et al., 2009). Nevertheless, it is effective in growth inhibition of human 
tumor xenografts that harbor mutations in PI3K or PTEN (Raynaud et al., 2009; Workman et al., 




preliminarily evidence that GDC-0941 possess potential antitumor activity. In addition, 
GDC-0941 is well tolerated with frequently adverse effects such as moderate nausea, fatigue, 
diarrhea, and dysgeusia (reviewed in (Lim et al., 2015; Markman et al., 2010)). 
MK-2206 is an orally applied allosteric inhibitor of AKT with antitumoral effects in several 
preclinical investigations e.g. in colon cancer and nasopharyngeal cancer cells in vitro and in 
vivo (Agarwal et al., 2014; Zhao et al., 2014). MK-2206 furthermore synergizes with cytotoxic 
drugs or other targeted therapies in preclinical studies (Hirai et al., 2010). Clinical trials using 
MK-2206 furthermore resulted in promising outcomes with robust abrogation of AKT signaling 
(Yap et al., 2011). On the basis of these positive results, several phase II studies of MK-2206 in 
advanced ovarian and breast cancers are currently in progress (Lim et al., 2015). 
The most extensively investigated drugs targeting the PI3K/AKT/mTOR pathway are mTOR 
inhibitors (e.g. rapamycin, everolimus). They demonstrate antitumoral activity in haematological 
malignancies and solid tumors refractory to standard chemotherapies (reviewed in (Lim et al., 
2015)). Rapamycin (sirolimus) is an antibiotic originally derived from Streptomyces 
hygroscopicus from the island of Rapa Nui. It binds to FKBP12 to form a complex that interacts 
with the FKBP12-rapamycin-binding domain of mTOR in the mTORC1 resulting in inhibition of 
downstream signaling (Guertin and Sabatini, 2009). Nevertheless, some cellular models exist in 
which rapamycin also disrupts mTORC2 (Sarbassov et al., 2006). Because rapamycin showed 
antiproliferative effects when used as an immunosuppressive agent in transplant medicine, it was 
also tested for potential antitumoral properties (Law, 2005; Vemulapalli et al., 2011). However, 
the oral bioavailability and chemical stability of rapamycin is low and limits its clinical 
development as an anticancer agent (Wan and Helman, 2007). Nevertheless, synthetic 
derivatives of rapamycin (rapalogs) with improved pharmaceutical properties have been 
developed. One of the main rapalogs represents everolimus (RAD001) which is currently in 
clinical development (reviewed in (Lim et al., 2015)). It is orally bioavailable and shows 
impressive antiproliferative effects in several human tumor cell lines and human tumor 
xenografts (reviewed in (Fasolo and Sessa, 2012)). Furthermore, it provides encouraging 
outcomes in multiple phase II studies, e.g. in patients with relapsed gastric (Ohtsu et al., 2013) 
and with recurrent endometrial cancer (Ray-Coquard et al., 2013). Moreover, everolimus is also 
approved for treatment of advanced RCC after progression with sunitinib or sorafenib.  
However, the efficacy of rapamycin and everolimus may be partially limited because they do not 
inhibit mTORC2 mediated phosphorylation of AKT. In addition, blocking of mTORC1 releases 





increase of AKT activity (O'Reilly et al., 2006). Indeed, increased phosphorylated AKT has been 
observed in tumors from patients treated with everolimus (O'Reilly et al., 2006). 
2.7 Interaction of HH and PI3K/AKT/mTOR signaling  
Recently it has been assumed that different tumor related signaling pathways (e. g. 
PI3K/AKT/mTOR signaling) interact with HH signaling by influencing the activity of GLI 
transcription factors (Aberger et al., 2012). Indeed, several preclinical studies provide evidence 
for interactions between the HH pathway and PI3K/AKT/mTOR signaling cascade at several 
levels. Figure 4 shows a schematic illustration of the hitherto known crosstalk of both pathways. 
Since one focus of this work was on the evaluation of combination therapies using SMO 
antagonists plus PI3K/AKT/mTOR inhibitors in RMS, the figure also includes the respective 
inhibitors used in this study. 
So far, several studies verified the crosstalk of HH pathway and PI3K/AKT/mTOR signaling on 
molecular level and showed that each pathway can influence the respective other. These studies 
showed on the one hand that PI3K/AKT/mTOR signaling can stimulate the activity of the HH 
pathway. For instance, Akt induces noncanonical activation of HH signaling by stabilization of 
the Gli transcriptions factors whereas inhibition of PI3K signaling inhibits Shh induced HH 
signaling (Riobo et al., 2006). Furthermore, stimulation of PI3K/Akt/mTor signaling by Igf1 can 
synergize with HH ligands to potentiate HH pathway activation (Rao et al., 2004; Riobo et al., 
2006). Beyond that, mTOR/S6K1 mediates a SMO independent modulation of GLI activity in 
EAC which results in enhanced GLI transcriptional activity and oncogenic function through 
phosphorylation of GLI1. This result was further strengthened by a combined inhibition of the 
canonical and the noncanonical HH pathway using GDC-0449 and everolimus which led to an 
improved efficacy of tumor growth inhibition in EAC xenografts in comparison to the single 
treatments (Wang et al., 2012). Moreover, it has been shown that the PI3K/AKT pathway 
cooperates with HH signaling to strengthen proliferation and survival of EAC cells in vitro (Wei 
and Xu, 2011). Another study reported a crosstalk between HH and PI3K/AKT pathway in 
tamoxifen resistant breast cancer cells, in which PI3K/AKT signaling protected GLI1 from 
proteasomal degradation (Ramaswamy et al., 2012). It also has been demonstrated that GLI1 
expression and transcriptional activity is regulated through osteopontin mediated induction of 
AKT/GSK3b signaling (Das et al., 2013). Finally, dominant active AKT can enhance the nuclear 
localization of GLI1, while AKT inhibition results in cytoplasmic accumulation of GLI1 in a 





Figure 4: Interaction of HH and PI3K/AKT/mTOR signaling and associated inhibitors. The left side of the 
picture illustrates the HH signaling pathway and the right side shows a simplified scheme of the PI3K/AKT/mTOR 
pathway. Crosstalk of both pathways is reported due to activation and stabilization of GLI transcriptions factors by 
AKT and mTOR, which results in noncanonical activation of HH signaling. In addition, it has been shown that vice 
versa active HH signaling can result in activation of PI3K/AKT signaling by an unknown mechanism (illustrated by 
arrows with “?”). Inhibitors used in this thesis are represented in blue boxes and corresponding pharmacological 
targets at several points along the pathway are indicated in red ⊣. 
On the other hand, HH signaling can stimulate the activity of the PI3K/AKT/mTOR pathway, 
e.g. in bone marrow derived endothelial progenitor cells and pancreatic duct epithelial cells 
active Hh signaling can result in activation of PI3K/Akt (Fu et al., 2006; Morton et al., 2007). 
Similarly, SHH treatment activated AKT in human gastric cancer cells and conversely 
PI3K/AKT pathway inhibition blocked SHH induced epithelial mesenchyme transition (EMT) 
and reduced tumor invasiveness and metastasis (Yoo et al., 2011). 
Finally, also in RMS the two pathways seem to interact since the inhibition of mTOR by 
rapamycin blocks Hh target gene transcription (measured by Gli1, Gli2 and Ptch) and reduces 




























All these findings indicate that the HH and PI3K/AKT/mTOR signaling pathways can regulate 
each other in a positive feedback loop and can cooperate in tumor formation. The crosstalk of 
both pathways provides rationales for combining SMO antagonists with inhibitors of the 
PI3K/AKT/mTOR pathway to synergistically block both oncogenic pathways and to improve 
and optimize tumor therapies. Indeed, several clinical trials are in process, e.g. the treatment of 
advanced solid tumors (including pancreatic cancer) or recurrent glioblastoma, CRC, breast and 
pancreatic cancer with GDC-0449 plus sirolimus or LDE225 plus the PI3K inhibitor BKM120, 




3 AIM OF THE STUDY 
The aim of this thesis was to evaluate novel therapeutic strategies for RMS treatment. The HH 
and the PI3K/AKT/mTOR pathways play an important role in many cancers including RMS.  
First, the HH signaling pathway was targeted by SMO inhibitors in order to analyze if they might 
be beneficial for RMS treatment. Hence, potential antitumoral effects of GDC-0449, LDE225, 
HhA and cyclopamine were compared in four human RMS cell lines, i.e. two ERMS (RD, 
RUCH-2) and two ARMS (RMS-13, Rh41) cell lines. For this purpose the effects on HH 
signaling activity (measured by GLI1 expression), on IGF2 expression and on the differentiation 
status were investigated. Moreover, effects on cellular proliferation and on apoptosis as well as 
the impact on the PI3K/AKT/mTOR pathway, on AMPK activity and on autophagy were 
analyzed. 
Second, in order to enhance possible anticancer effects and to test for potential cooperative 
effects, SMO antagonists were combined with PI3K/AKT/mTOR pathway inhibitors. The latter 
included the dual PI3K/mTOR inhibitor PI103, the specific PI3K inhibitor GDC-0941, the pure 
AKT inhibitor MK-2206 and the mTOR inhibitors everolimus and rapamycin. Initial 
experiments indicated that HhA was the most promising of the four SMO antagonists for 
combination treatment. Therefore, HhA was used for further experiments in order to find a 
valuable drug combination. Finally, since HhA plus GDC-0941 showed cooperative anticancer 








4 MATERIAL  
4.1 Technical equipment 
Table 1: List of laboratory equipment 
Equipment Supplier 
-20 °C Freezer Liebherr GmbH, Ochshausen 
-80 °C Freezer (MDF-U71V) Sanyo Electric Co., Ltd., Japan 
4 °C Fridge  Robert Bosch GmbH, Stuttgart 
Agarose gel electrophoresis chamber  Peqlab Biotechnology GmbH, Erlangen 
Autoclave (Systec DX-150) Systec GmbH & Co. KG, Linden 
Biophotometer (6131)  Eppendorf AG, Hamburg 
Centrifuges (Biofuge fresco, primo) Kendro Laboratory Products GmbH, Hanau 
Cold Plate (EG 1150 C) Leica Microsystems GmbH, Wetzlar 
Digital monochrome printer (P91D) Mitsubishi, Ratingen 
Digital photo camera (PowerShot G2) Canon Deutschland GmbH, Krefeld 
Dissecting set Karl Hammacher GmbH, Solingen 
Electronic pipettor (Accu-jet)  Brand GmbH & Co. KG, Wertheim 
Electrophoresis System (XCell4 SureLock™ 
Midi-Cell) 
Invitrogen GmbH, Karlsruhe 
FACS Calibur  BD Biosciences GmbH, Heidelberg 
Freezing Container (Mr. FrostyTM) Thermo Fisher Scientific GmbH, Schwerte 
Heating block (Thermomixer)  Eppendorf AG, Hamburg 
Heating stirrer (MR 3000/3001)  Heidolph Instruments GmbH & Co. KG, 
Schwabach 
High-precision scales (Sartorius Basic plus) Sartorius AG, Göttingen 
Hybridization oven (HB-1000 Hybridizer)  UVP, Inc., Upland, USA 
Imaging system Fluorchem Q Fisher Scientific GmbH, Schwerte 
Incubator (6000, BBD 6220)  Kendro Laboratory Products GmbH, Hanau 
Inverted tissue culture fluorescence microscope 
(Axiovert 25) 
Carl Zeiss Jena GmbH, Jena 
Laboratory animal computed tomography system 
(QuantumFX) 
PerkinElmer Health Sciences, Hopkinton USA 
Liquid nitrogen tank  L’air liquid S.A., Paris, France 
Mastercycler (EP gradient S) Eppendorf AG, Hamburg 






Microscope (Olympus BX 60) Olympus Deutschland GmbH, Hamburg 
Microtom (HN 40)  Leica Microsystems GmbH, Wetzlar 
Microwave (Dimension 4)  Panasonic, Hamburg 
Mini centrifuge  Carl Roth GmbH & Co. KG, Karlsruhe 
Multifuge (Heraeus 3LR) Thermo Scientific, Wilmington, USA 
Orbital shaker (Unimax 1010) Heidolph Instruments GmbH & Co. KG, 
Schwabach 
Paraffin dispenser (Dispenser PAG 12)  Medite GmbH, Burgdorf 
Paraffin tissue floating bath Medax GmbH & Co. KG, Rendburg 
PCR machine  Eppendorf, Hamburg 
pH-meter (inoLab pH Level 1)  WTW GmbH, Vienna, Austria 
Pipettes (Multipette, One-channel) Eppendorf AG, Hamburg 
Power supply for electrophoresis  Peqlab Biotechnology GmbH, Erlangen 
Real-Time PCR System (ABI Prism 7900HT) Life Technologies GmbH, Darmstadt 
Spectrophotometer (NanoDrop 8000 ) Thermo Scientific, Wilmington, USA 
Stereo microscope (Stemi 2000)  Carl Zeiss Jena GmbH, Jena 
Sterile bench (Euroflow Class IIA) Clean Air Techniek bv, Woerden, Netherlands 
Tissue embedding and rehydrating machine (TP 
1020) 
Leica Microsystems GmbH, Wetzlar 
Trans-Blot SD semi-dry transfer cell  Bio-Rad Laboratories GmbH, Munich 
UV transilluminator Intas Science Imaging GmbH, Göttingen 
Vacuum pump  Schütt Labortechnik, Göttingen 
Vortexer-Genie 2  Scientific Industries, Woburn, USA 








Table 2: List of consumable materials 
Consumer good Supplier 
1.5 ml reaction tubes Ochs GmbH, Bovenden/Lenglern 
1.5 ml safeseal microtubes Sarstedt AG & Co., Nürnberg 
2.0 ml reaction tubes Sarstedt AG & Co., Nürnberg 
6-well tissue culture plate Sarstedt AG & Co., Nürnberg 
15 ml centrifuge tubes Greiner Bio-One GmbH, Frickenhausen 
50 ml centrifuge tubes Greiner Bio-One GmbH, Frickenhausen 
96-well assay plate Nunc GmbH & Co. KG, Wiesbaden 
96-well reaction plate (black) Costar Corning Incorporated, Corning, USA 
96-well PCR plate (non-skirted) 4titude Ltd., Berlin 
384-well PCR plate (Framestar) 4titude Ltd., Berlin 
BD DiscarditTM II (2, 10, 20 ml) BD Biosciences GmbH, Heidelberg 
BD Microfine + Demi  BD Biosciences GmbH, Heidelberg 
BD Plastipak  BD Biosciences GmbH, Heidelberg 
Blotting paper (GB 33 B003) Heinemann Labortechnik GmbH, Duderstadt 
Cell culture dishes (Nunclon Surface) Nunc GmbH & Co.KG, Wiesbaden 
Cell scraper Sarstedt AG & Co., Nürnberg 
Cell strainers (40 µm) BD Biosciences GmbH, Heidelberg 
Combitips (0.2, 0.5, 2.5, 5, 10, 25, 50 ml) Eppendorf AG, Hamburg 
Coverslips Menzel GmbH & Co.KG, Braunschweig 
CryoPure tubes Sarstedt AG & Co., Nürnberg 
Disposable needles (Sterican Ø 0,45 x 12 mm) B. Braun Medical AG, Emmenbrücke 
Feeding tubes (1.0 x 60 mm) Unimed SA, Lausanne, Schweiz 
Filter tips (10 μl) Sarstedt AG & Co., Nürnberg 
Filter tips (100 μl, 200 μl, 1000 μl) Kisker Biotech GmbH & Co. KG, Steinfurt 
Flow cytometry tube Sarstedt AG & Co., Nürnberg 
Fluted filters  Sartorius AG, Göttingen 
Glassware Schott AG, Mainz 
Milliporefilter (Nuclepore Track-Etch Membran) Whatman GmbH, Dassel 
Miscroscope slides (SuperFrost Plus) Menzel GmbH & Co.KG, Braunschweig 
Neubauer counting chamber Brand GmbH & Co KG, Wertheim 






4.3 Reagents and chemicals  
Chemicals which are not listed below were purchased from Sigma-Aldrich Chemie GmbH, 
Steinheim. 
Table 3: Utilized reagents and chemicals 
 
Consumer good Supplier 
NuPAGE Novex 4 – 12 % Bis-Tris Midi Gel Invitrogen GmbH, Karlsruhe 
Pasteur pipettes  Brand GmbH & Co.KG, Wertheim 
Petri dishes Ochs GmbH, Bovenden/Lenglern 
Pipette tips (10 μl, 200 μl) Ochs GmbH, Bovenden/Lenglern 
Pipette tips (20 µl, 1000 μl)  Sarstedt AG & Co., Nürnberg 
QPCR adhesive clear seal  4titude Ltd., Berlin 
Scalpel blade (10, 24)  Aesculap AG & Co.KG, Tuttlingen 
Serological pipettes (2 ml, 5 ml, 10 ml, 25 ml, 
50 ml) 
Sarstedt AG & Co., Nürnberg 
Sterile filter Omnilab-Krannich, Göttingen 
Syringe 30, 50 ml  Terumo Medical Corp., Elkton, MD, USA 
Chemicals and reagents Supplier 
50 bp, 100 bp plus, 1 kb DNA Ladder  Fermentas GmbH, St. Leon-Rot 
Acetic acid  Carl Roth GmbH & Co. KG, Karlsruhe 
Agarose  Bio-Budget Technologies GmbH, Krefeld 
Ampuwa  
Fresenius Kabi Deutschland GmbH, Bad 
Homburg 
AnnexinV-FITC BD Biosciences GmbH, Heidelberg  
Boric acid  Carl Roth GmbH & Co. KG, Karlsruhe 
Bovine serum albumin (BSA) Carl Roth GmbH & Co. KG, Karlsruhe 
Chloroform Carl Roth GmbH & Co. KG, Karlsruhe 
Citric acid  Carl Roth GmbH & Co. KG, Karlsruhe 
Collagenase H Roche Diagnostics GmbH, Mannheim 
Contrast agent Imeron 300 Bracco Imaging GmbH, Konstanz 
Deoxyribonucleotide triphosphate (dNTP) Roche Diagnostics GmbH, Mannheim 







Chemicals and reagents Supplier 
DNase/RNase-free distilled water  GIBCO Invitrogen GmbH, Karlsruhe 
Doxorubicin 
Pharmacy of the university medical center, 
Göttingen 
Eosin Y  Merck KGaA, Darmstadt 
Ethanol (EtOH) 99 %  J.T. Baker B.V., Deventer, Netherlands 
Ethidium bromide (0.07 %)  inna-TRAIN-Diagnostics, Kronberg 
Ethylenediaminetetraacetic acid (EDTA)  ICN Biochemicals Inc., Aurora, USA 
EtOH 99 % denatured  
CVH Chemie-Vertrieb GmbH & Co. 
Hannover KG, Hannover 
Glycergel mounting medium  Dako GmbH, Hamburg 
Haematoxylin, Mayer’s  Merck KGaA, Darmstadt 
Hydrogen peroxide Carl Roth GmbH & Co. KG, Karlsruhe 
Isoflurane (FORENE®)  Abbott GmbH & Co. KG, Wiesbaden 
Isopropyl alcohol Carl Roth GmbH & Co. KG, Karlsruhe 
Methanol Carl Roth GmbH & Co. KG, Karlsruhe 
NuPAGE MES SDS Running Buffer, 20 x  Invitrogen GmbH, Karlsruhe 
Paraformaldehyde  Carl Roth GmbH & Co. KG, Karlsruhe 
Pertex mounting medium  Medite Medizintechnik GmbH, Burgdorf 
Phosphatase inhibitor cocktail tablets (PhosSTOP) Roche Diagnostics GmbH, Mannheim 
Phosphate buffered saline (PBS)-Tablets  GIBCO Invitrogen GmbH, Karlsruhe 
Potassium aluminum sulfate Merck KGaA, Darmstadt 
Powdered milk Carl Roth GmbH & Co. KG, Karlsruhe 
Propidium Iodide (PI) Miltenyi Biotec, Bergisch Gladbach 
Protease inhibitor cocktail tablets (Complete, mini) Roche Diagnostics GmbH, Mannheim 
Proteinase K Carl Roth GmbH & Co. KG, Karlsruhe 
Random Hexamer-Oligonucleotides  Invitrogen GmbH, Karlsruhe 
SeeBlue® Plus2 Pre-Stained Standard  Invitrogen GmbH, Karlsruhe 
Sodiumdodecylsulfate (SDS)  Carl Roth GmbH & Co. KG, Karlsruhe 
Trichloro acetaldehyde hydrate Merck KGaA, Darmstadt 
TRIzol Reagent  Invitrogen GmbH, Karlsruhe 
Water soluble tetrazolium salt-1 (WST-1) reagent  Roche Diagnostics GmbH, Mannheim 




4.4 Signaling pathway inhibitors 
Drugs, their respective solvents and final concentrations for in vitro analyses are listed in Table 
4. 







Cyclopamine EtOH 0.1-10 µM Sigma-Aldrich, Steinheim 
Everolimus EtOH 50 nM Sigma-Aldrich, Steinheim 
GDC-0449  
(Vismodegib) 
DMSO 0.1-50 µM 
Selleckchem, Munich (in vitro); 
Genentech, San Francisco, USA (in 
vivo) 
GDC-0941 DMSO 10 µM (500 nM in Rh41) Genentech, San Francisco, USA 
HhA  
(HhAntag691) 




DMSO 0.1-50 µM Active Biochem, Bonn 
MK-2206 DMSO 
5 µM (1 µM in RMS-13 
and Rh41) 
Selleckchem, Munich 
PI103 DMSO 3 µM (200 nM in Rh41) Axxora Deutschland GmbH, Lörrach 
Rapamycin DMSO 100 nM Calbiochem, Merck KGaA, Darmstadt 





4.5 Kits and ready-to-use reaction systems  
Unless indicated otherwise, all kits and ready-to-use reaction systems were used according to the 
manufacturer’s instructions. 
Table 5: Kits and ready-to-use reaction systems 
 
4.6 Buffers and solutions  
Unless mentioned otherwise, all solutions were prepared with double distilled water (ddH2O). 




Reaction system Supplier 
5 x 1st strand buffer  Invitrogen GmbH, Karlsruhe 
10 x AnnexinV binding buffer BD Biosciences GmbH, Heidelberg 
Cell Proliferation ELISA, BrdU 
(chemiluminescent) 
Roche Diagnostics GmbH, Mannheim 
Dako EnVisionTM detection System  Dako Denmark A/S, Glostrup, Denmark 
Pierce BCA Protein Assay Kit Fisher Scientific GmbH, Schwerte 
Pierce ECL western blot substrate Fisher Scientific GmbH, Schwerte 
Platinum SYBR Green qPCR SuperMix Invitrogen GmbH, Karlsruhe 
Reverse Transcriptase (SuperScriptII®) Invitrogen GmbH, Karlsruhe 
Taq-Polymerase (MolTaq) Molzym GmbH & Co. KG, Bremen 
Buffer Composition 
6 x SDS loading buffer 35 % (v/v) Glycerol 
 9 % (w/v) SDS 
 8.5 % (w/v) DTT 
 0.1 % (w/v) Bromphenolblue 
 dissolved in Upper gel buffer 
10 x PBS, pH 7.4 1.4 M NaCl 
 65 mM Na2HPO4 
 27 mM KCl 







10 x Tris-boric acid-EDTA (TBE),  890 mM Tris/HCl  
pH 8.0 730 mM Boric acid 
 12.5 mM EDTA 
10 x Tris-buffered saline (TBS),  1.5 M NaCl 
pH 7.4 0.5 M Tris/HCl  
AEC chromogen, pH 5.2  70 mM Sodium acetate trihydrate 
 30 mM Acetic acid 
 
16 mM 3-Amino-9 Ethylcarbazole (dissolved 
in dimethylformamide) 
Blotting buffer 20 % (v/v) Methanol 
 6 % (w/v) Tris 
 3 % (w/v) Glycine 
 0,0375 % (v/v) SDS 
BSA-azide  0.02 % Sodium azide 
 2 % BSA  
 dissolved in PBST 
Citric acid buffer, pH 6.0 10 mM Sodium Citrate 
Collagen solution  0.1 M Acetic acid  
 1 mg/ml Collagen 
Cresol 0.1 % (w/v) Cresol 
 saturated sucrose solution 
dNTP-Mix 10 mM dATP 
 10 mM dCTP 
 10 mM dGTP 
 10 mM dTTP 
Eosin solution 80 % (v/v) EtOH 
 1 % (w/v) Eosin y (water soluble) 
Haematoxylin solution, Mayer’s 5 % (w/v) Potassium aluminum sulfate 
 5 % (w/v) Trichloro acetaldehyde hydrate 
 1 % (w/v) Citric acid 
 0.1 % (w/v) Haematoxylin 









Lysis buffer, pH 8.8 150 mM NaCl 
 30 mM Tris/HCl  
 10 % (v/v) Glycerol 
 1 % (v/v) Triton X-100 
 Protease and phosphatase inhibitors (1 tablet/50 ml) 
 2 mM DTT (added directly before use) 
 
500 μM Phenylmethanesulfonylfluoride (PMSF) (added 
directly before use) 
Methyl cellulose tween (MCT) 0.5 % (w/v) Methylcellulose 
 0.2 % (w/v) Tween-80 
Paraformaldehyde (PFA) 4 % (w/v) Paraformaldehyde dissolved in PBS 
PBS (cell culture)  1 PBS tablet ad 500 ml ddH2O 
PBS-Tween (PBST) 0.1 % Tween-20 dissolved in PBS 
Proteinase K, pH 8.0 50 mM Tris/HCl  
 5 mM EDTA 
 10 mg/ml Proteinase K 
STE-Buffer, pH 8.0 100 mM NaCl 
 50 mM Tris/HCl  
 1 mM EDTA 
 1 % (w/v) SDS 
TBS-Triton X-100 (TBST) 0.1 % Triton X-100 dissolved in TBS 
Trypan blue 0.4 % (w/v) Trypan blue dissolved in PBS 
Upper gel buffer, pH 6.8 6 % (w/v) Tris 




4.7 Media and reagents for cell culture 
Table 7: Media and reagents used for cell culture 
 
4.8 Cell lines and primary RMS cells 
Table 8: List of cell lines and their corresponding culture conditions 
 
  
Media and reagents Supplier 
Accutase  PAA Laboratories GmbH, Pasching 
Dulbecco’s Modified Eagle Medium (DMEM) Gibco, Invitrogen GmbH, Karlsruhe 
Fetal calf serum (FCS) Gibco, Invitrogen GmbH, Karlsruhe 
Penicillin (10.000 U/ml)/Streptomycin (10 mg/ml) (P/S) PAN Biotech GmbH, Aidenbach 
RPMI 1640 (RPMI) Gibco, Invitrogen GmbH, Karlsruhe 
TrypLE Express Gibco, Invitrogen GmbH, Karlsruhe 
Cell line Subtype Medium and supplements Supplier 
RD human ERMS DMEM, 10 % FCS, 1 % P/S ATCC 
RUCH-2 human ERMS DMEM, 10 % FCS, 1 % P/S ATCC 
RMS-13 human ARMS RPMI, 10 % FCS, 1 % P/S ATCC 
Rh41 human ARMS RPMI, 20 % FCS, 1 % P/S ATCC 
Primary Ptch+/– RMS 
cells 





4.9 Synthetic DNA-oligonucleotides  
Synthetic DNA-oligonucleotides (primers) were obtained from Eurofins MWG Operon, 
Ebersberg. For long-term storage (at -80 °C) 100 μM stock solutions in ddH2O were prepared 
and 10 μM working solutions were applied for polymerase chain reaction (PCR) methods. PCR 
for genotyping of Ptch
+/–
 mice was performed using primers presented in Table 9. 
 




Oligonucleotides used for analysis of gene expression levels via quantitative real-time PCR 
(qRT-PCR) are listed in Table 10. 
 




Primer sequence  




18S 18S-fwd CGCAAATTACCCACTCCCG 1 
 18S-rev2 TTCCAATTACAGGGCCTCGAA 1 
hGLI1 hsaGLI1 tqF AGCTACATCAACTCCGGCCA 11 
 hsaGLI1 tqR GCTGCGGCGTTCAAGAGA 12 
hIGF2 hIGF2 F2 GACACCCTCCAGTTCGTCTG 2 
 hIGF2 F1 ATTGGAAGAACTTGCCCACG 4 
hMYH1 hsMYH1F.1 TGTGCAGCAGGTGTACAATGC 13, 14 
 hsMYH1R.1 TGCACAGCTGCTCCAGGCT 15 
hMYOD hMYOD F CGAACCCCCAACCCGATA 3 







Primer sequence (5'-3' orientation) Reference 
neo-L 
Together with Pst4KF: 
634 bp (wild type allele) 
AGTGCCAGCGGGGCTGCTAAA 
(Hahn et 
al., 1998) mPTC11R3 
Together with Pst4KF: 
400 bp (mutant allele) 
CTGCCTGTTATGTGGTTCAAACCG 




4.10 Antibodies  
Table 11: Antibodies for western blot and immunohistochemistry 
Antibody Dilution Source Supplier 
Primary antibody    
Anti-AKT; (610861) 1:1000 Mouse, mAB BD Biosciences  
Anti-AMPK  1:1000 Rabbit, pAB Cell Signaling 
Anti-ß-Actin; (13E5) 1:1000 Rabbit, mAB Cell Signaling 
Anti-Caspase 3 1:1000 Rabbit, pAB Cell Signaling 
Anti-HSC70; (sc-7298) 1:10000 Mouse, mAB Santa Cruz 
Anti-IGF2; (LS-C165143) 1:500 Rabbit, pAB LSBio 
Anti-Ki67 1:50 Mouse, mAB BD Biosciences 
Anti-LC3-II; (D11 XP) 1:1000 Rabbit, mAB Cell Signaling 
Anti-pAKT (Ser473); (193H12) 1:1000 Rabbit, mAB Cell Signaling 
Anti-pAMPK (Thr172); (40H9) 1:1000 Rabbit, mAB Cell Signaling 
Anti-pS6 (Ser240/244) 1:1000 Rabbit, pAB Cell Signaling 
Anti-S6; (54D2) 1:1000 Mouse, mAB Cell Signaling 
    
Secondary antibody    
Anti-Mouse/HRP; (NA931) 1:5000 Sheep, pAB GE Healthcare 
Anti-Rabbit/HRP; (A0545) 1:5000 Goat, pAB Sigma-Aldrich 
Dako Envision/HRP undiluted  Dako 







4.11 Software  
Table 12: List of used software 
Software Developer 
Adobe Photoshop CS5 Adobe Systems Incorporated, San Jose, USA 
AlphaView Q SA 3.2.2 Cell Bioscience, California, USA 
CellSens Dimension Olympus GmbH, Hamburg 
Endnote X5  Thomson ISI ResearchSoft, California, USA 
FlowJo  Tree Star Inc., Oregon, USA 
GraphPad Prism 6  GraphPad Software, Inc., La Jolla, CA, USA 
Intas GDS  Intas Science Imaging Instruments GmbH, Göttingen 
Gen5 1.11 BioTek Instruments, Inc., Bad Friedrichshall 
Microsoft Office  Microsoft Co., Redmont, USA 
Fiji (Schindelin et al., 2012) 
Quantum FX μCT (SimpleViewer) PerkinElmer Health Sciences, Hopkinton USA 
SDS 2.2 Applied Biosystems, Darmstadt 
Statistica 10 StatSoft GmbH, Hamburg 
 
4.12 Databases 
Table 13: Databases to retrieve information 
Database Homepage 
BasicLocalAlignmentSearchTool (BLAST) http://blast.ncbi.nlm.nih.gov/Blast.cg 
Ensembl  http://www.ensembl.org/index.html 
MGI 3.43-mouse genome informatics http://www.informatics.jax.org/ 





5.1 Molecular biology methods  
5.1.1 Nucleic acid isolation  
5.1.1.1  Isolation of genomic DNA 
For isolation of genomic DNA (gDNA) from mouse tissue, tail biopsies were incubated 
overnight at 55 °C in 400 μl of STE buffer containing 0.5 mg/ml Proteinase K. Afterwards 
undigested tissue debris was removed by centrifugation for 10 min at 13000 rpm. The 
supernatant was transferred into a fresh reaction tube containing 1 ml cold 99 % EtOH and shook 
thoroughly in order to precipitate the nucleic acid. The gDNA was pelleted by centrifugation 
(25 min, 13000 rpm), washed with 500 μl 70 % ethanol and centrifuged again (10 min, 
13000 rpm). After drying of the gDNA for 10 min at 55 °C, gDNA was solved in 125 μl ddH2O 
for 10 min at 42 °C and 1400 rpm and stored at -20 °C for further analyses. 
5.1.1.2 Isolation of total RNA from cell culture  
Extraction of total RNA from cell culture was performed by using TRIzol reagent corresponding 
to the manufacturer’s instructions. If not stated otherwise all steps were performed on ice to 
avoid degradation of the RNA. Briefly, the cells were washed with cold PBS and detached by 
adding 1 ml TRIzol. Samples were transferred into 2 ml reaction tubes, vortexed for 2 min and 
incubated for 5 min at room temperature (RT). After addition of 200 μl chloroform and vortexing 
for 15 sec, samples were incubated for another 3 min at RT. After phase separation by 
centrifugation (10 min, 13000 rpm, 4 °C) the upper aqueous phase (containing the RNA) was 
transferred into 1 ml isopropyl alcohol and precipitated overnight at -20 °C. Afterwards the 
samples were centrifuged (30 min, 13000 rpm, 4 °C), the supernatant was removed and the pellet 
was washed two times with 500 µl 70 % DNase/RNase-free EtOH (-20 °C) by centrifugation 
(10 min, 13000 rpm, 4 °C). The pellet was dried for 10 min at RT and dissolved in 





5.1.2 Photometric quantification of nucleic acids 
DNA and RNA concentration was quantified using a Spectrophotometer (NanoDrop 8000). 
Nucleic acid quantity was assessed by determination of the optical density at 260 nm (OD260), 
because an OD260 of 1.0 equates 50 μg/ml pure DNA or 40 μg/ml pure RNA. The DNA or RNA 
concentrations were calculated according to the following formula:  
Concentration (ng/μl) = OD260 × 50 (DNA) or 40 (RNA) 
Because the OD at 280 nm (OD280) provides the protein concentration of the sample the ratio 
OD260/OD280 was used to evaluate the purity of the samples. Pure DNA and RNA preparations 
are generally recognized by OD260/OD280 values of ~1.8 and ~2.0, respectively. 
5.1.3 Reverse transcription of RNA (cDNA synthesis)  
For synthesis of complementary DNA (cDNA), 2 µg of RNA were reversely transcribed using 
the SuperScriptII Reverse Transcriptase System in a final reaction volume of 20 μl. First the 
RNA was incubated with 250 ng hexamers for 10 min at 70 °C. Next 10 mM DTT with 0.5 mM 
dNTPs dissolved in 1st strand buffer, were added and incubated at RT for 10 min. Following 
pre-warming to 42 °C for 2 min, 1 μl of SuperScriptII (100 U/μl) was added and the mixture was 
incubated for 1 h at 42 °C. Afterwards the synthesis reaction was stopped at 70 °C for 10 min. 
Under the assumption that the reverse transcription reaction is 50 % efficient, the final 
concentration of cDNA was 50 ng/μl. 
5.1.4 Polymerase chain reaction (PCR) 
5.1.4.1 PCR‐based genotyping of mouse tail gDNA  
PCR-based amplification of gDNA was carried out in reaction volumes of 10 or 20 μl per assay 





Table 14: Reaction mixture for genotyping of mouse tail gDNA 
Concentration Component 
10 – 100 ng gDNA template 
0.5 μM sequence-specific forward DNA oligonucleotide (forward primer) 
0.5 μM sequence-specific reverse DNA oligonucleotide (reverse primer) 
0.2 mM dNTP-Mix 
10 % (v/v)  Cresol 
1 x Polymerase buffer 
0.1 U Taq-Polymerase 
 
The primer sequences used for genotyping are given in Table 9. 
PCR steps were the following:  
1) Initiation step for 4 min at 95 °C 
2) Denaturation step for 30 sec at 95 °C 
3) Annealing step for 75 sec at 60 °C  
4) Elongation step for 90 sec at 72 °C 
The steps 2) to 4) were repeated for 35 cycles. The reaction was terminated by a final elongation 
step for 5 min at 72 °C. The samples were subsequently analyzed by agarose gel electrophoresis. 
5.1.4.2 Quantitative Real‐Time PCR (qRT‐PCR)  
Gene expression was analyzed using SYBR Green based assays. Primers for amplification of the 
target transcripts are listed in Table 10. The primer pairs used in this thesis were intron spanning, 
except of the primers for 18S and hMYOD that were located within a single exon. The assays 
were performed in a total reaction mixture of 10 μl using the reagents listed in Table 15. 
Table 15: Reaction mixture for qRT-PCR 
Amount Component 
2 µl cDNA template 
0.4 μM sequence-specific forward DNA oligonucleotide (forward primer) 
0.4 μM sequence-specific reverse DNA oligonucleotide (reverse primer) 
0.41 µl ddH2O 
0.4 µl SYBR Green 
 
Gene expression levels were calculated using the standard curve method. For quantification of 





cDNA for 18S rRNA) of a standard sample. Standard samples were derived from tissue or cells 
known to express the respective gene. The logarithm of the amount of cDNA for each dilution 
was plotted against the measured cycle threshold value of the standard curve. The derived linear 
trend line with the corresponding equation (y = mx + b) served to interpolate the amount of 
cDNA in each sample. Finally, the transcript levels of each sample were normalized to the 
corresponding expression of the housekeeper gene 18S rRNA. The samples were measured in 
triplicates. Analysis was done using the SDS 2.2, Microsoft Excel and GraphPad Prism 6 
software. 
5.1.5 Agarose gel electrophoresis  
Gel electrophoresis was performed to separate DNA fragments according to their specific size. 
Agarose gels composed of 1 % (w/v) agarose in 1 x TBE buffer were prepared by boiling for 
2-3 min at 1000 W in a microwave. After cooling, 5-7 drops of 0.07 % ethidium bromide were 
added to the liquid gels, which were subsequently hardened in the electrophoresis chamber. Gels 
were put in TBE buffer in the electrophoresis chamber, DNA samples and an appropriate DNA 
ladder were loaded onto the gels. The gels were run constantly at 100 V. For documentation an 
UV transilluminator was used. 
5.2 Cell biology methods  
5.2.1 Cell culture 
An overview about the used cell lines and respective culture conditions is given in Table 8. All 
RMS cell lines were cultured in an incubator at constant 37 °C, 5 % CO2 and 95 % humidity. 
Every third to forth day the media were refreshed and cells were splitted when reaching 80 to 
90 % confluence. Splitting of the cells was performed by detaching the cells with 1-3 ml of 
TrypLE Express. When the cells started to detach the reaction was stopped by adding of FCS 
containing medium. The cells were transferred to a new culture plate containing fresh medium. 
For in vitro assays, certain numbers of RMS cells were seeded in different plates (see Table 16) 





Table 16: Cell culture preparations for in vitro assays 
 
5.2.2 Cryopreservation of eukaryotic cells  
For long term storage in liquid nitrogen, RMS cell lines that were 90 % confluent were rinsed 
with PBS and detached as described. The cells were transferred into a 15 ml reaction tube and 
pelleted by centrifugation (5 min, 300 x g, 4 °C). Afterwards the cells were resuspended in 10 ml 
culture medium supplemented with 5 % DMSO. Subsequently, 1 ml aliquots were prepared and 
frozen in cryo tubes at -80 °C in the freezing device Mr. Frosty
TM
. After 16 h the cells were 
transferred in liquid nitrogen. 
For thawing, cells were rapidly warmed and transferred to 10 ml medium, pelleted (5 min, 
300 x g, 4 °C) and resuspended in fresh culture medium. Cells were subsequently transferred to a 
cell culture dish and stored in an incubator. To ensure a complete elimination of DMSO, the 
medium was immediately replaced the next day. 
5.2.3 Isolation and culture of primary cells 
Primary RMS cells were isolated from RMS bearing Ptch
+/–
 mice. Animals were euthanized and 
tumors were excised using scalpels and scissors followed by washing in PBS. One part of the 
tumor was embedded in paraffin in order to confirm the identity as RMS by haematoxylin eosin 
(HE) staining. The remaining tumor tissue was chopped using a razor blade and incubated with 
3 mg/ml collagenase H in DMEM (50 min, 1000 rpm, 37 °C). The resulting cell suspension was 
triturated through a 1 ml pipette. After sedimentation of undigested tissue, the tumor cells within 
the supernatant were separated using a cell strainer and centrifuged for 5 min at 300 x g and 
4 °C. The pellet was solved in DMEM supplemented with 10 % FCS and 1 % P/S and plated on 
collagen coated 6-well plates for further analyses. The next day the cells were washed to remove 
remaining blood cells and cell debris. Experiments were started immediately or within the next 
three days. 
Assay Format Seeded cells/well 
qRT-PCR, Apoptosis  6-well plates 105 (ERMS) or 15 x 104 cells (ARMS) 
Proliferation, Viability 96-well plates 4000 





5.2.4 Proliferation assay  
Cellular proliferation was analyzed using the 5-Bromo-2-Deoxyuridine (BrdU) cell proliferation 
kit according to the manufacturer’s instructions. Briefly, 4000 cells were seeded in 96-well plates 
and were incubated for 24 h with the respective inhibitors in the presence of BrdU. After fixation 
of the cells and denaturation of the DNA for 30 min, peroxidase coupled BrdU antibody 
(anti-BrdU-POD) was added for 1 h. Subsequently, cells were washed thoroughly followed by 
adding peroxidase substrate. Measurement of BrdU incorporation via luminescence was 
performed in a microplate reader. The analyzed luminescence is proportional to newly 
synthesized DNA and hence to the proliferation of the cells. All samples were measured in 
triplicates, analyzed and plotted using GraphPad Prism 6. 
5.2.5 Analysis of cellular proliferation by counting 
In order to confirm the results from the BrdU incorporation assay, proliferation was estimated by 
counting of the cells. For that purpose 10
5
 cells/well (ERMS) or 15 x 10
4
 cells/well (ARMS) 
were seeded in 6-well plates followed by incubation with the corresponding inhibitors for 24 h. 
Cells were washed with PBS, detached with 1 ml TrypLE Express/well, transferred into a 50 ml 
reaction tube and pelleted by centrifugation (5 min, 300 x g, 4 °C). After removal of the 
supernatant, the pellet was resuspended in 1 ml culture medium. Subsequently, the cell 
suspension was diluted in trypan blue solution to distinguish between live and dead cells. 
Counting was performed using a Neubauer counting chamber. 
5.2.6 Cell viability assay 
Cellular viability was measured using the tetrazolium salt WST-1. RMS cell lines were seeded in 
96-well plates (4000/well) and incubated for 24 h with the respective drugs. 4 h before analysis, 
10 μl WST-1 reagent/well (equates to a final 1:10 dilution of WST-1) was added as 
recommended by the manufacturer. WST-1 is cleaved to a soluble formazan dye in the presence 
of NAD(P)H in viable cells and the amount of produced formazan dye (quantified in a 
microplate reader at a wavelength of 450 nm) correlates with the metabolic activity of the cells. 




5.2.7 Apoptosis assay 
Cellular apoptosis was analyzed via flow cytometry after staining of the cells with AnnexinV 
coupled with fluorescein isothiocyanate (FITC) and Propidium Iodide (PI) according to 
manufacturer’s instructions. During early apoptosis, the membrane phospholipid 
phosphatidylserine (PS) is translocated from the inner to the outer leaflet of the plasma 
membrane. AnnexinV which specifically binds PS in a Ca
2+
 dependent manner can therefore 
detect apoptotic cells at an early stage. Because ongoing loss of membrane integrity also leads to 
binding of AnnexinV to PS in the cytosolic membrane leaflet, AnnexinV was combined with PI 
that can intercalate into the DNA of dead and apoptotic cells with damaged cell membranes. This 
allows for differentiation of early and late cell death. Thus, viable cells are AnnexinV negative 
and PI negative (AnnexinV-/PI-), early apoptotic cells are AnnexinV positive and PI negative 
(AnnexinV+/PI-), late apoptotic cells are AnnexinV positive and PI positive (AnnexinV+/PI+) 
and AnnexinV negative and PI positive (Annexin V-/PI+) cells are necrotic.  
For the analysis, 10
5
 cells/well (ERMS) or 15 x 10
4
 cells/well (ARMS) were seeded in 6-well 
plates and incubated with the respective drugs for 48 h. Cells were rinsed in PBS, detached with 
1 ml accutase/well, transferred into a 15 ml reaction tube and pelleted by centrifugation (5 min, 
300 x g, 4 °C). After washing with PBS the cells were incubated with 100 µl AnnexinV binding 
buffer supplemented with 2 µl AnnexinV-FITC for 10 min, followed by incubation with PI for 
5 min. Before measurement on a FACS Calibur 300 µl of AnnexinV binding buffer was added to 
the cell suspension. Incubations were conducted at RT and under exclusion of light. 
Measurement of fluorescence was performed in channel FL-1 for AnnexinV-FITC (emission 
maximum of FITC is about 519 nm) and in channel FL-3 for PI (emission maximum of PI is 
about 617 nm). The samples were measured in duplicates, analyzed and displayed using the 
software FlowJo, Microsoft Excel and GraphPad Prism 6. 
5.3 Protein chemistry and immunohistochemistry (IHC) 
5.3.1 Protein isolation from cell culture  
For protein isolation from cell culture, cells were washed and scraped in 2 ml cold PBS using a 
cell scraper and centrifuged (5 min, 1800 rpm, 4 °C). After removing of the supernatant, the 
pellet was resuspended in 800 µl PBS and transferred into a 1.5 ml reaction tube in order to 





nitrogen and thawing on ice for 20 min followed by incubation with 80-100 µl lysis buffer 
(supplemented with 500 μM PMSF und 2 mM DTT) for 30 min on ice. Subsequently the lysates 
were centrifuged (30 min, 13000 rpm, 4 °C) and the soluble proteins in the supernatant were 
transferred to a new 1.5 ml reaction tube and stored at -80 °C until use. 
5.3.2 Determination of protein concentration 
The protein concentration was measured using the Pierce BCA Protein Assay Kit according to 
manufacturer’s instructions. This method is based on bicinchoninic acid (BCA) for the 




 by the 
proteins in an alkaline environment, BCA reacts with Cu
1+
 to form a purple colored reaction 
product. The amount of the produced complex is proportional to increasing protein 
concentrations in the samples and can be measured at 540 nm with a microplate reader. 
Triplicates of 1 µl of each protein sample were pipetted in a 96-well plate. Known concentrations 
(0-2000 μg/ml) of BSA were used to create a standard curve for calculation of the protein 
concentrations. After addition of 200 µl/well BCA reagent and an incubation for 30 min at 
37 °C, the plate was analyzed in the microplate reader.  
5.3.3  Western blot  
For western blot analysis, protein lysates were denatured in SDS loading buffer for 5 min at 
96 °C and 450 rpm in a shaker. Afterwards 30-40 µg proteins were loaded on 4-12 % Bis-Tris 
Gels (NuPAGE Novex) and electrophoresed in running buffer (NuPAGE MES SDS) at 160 mA, 
160 V and 100 W for 1.5-2 h. A protein marker (SeeBlue
®
 Plus2 Pre-Stained) with proteins of 
defined molecular weight, was loaded to estimate the size of the protein bands later. After 
separation of the proteins during gel electrophoresis, they were blotted onto a nitrocellulose 
membrane. The transfer of the proteins from the gel to the membrane was performed by 
semi-dry blotting in blotting buffer at 120 mA, 20 V and 100 W for 80 min. After blocking with 
5 % (w/v) milk powder/PBST for 1 h at RT followed by washing three times in PBST for 
10 min, the membrane was incubated with primary antibodies (see Table 11) at 4 °C overnight. 
The next day, the membrane was washed again three times for 10 min in PBST and subsequently 
incubated with HRP conjugated secondary antibodies for 1 h at RT (see Table 11). After 
additional washing steps in PBST the detection reagent ECL was pipetted onto the membrane, 




Fluorchem Q Imaging system. All primary antibodies were dissolved in BSA-azide/PBST 
(except of IGF2 which was dissolved in 5 % milk powder/PBST) and all secondary antibodies 
were dissolved in 5 % milk powder/PBST. 
5.3.4  Haematoxylin eosin (HE) staining 
For HE staining, tissue fixed in 4 % PFA was embedded in paraffin and cut into 4-5 μm sections 
and mounted onto glass slides. The sections were then deparaffinized two times in xylene for 
10 min and subsequently rehydrated by descending ethanol solutions (99 % to 70 %). After 
thorough washing with ddH2O, slides were transferred in haematoxylin solution for 15 min. 
Coloring occurred after washing with lukewarm tap water for at least 5 min. Slides were then 
quickly placed in 1 % eosin solution for a maximum of 20 sec and washed again with ddH2O. 
The sections were dehydrated using ascending ethanol solutions (70 % to 99 %). Afterwards the 
slides were placed again in xylene prior mounting in pertex. Finally in order to harden the 
mounting medium, the slides were incubated at 55 °C for at least 20 min. 
5.3.5 Ki67-staining  
For immunohistochemical staining of Ki67 positive cells, sections of paraffin embedded tumors 
were mounted onto superfrost slides. Tissue was deparaffinized and rehydrated as described 
above (see 5.3.4). After rinsing in ddH2O, antigen retrieval was performed by boiling the slides 
in citric acid buffer (pH 6.0) once for 4 min and four times for 3 min at 600 W in a microwave. 
After cooling down to RT and washing two times for 2 min with TBS, the slides were blocked 
for 20 min with 3 % H2O2 to inhibit endogenous peroxidases. Then the sections were washed for 
5 min in ddH2O and rinsed with TBS. The following steps were performed in moist chambers. In 
order to block nonspecific antibody binding, slides were incubated with 0.2 % casein in TBS for 
20 min at RT. Incubation with the primary antibody in TBS solution was performed overnight at 
4 °C. After washing three times with TBST, the slides were incubated with the secondary 
antibody for 30 min at RT. Prior adding of diaminobenzidine chromogen for 10 min at RT, the 
slides were again washed in TBST. To stop the reaction, slides were washed with ddH2O. 
Counterstaining with haematoxylin was performed for 5 sec followed by washing with lukewarm 
tap water for 5 min and sections were mounted with glycergel. 
Quantification of Ki67 positive cells was done on a microscope (Olympus BX 60) using 





were taken at a 200 x magnification. The pictures were analyzed by the freely available software 
Fiji (Schindelin et al., 2012). All nuclei per image as well as Ki67 positive cells were 
automatically counted (if tumors were very small, at least 6000 cells per section were counted). 
In addition manual counting of Ki67 positive cells was performed to control and confirm the 
automatic counting. The ratio of Ki67 positive cells/all nuclei per picture was determined and 
used for further calculations. 
5.4 Animal experiments  
5.4.1 Mouse lines 
The wild type inbred mouse strains C57BL/6N (B6) and Balb/c (Balb) were bred in-house or 
purchased from Jackson Laboratories (Bar Harbor, USA) or Charles River Laboratories 
(Sulzfeld, Germany). B6-Ptch
neo67/+
 mice harbour a heterozygous deletion of exon 6 and 7 within 
the Ptch gene. For in vivo studies heterozygous B6-Ptch
neo67/+
 mice were bred to Balb mice. The 
resulting B6xBalbc-Ptch
neo67
 mice were used for further studies and were henceforth named 
Ptch
+/–
 mice. All experiments using animals were performed in agreement with all relevant legal 
and ethical requirements. 
5.4.2 Breeding of mice  
The mouse strains used in this thesis were bred and housed in the animal facility of the Institute 
of Human Genetics, University of Göttingen, Germany. Animals were kept in Makrolon cages 
type II and III. Mice were exposed to a 12 h light-dark cycle (light period: 6 a.m.-6 p.m.), a 
temperature of 20±2 °C and a relative humidity of 50±10 %. Rodent pellets and tap water were 
given ad libitum. 
5.4.3 Tail biopsy and genotyping of mice  
To identify the genotype and to mark the mice, tail clipping (0.2 cm cut from the tip of the tail) 
and ear marking were done at 4 weeks of age by the staff of the animal facility. Genotyping was 
performed by isolation of gDNA from tail tissue followed by PCR using the primers and 




5.4.4 Monitoring of RMS bearing mice 
In order to record the occurrence and estimate the size of RMS, Ptch
+/–
 mice were monitored 
once a week manually by palpation and carefully viewing. 
5.4.5 Formulation of the drugs for in vivo treatment 
HhA and GDC-0941 were obtained from Genentech. For in vivo treatment both drugs were 
dissolved in methyl cellulose tween (MCT) as recommended by the manufacturer. In short, MCT 
powder was first solved in 40 ml hot ddH2O (80 ºC-90 °C) while stirring. Then 40 ml cold 
ddH2O was slowly added. The resulting MCT suspension was refrigerated overnight. The next 
day, the clear solution was equilibrated to RT prior and then tween-80 was added. After filling 
up to 100 ml with ddH2O, the MCT solution was sterile filtered and stored at 2-8 °C no longer 
than a month before use. The solution was used as the vehicle in the control group and to 
dissolve HhA and GDC-0941. The stock solution for GDC-0941 was stored for a maximum of 
three days at RT. HhA was prepared directly before oral application. 
5.4.6 Treatment of Ptch+/– mice with HhA and GDC-0941  
Tumor bearing mice were randomized into four groups. Mice were treated daily for five weeks 
with the same dosing volume of vehicle MCT, 100 mg/kg HhA, 75 mg/kg GDC-0941 or with the 
combination of HhA plus GDC-0941. Oral treatment was performed using feeding tubes. For the 
combination treatment the drugs were administered separately with an interjacent time span of at 
least 5 h. This was necessary to avoid potential drug-drug interactions or complexations, which 
could have lowered the intestinal resorption and hence the therapeutic efficacy of the drugs. 
During the treatment mice were weighed twice a week and their physical condition was 
monitored. The animals were kept until completion of the study, than all mice were sacrificed 
and tumors were excised. However, animals were sacrificed earlier if they lost 20 % of their 
body weight, were at poor general condition or if the tumor exceeded a size of 1.5 cm. The 
tumors tissue was formalin fixed and embedded in paraffin for HE staining and IHC. Due to the 
small size of the treated tumors (especially after combination therapy) it was not possible to 





5.4.7 Measurement of tumor growth using volumetric computer 
tomography (VCT) 
The tumor growth during in vivo treatment with HhA and GDC-0941 was analyzed using VCT. 
The tumor volume was measured at three time points; at therapy start, two weeks after therapy 
begin and at end of the treatment. Mice were anaesthetized with isoflurane vapor before and 
during the scan procedure. In order to visualize the tumors 200 µl of contrast agent Imeron 300 
(Struffert et al., 2010) were injected into the tail vein approximately 30 sec prior imaging. A low-
dose laboratory animal CT system (QuantumFX, Perkin Elmer) (Osborne et al., 2012) was used 
for in vivo imaging of tumor bearing mice. The data sets were acquired using a field of few of 4 
x 4 cm
2
 centered on the tumor site. The system was operated at 70 kVp, 200 µA using 17 sec 
total scanning time in a 360° rotation mode. Data sets were reconstructed with a voxel size of 
XYZ µm.  
5.5 Statistics  
Unless indicated otherwise, statistical and graphical analyses were conducted using the programs 
GraphPad Prism 6, MS office Excel or Statistica 10. Data were considered significant if p values 
were <0.05.When comparing two samples, statistical differences were analyzed using Student’s 
t-test. In order to analyze statistical differences for experiments using more than two treatment 
schemes Tukey’s test in conjunction with ANOVA was applied. 
Statistical analysis of the in vivo data was done with the aid of Albert Rosenberger (department 
of genetic epidemiology, university medical center Göttingen). Differences in tumor growth 
between the cohorts were analyzed using a mixed, linear model. The logarithm of the tumor size 
was generated to achieve the assumption of a Gaussian distribution. In few cases more than one 
tumor per mouse was observed, hence the factor mouse was considered as random effect. The 
expected tumor size per treatment group was adjusted to the tumor size at time points of the 





6.1 Effects of four SMO antagonists on RMS cell lines  
In order to investigate the impact of SMO inhibitors on RMS cells, the potential antitumoral 
effects of the approved SMO inhibitor GDC-0449 was compared with that of LDE225, HhA and 
cyclopamine. The effects were analyzed in the ERMS cell lines RD and RUCH-2 and in the 
ARMS cell lines RMS-13 and Rh41. 
6.1.1 Modulation of gene expression by GDC-0449, LDE225, HhA and 
cyclopamine 
Initially, the effects of GDC-0449, LDE225, HhA, and cyclopamine on HH pathway inhibition 
(indicated by GLI1 expression), on IGF2 expression and on modulation of the differentiation 
status of the four RMS cell lines were examined. 
6.1.1.1 Effects on GLI1 expression  
As known from previous studies, all four RMS cell lines express major components of the HH 
signaling pathway including GLI1 and PTCH, which are the main target genes of HH signaling 
(Graab et al., 2015; Ridzewski et al., 2015). This indicates that the RMS cell lines used in this 
thesis show HH pathway activity. Since the most reliable indicator for active HH signaling is 
GLI1 mRNA expression (reviewed in (Scales and de Sauvage, 2009)), the effects of the SMO 
antagonists on the pathway’s activity was analyzed by GLI1 qRT-PCR. First, the optimal 
concentrations under which each inhibitor may block HH signaling were determined. 
 
In the ERMS cell line RD a significant inhibition of GLI1 expression was observed for 1, 10 and 
50 μM GDC-0449 and LDE225 (Figure 5). A significant decrease of GLI1 expression was also 
revealed for 1-50 µM HhA. Interestingly, 30 μM of GDC-0449 or LDE225 did not block HH 
signaling activity, but rather restored HH signaling activity to basal level or above. Moreover, a 
triphasic change in GLI1 expression was observed after treatment with GDC-0449, LDE225 or 
HhA i.e. a decrease at 10 µM, a re-increase at 30 µM compared to 10 µM and again a decrease at 
50 µM. Cyclopamine was not able to decrease GLI1 expression indeed it rather enhanced GLI1 





In RUCH-2 cells GDC-0449 did not significantly modulate GLI1 expression at any 
concentration (Figure 5). However, LDE225 and HhA decreased GLI1 transcription at 30 and 
50 μM and at 10 and 50 μM, respectively. Cyclopamine increased GLI1 expression at 
concentrations of 0.1, 1 and 5 μM, which was similar to its action in RD cells (Figure 5).  
In RMS-13 cells, which show amplification of GLI1 (Roberts et al., 1989), the SMO inhibitors 
did not decrease GLI1 mRNA levels at any applied concentration. In contrast, GLI1 expression 
was rather stimulated. This was especially obvious for LDE225, HhA and cyclopamine (Figure 
5).  
In Rh41 cells the dose response analyses revealed that GDC-0449 moderately inhibited GLI1 
expression at any used concentration (Figure 5). LDE225 decreased GLI1 expression at 
concentrations of 10 and 30 μM, but increased it at a concentration of 50 μM. HhA blocked 
GLI1 transcription at 0.1 and 1 μM, while higher concentrations also restored or increased GLI1 
expression levels. Cyclopamine never inhibited GLI1 expression, but activated GLI1 expression 
significantly at 1-10 μM (Figure 5). 
 
Together, these findings indicate that tumor intrinsic HH pathway activity (evaluated by GLI1 
expression) in ERMS and ARMS cell lines can be modulated by treatment with SMO 
antagonists. However, the data show that the drugs exert heterogeneous effects on GLI1 
expression despite blocking the same molecular target (i.e. SMO). In addition, the 
responsiveness of the cell lines to the SMO inhibitors is very variable. Except for cyclopamine, 
which never repressed HH signaling activity in any of the used RMS cell lines, all other SMO 
antagonists induced effects that differed from cell line to cell line. Moreover, the data 
demonstrate that SMO inhibitors (depending on their concentration) might paradoxically induce 






Figure 5: Modulation of HH signaling activity by SMO antagonists. Relative GLI1 expression in RD, RUCH-2, 
RMS-13 and Rh41 cells after incubation (24 h) with GDC-0449, LDE225, HhA and cyclopamine (cp) at the 
indicated concentrations. Gene expression was normalized to 18S rRNA expression levels. The corresponding 
solvent controls (solv) were set to 1. All data represent at least two independent experiments measured in triplicates. 

















































































































































6.1.1.2 Effects on IGF2 expression 
Next, the effects of the drugs on IGF2 expression were analyzed because this gene plays an 
important role in the pathology of RMS (Martins et al., 2011) and is regulated by HH signaling 
in specific cellular settings (Corcoran et al., 2008; Hahn et al., 2000). RUCH-2 did not express 
IGF2, whereas the remaining three cell lines did. As shown in Figure 6, all SMO antagonists 
modulated the expression levels of IGF2, however to a variable extent. 
In RD cells IGF2 expression was significantly decreased by 0.1, 30 and 50 μM GDC-0449, by 
50 μM LDE225 as well as by 10, 30 and 50 μM HhA. Cyclopamine had no effect, whereas 
0.1 μM HhA slightly enhanced the IGF2 mRNA level (Figure 6). In RMS-13 cells IGF2 
transcription was significantly blocked upon treatment with 0.1 and 1 μM GDC-0449 and with 
50 μM LDE22 or HhA. In contrast, incubation with 0.1 and 1 μM HhA as well as with 1-10 μM 
cyclopamine resulted in a significant induction of IGF2 mRNA expression (Figure 6). A 
different situation was observed in Rh41 cells. In this cell line the IGF2 mRNA level was 
significantly inhibited only with 10 μM cyclopamine, while all other drugs rather increased it. 
The induction of IGF2 expression was specifically obvious upon treatment with GDC-0449, 
which stimulated IGF2 expression at any concentration (Figure 6). 
 
In summary, these data demonstrate that SMO inhibitors can regulate IGF2 expression in RMS 
cell lines. Similar to GLI expression, the drugs exert different effects on IGF2 transcription and 
the response of the RMS cell lines to the inhibitors is heterogeneous. Except for cyclopamine in 
RMS-13 cells, the modulation of IGF2 expression (Figure 6) is not necessarily correlated with 
the corresponding GLI1 expression (Figure 5). It rather seems that the modulation of GLI1 






Figure 6: Modulation of IGF2 transcription by SMO antagonists. Relative IGF2 mRNA expression in RD, 
RMS-13 and Rh41 cells after incubation (24 h) with GDC-0449, LDE225, HhA and cyclopamine (cp) at the 
indicated concentrations. Gene expression was normalized to 18S rRNA expression levels. The corresponding 
solvent controls (solv) were set to 1. All data represent at least two independent experiments measured in triplicates. 





































































































6.1.1.3 Effects on the expression of muscle differentiation markers 
In addition, the expression of the early and late muscle differentiation markers MYOD (Figure 7) 
and Myosin Heavy Chain 1 (MYH1) (Figure 8) respectively, were examined. While RUCH-2 
cells neither expressed MYOD nor MYH1, modulation of the corresponding transcription levels 
was revealed in the three other RMS cell lines.  
In RD cells MYOD mRNA expression was significantly decreased by 0.1 and 50 μM GDC-0449, 
although 1 μM GDC-0449 induced it (Figure 7). An inhibition of MYOD transcription was also 
observed for 0.1, 10 and 50 μM LDE225, for 10, 30 and 50 μM HhA as well as for 0.1 and 1 μM 
cyclopamine. In RMS-13 cells MYOD expression was blocked after treatment with 1 and 30 μM 
GDC-0449, 30 and 50 μM LDE225 or HhA and with 0.1 and 1 μM cyclopamine (Figure 7). In 
contrast to RD and RMS-13, in Rh41 cells MYOD expression was induced by GDC-0449 and 
LDE225 at any concentration. MYOD transcription was also stimulated by 10, 30 and 50 μM 
HhA. However cyclopamine showed no effect on MYOD expression in this cell line (Figure 7). 
 
MYH1 transcription in RD cells was significantly repressed by 30 and 50 μM GDC-0449, by 10, 
30 and 50 μM LDE225 and by 1-50 μM HhA (Figure 8). An induction of MYH1 expression in 
RD cells was revealed by cyclopamine at any concentration (Figure 8). In RMS-13 cells MYH1 
expression was slightly induced by 0.1 and 30 μM GDC-0449 and by 1-30 μM LDE225. HhA 
increased the expression of MYH1 at a concentration of 0.1 and 1 μM, but decreased it at a 
concentration of 30 and 50 μM. Inhibition of MYH1 transcription was also seen with 5 μM 
cyclopamine (Figure 8). In Rh41 cells the dose response analyses showed an induction of MYH1 
mRNA expression by 0.1, 10 and 30 μM GDC-0449 and by 1 and 30 μM LDE225, whereas 
50 μM LDE inhibited it. HhA activated the transcription of MYH1 at a concentration of 0.1 and 
1 μM, but repressed it at a concentration of 30 and 50 μM. Treatment of cyclopamine resulted in 
an inhibition of MYH1 expression at 1-10 μM (Figure 8). 
 
These findings show that inhibition of SMO by the four drugs is able to modulate the expression 
of the muscle differentiation markers MYOD and MYH1. However, the effects of the drugs are 






Figure 7: Modulation of MYOD transcription by SMO antagonists. Relative MYOD mRNA expression in RD, 
RMS-13 and Rh41 cells after incubation (24 h) with GDC-0449, LDE225, HhA and cyclopamine (cp) at the 
indicated concentrations. Gene expression was normalized to 18S rRNA expression levels. The corresponding 
solvent controls (solv) were set to 1. All data represent at least two independent experiments measured in triplicates. 













































































































Figure 8: Modulation of MYH1 transcription by SMO antagonists. Relative MYH1 mRNA expression in RD, 
RMS-13 and Rh41 cells after incubation (24 h) with GDC-0449, LDE225, HhA and cyclopamine (cp) at the 
indicated concentrations. Gene expression was normalized to 18S rRNA expression levels. The corresponding 
solvent controls (solv) were set to 1. All data represent at least two independent experiments measured in triplicates. 

















































































































6.1.2 Modulation of cellular viability, proliferation and apoptosis 
6.1.2.1 Effects on cellular viability 
RD cells showed a triphasic change in GLI1 expression upon treatment with GDC-0449, 
LDE225 or HhA (i.e. a decrease at 10 µM, a re-increase at 30 µM compared to 10 µM and again 
a decrease at 50 µM; see Figure 5). In order to exclude that this was due to toxic effects of the 
drugs, cellular viability/metabolic activity was analyzed via WST assay. 
As shown in Figure 9, treatment with different concentrations of SMO inhibitors was well 
tolerated by RD cells. GDC-0449 and cyclopamine did not reduce viability at any of the applied 
concentrations. A significant decrease in cellular viability was detected for 50 µM LDE225 and 




Figure 9: Cell viability/metabolic activity of RD cells after treatment with SMO antagonists. GDC-0449, 
LDE225, HhA and cyclopamine (cp) were incubated for 24 h with the cells at the indicated concentrations. Cellular 
viability was determined by WST assay. The respective solvent controls (solv) were set to 100 %. The data 
summarize two independent experiments and are represented as mean +/-SEM; *, p<0.05; **, p<0.01. 
Thus, RD cells showed no triphasic changes in cellular viability/metabolic activity upon 
treatment with GDC-0449, LDE225 or HhA. Instead, cellular viability continuously decreased 
with increasing doses of the drugs. In conclusion the re-increase of GLI1 expression at 30 µM 
GDC-0449, LDE225 or HhA (compared to 10 µM) is not correlated with increased cell viability 

































6.1.2.2 Effects on cellular proliferation 
Next GDC-0449, LDE225, HhA, and cyclopamine were compared with respect to their potential 
to inhibit cellular proliferation. For this purpose concentrations were selected that either have 
reduced or did not impact on GLI1 expression in most experimental settings (10 μM and 30 μM, 
respectively). Cyclopamine was applied only at a concentration of 5 μM. BrdU incorporation 
into the DNA of the cells was measured as an indicator of proliferative activity. 
In RD cells 30 μM LDE225, 10 and 30 μM HhA decreased the proliferation rate approximately 
by 55 %, 30 % and 50 %, respectively (Figure 10 A). 30 μM GDC-0449, 10 μM LDE225 and 
cyclopamine did not show any antiproliferative effects, whereas 10 μM GDC-0449 significantly 
increased the proliferation rate of the cells (Figure 10 A). This was similar in RUCH-2 cells 
(Figure 10 B), in which proliferation was significantly reduced by 30 μM LDE225, 10 and 
30 μM HhA. As in RD cells 30 μM GDC-0449 and 10 μM LDE225 showed no impact on the 
proliferation rate, whereas 10 μM GDC-0449 and 5 μM cyclopamine significantly increased 
proliferation (by approximately 50 % and 100 %, respectively; Figure 10 B). In RMS-13 cells 
antiproliferative effects were observed upon treatment with 30 μM GDC-0449, 10 and 30 μM 
LDE225 and by 30 μM HhA (Figure 10 C). In Rh41 none of the SMO inhibitors reduced the 
proliferation rate (Figure 10 D). However, proliferation inducing effects were seen for 10 μM 
and 30 μM GDC-0449, as well as for 10 μM LDE225 and for cyclopamine (Figure 10 D). 
 
In summary, the BrdU incorporation assay reveals that the antiproliferative effects of SMO 
antagonists varies between the RMS cell lines. Apparently, LDE225 and HhA are the most 
potent inhibitors since antiproliferative effects are seen in many settings (e.g. 30 µM HhA 
reduced proliferation in RD, RUCH-2 and RMS-13 cells). Paradoxically, treatment with 
GDC-0449 or cyclopamine rather induces proliferation (particularly obvious for cyclopamine in 






Figure 10: Modulation of proliferation by SMO antagonists. Measurement of BrdU incorporation in RD (A), 
RUCH-2 (B), RMS-13 (C) and Rh41(D) cells after incubation for 24 h with GDC-0449, LDE225, HhA and 
cyclopamine (cp) at the indicated concentrations. BrdU incorporation is shown as the percentage of the respective 
solvent controls (solv) that were set to 100 %. The data summarize three independent experiments and are 
represented as mean +/-SEM; *, p<0.05; **, p<0.01; ***, p<0.001. 
In addition to the BrdU incorporation analysis, proliferation was calculated by simple counting 
of RD and Rh41 cells (see 5.2.5) after treatment with SMO antagonists.  
In RD cells a significant reduction of the cell number was revealed upon treatment with 30 µM 
LDE225 and with 10 µM and 30 µM HhA (Figure 11 A), thus confirming the results of the BrdU 
assay. In Rh41 cells treatment with 10 µM HhA significantly decreased the amount of the cells 
(Figure 11 B), whereas 10 µM GDC-0449 and 10 µM LDE225 increased the cell number. 
However, the latter increase was not significant compared to the control. Although the changes 
in cell numbers confirmed the BrdU data (compare Figure 10 with Figure 11), the effects were 



































































































































cell division. For instance Rh41 have a cell doubling time of 44 h (Kang et al., 2011), hence it is 
possible that at the time point of measurement (24 h) most cells had incorporated BrdU during 
S-phase, but have not divided yet. 
 
 
Figure 11: Determination of the cell numbers after treatment with SMO antagonists. Treatment was performed 
according to the experimental setup of the BrdU incorporation assay. RD (A) and Rh41 (B) cells were incubated for 
24 h with GDC-0449, LDE225, HhA and cyclopamine (cp) at the indicated concentrations. Proliferation was 
determined by cell counting. The respective solvent controls (solv) were set to 100 %. The data summarize three 
independent experiments and are represented as mean +/-SEM; *, p<0.05; **, p<0.01. 
6.1.2.3 Effects on apoptosis 
Next, the effects of GDC-0449, LDE225, HhA, and cyclopamine were compared concerning 
their potential to induce apoptosis. In order to measure apoptosis, a flow cytometry based assay 
with AnnexinV-FITC and PI was performed and the apoptosis rate was calculated by the amount 
of AnnexinV positive cells. For this purpose early-apoptotic (AnnexinV positive/PI negative) 
and late-apoptotic (AnnexinV positive/PI positive) cells were summed up (see 5.2.7). Analysis of 
apoptosis in RUCH-2 cells was not possible because of highly unstable results obtained from 
three independent measurements. 
In RD cells (Figure 12 A) 30 μM LDE225 and 30 µM HhA significantly increased the apoptosis 
rate. 10 μM LDE225, 10 µM HhA as well as GDC-0449 and cyclopamine did not trigger 
apoptosis. The SMO inhibitors had similar effects in RMS-13 (Figure 12 B). Besides a strong 
induction of apoptosis upon treatment with 30 µM LDE225 and 30 µM HhA, the apoptosis rate 
was also significantly increased using 10 µM HhA and 30 µM GDC-0449, whereas cyclopamine 




























































effects as in RMS-13 cells. In addition, a slight but significant induction of apoptosis was also 
caused by 10 µM GDC-0449.  
 
In summary, the results show that 30 µM LDE225 and HhA exert proapoptotic effects in all 
three RMS cell lines, whereas low doses of HhA increases apoptosis in RMS-13 and Rh41 and 
10 µM LDE225 does not induce apoptosis at all. In contrast, 10 and 30 µM GDC-0449 only 
marginally stimulate apoptosis in RMS-13 and Rh41, and cyclopamine is not able to induce 
proapoptotic effects in any of the examined RMS cell lines. 
 
 
Figure 12: Modulation of apoptosis by SMO antagonists. RD (A), RMS-13 (B) and Rh41 (C) cells were 
incubated for 48 h with GDC-0449, LDE225, HhA and cyclopamine (cp) at the indicated concentrations. Apoptotic 
cells are illustrated as AnnexinV positive cells in percent. All data represent three independent experiments 











































































































In conclusion, these data demonstrate that SMO inhibitors differ remarkably in their potential to 
modulate cellular proliferation and to induce apoptosis in the RMS cell lines. Thus, cyclopamine 
neither reduces the proliferation rate nor induces apoptosis in the used cell lines. It rather 
enhances the proliferation rate of RUCH-2 and Rh41 cells (Figure 10 B, D). Moreover, 
GDC-0449 is less effective compared to LDE225 or HhA, which have the capacity to trigger 
antiproliferative effects and to induce apoptosis that is dependent on the cell line and the applied 
drug concentration. 
6.1.3 Effects on PI3K/AKT/mTOR signaling, on AMPK activity and on 
LC3-II expression  
It is known that HH signaling can influence the activation status of PI3K/AKT signaling (Fu et 
al., 2006; Morton et al., 2007; Riobo et al., 2006), the activity of mTOR(Wang et al., 2012) and 
can inhibit autophagy (Jimenez-Sanchez et al., 2012). Moreover, HH inhibitors can impact on a 
noncanonical SMO/Ca
2+
/AMPK dependent signaling cascade (Teperino et al., 2012). Due to 
these data, the impact of the four SMO inhibitors on the phosphorylation status of AKT and 
AMPK was investigated. Analysis of the phosphorylation status of S6 served as surrogate 
readout for mTOR activity. For analysis of caspase 3 activity an antibody was used, that detects 
the inactive preform (35 kDa) of caspase 3 as well as its activated cleavage products (19 and 17 
kDa). Autophagy was examined by the expression levels of the cytosolic LC3-I (16 kDa) and the 
LC3-II (14 kDa). LC3-II is the lipidated form of LC3-I and specifically associates with 
autophagosome membranes and thus reflects autophagosome numbers (Mizushima et al., 2010). 
In the following the most important and clear-cut results from at least two independent western 
blot analyses are summarized. 
In RD cells, GDC-0449, LDE225 and cyclopamine did not modulate the phosphorylation status 
of AKT or S6 in comparison to the solvent (Figure 13 A). In contrast, incubation with HhA 
decreased AKT/pAKT levels, whereas cyclopamine rather increased it. An induction of AMPK 
phosphorylation was observed with 30 μM GDC-0449 and with 10 and 30 μM LDE225. Activity 
of caspase 3 was induced by 30 μM LDE225 (indicated by an increase of cleaved caspase 3 
levels) as well as autophagy. Increased LC3-II levels were also seen by treatment with HhA and 
cyclopamine at any concentration (Figure 13 A). In RUCH-2 cells and similar to RD cells, HhA 
reduced AKT/pAKT levels, 30 μM LDE225 induced caspase 3 activity and autophagy (Figure 
13 B). Additionally, 30 μM LDE225 reduced pAMPK phosphorylation. An increase in LC3-II 




found for 30 μM LDE225 on caspase 3 activation and on LC3-II levels (Figure 13 C). LC3-II 
was also increased by 30 μM HhA and by cyclopamine at any concentration. In Rh41 cells 
GDC-0449 and HhA did not exert any obvious effects (Figure 13 D). Activation of caspase 3 and 
increased LC3-II levels were detected upon treatment with 30 µM LDE225. An increase in 
LC3-II was also seen after treatment of Rh41 cells with cyclopamine. 
 
Figure 13: Impact of SMO antagonists on PI3K/AKT/mTOR signaling, phosphorylation of AMPK and 
LC3-II protein levels. Western blot analysis of RD (A), RUCH-2 (B), RMS-13 (C) and Rh41 (D) cells after 
incubation for 48 h with GDC-0449, LDE225, HhA and cyclopamine (cp) at the indicated concentrations. HSC70 
















































































Again, these data demonstrate that SMO inhibitors exert highly diverse effects on the above 
mentioned parameters and that the response of the cell lines is very heterogeneous. Whereas 
GDC-0449 hardly triggered any effects, 30 µM LDE225 activated caspase 3 and autophagy in all 
cell lines and cyclopamine usually induced pAKT and activated autophagy. HhA inhibited 
pAKT expression in ERMS cells and increased LC3-II levels (Figure 13 A, B), whereas these 
effects are variable in ARMS cells (Figure 13 C, D). Interestingly, HhA did not stimulate 
caspase 3 activation in any of the RMS cell lines although AnnexinV positive cells were 
increased upon HhA treatment (Figure 12). This may indicate a caspase 3 independent apoptosis 
mechanism for HhA.  
 
In addition to the western blot analyses of human RMS cell lines, the effects of SMO antagonists 
were also investigated in murine primary RMS cells, which were isolated from RMS bearing 
Ptch
+/–
 mice (as described in chapter 5.2.3) and incubated with 10 µM of each drug for 24 h.  
Similarly to human RMS cell lines, GDC-0449 did not impact on PI3K/Akt/mTOR signaling or 
Lc3-II expression (Figure 14). Treatment with LDE225 induced pAmpk/Ampk, comparable to 
the findings in RD cells (Figure 13 A). Analogue to human ERMS cells, HhA reduced pAkt/Akt 
and induced Lc3-II (compare Figure 13 A, B with Figure 14). HhA additionally decreased the 
protein level of Igf2. Furthermore and corresponding to the analyzed human cell lines (Figure 
13), cyclopamine stimulated autophagy in primary murine RMS cells (Figure 14).  
Together these data demonstrate that SMO inhibitors also exert heterogeneous effects in primary 



















Figure 14: Impact of SMO antagonists on PI3K/Akt/mTOR signaling, phosphorylation of Ampk and Lc3-II 
protein levels in murine primary RMS cells. Isolated primary RMS cells were incubated for 24 h with 10 µM 
GDC-0449, LDE225, HhA or cyclopamine (cp) and analyzed by western blot. Hsc70 expression levels served as 
loading control. The data represent the results from one experiment. solv, solvent. 
The findings that HhA reduced phosphorylation of AKT in the human ERMS cell lines RD and 
RUCH-2 (Figure 13 A, B) as well as in murine primary RMS cells (Figure 14) suggests that 
SMO potentially regulates AKT phosphorylation in ERMS subtypes. In order to verify the 
speculation that SMO might control AKT phosphorylation, RD cells were incubated with the 
SMO agonist (SAG).  
As revealed by western blot analysis phosphorylation of AKT was increased by 100 nM and 
1 µM SAG (Figure 15 A), which was suppressed when the cells were concomitantly incubated 
with HhA. This indicates that HhA indeed regulates AKT phosphorylation at the level of SMO. 
Phosphorylation of S6 was marginally reduced after treatment with 10 µM HhA plus 1 µM SAG. 
IGF2 was slightly reduced by 10 µM HhA, but its expression was strongly stimulated by 100 nM 
SAG, verifying that IGF2 is a downstream target of HH signaling. Combination of HhA and 
SAG resulted in a decrease in IGF2 levels compared to the control at any concentration. 
Induction of autophagy was observed after incubation with HhA and also with 1 µM SAG. The 
latter drugs apparently cooperated in LC3-II induction as demonstrated when both were 
combined (10 µM HhA plus 1 µM SAG, Figure 15 A). There were no detectable differences in 














































of SAG on HH pathway activation was analyzed via GLI1 specific qRT-PCR (Figure 15 B). 
However, SAG did not stimulate HH signaling activity at any concentration.  
 
Together, these findings indicate that SMO might be involved in pAKT regulation, although this 
seems to be independent of GLI1 expression. However, these results are preliminary and the 
respective experiments have to be repeated in the future.  
 
 
Figure 15: Effects of SMO activation by SAG on PI3K/AKT/mTOR signaling, IGF2 and autophagy as well as 
on HH signaling activity. (A) Western blot analysis of RD cells after incubation for 48 h with HhA and/or SAG at 
the indicated concentrations. ß-Actin expression levels served as loading control. (B) Relative GLI1 expression in 
RD cells after incubation (24 h) with SAG at the indicated concentrations. Gene expression was measured in 
triplicates and normalized to 18S rRNA expression. The corresponding solvent control (solv) was set to 1 and the 



















































































































6.2 Effects of SMO antagonists in combination with 
PI3K/AKT/mTOR inhibitors on RMS cell lines 
The second part of this thesis focused on the combination of SMO antagonists with inhibitors of 
the PI3K/AKT/mTOR pathway in order to improve potential anticancer effects.  
Indeed, the combination of the dual PI3K/mTOR inhibitor PI103 with DOX, that is applied in 
the therapy of RMS, significantly enhanced apoptosis in RD, RMS-13 and Rh41 cells when 
compared to single drug treatments (Figure 16). 
 
 
Figure 16: Cooperative effects on apoptosis upon treatment with a PI3K/mTOR inhibitor plus DOX. RD, 
RMS-13 and Rh41 cells were incubated for 24 h with 1 µM DOX and/or 3 µM PI103. Apoptotic cells are illustrated 
as AnnexinV positive cells in percent. The data represent two independent experiments for RD and one experiment 
each for RMS-13 and Rh41 and are displayed as mean +/-SEM; *, p<0.05; compared to solvent; #, p < 0.05 
compared to cells treated with either drug alone. Comparisons were made with ANOVA/Tukey’s testing. 
Because i) PI3K/AKT/mTOR inhibition has antitumoral effects by itself (e.g. induced apoptosis 
in several RMS cells lines; Figure 16), ii) PI3K/AKT/mTOR inhibitors cooperate with other 
drugs in the induction of antitumoral effects (i.e. PI103 cooperated with DOX in induction of 
apoptosis; Figure 16) and iii) PI3K/AKT/mTOR signaling cooperates with HH signaling in 
tumor formation (see 2.7), SMO antagonists were combined with PI3K/AKT/mTOR inhibitors 
and the effects on the respective signaling pathways, proliferation, apoptosis, muscle 
differentiation, on AMPK activation and on autophagy were investigated. In order to block 












































































































GDC-0941, the pure AKT inhibitor MK-2206 and the mTOR inhibitors everolimus and 
rapamycin were applied (see Figure 4).  
6.2.1 Proapoptotic effects in RD cells 
Initially, it was analyzed whether potential cooperative antitumor effects of PI3K/AKT/mTOR 
inhibitors plus SMO inhibitors are influenced by the concentration of the latter drugs. For that 
purpose, low (10 µM) and high (30 µM) concentrations of the corresponding SMO antagonists 
were applied and apoptosis was measured by FACS exemplarily in the ERMS cell line RD. 
A significant induction of apoptosis was revealed after treatment with PI103 and GDC-0941 
(approximately up to 12 % and 8 % respectively), whereas MK-2206, everolimus and rapamycin 
had no effect (Figure 17).  
As described before (see Figure 12 A) neither 10 µM nor 30 µM GDC-0449 stimulated apoptosis 
(Figure 17 A). The combination of 10 µM GDC-0449 plus GDC-0941 or rapamycin significantly 
strengthened the apoptosis rate compared to the single drug treatments. Cooperative proapoptotic 
effects were also observed for 30 µM GDC-0449 plus MK-2206 or rapamycin (Figure 17 A). 
Treatment with 10 µM LDE225 did not trigger apoptosis, whereas 30 µM strongly induced it 
compared to solvent control (Figure 17 B). Cooperative proapoptotic effects were observed for 
30 µM LDE225 plus PI103 or plus GDC-0941. 
As already shown in Figure 12 A, 30 µM HhA increased the number of AnnexinV positive cells 
(Figure 17 C). Cooperative proapoptotic effects were revealed for the combination of 10 µM 
HhA plus PI103 and GDC-0941, whereas an enormous induction of apoptosis was achieved by 
10 µM or 30 µM HhA plus MK-2206 (up to 45 % and 68 %, respectively). 
Single treatment with 10 µM cyclopamine only marginally induced apoptosis (Figure 17 D). 
Cooperative proapoptotic effects were detected for 5 and 10 µM cyclopamine plus GDC-0941 or 
MK-2206. 
 
Together, the data demonstrate that SMO antagonists in combination with PI3K/AKT/mTOR 
inhibitors cause different effects on apoptosis in RD cells. In the following experiments 10 µM 
concentrations of GDC-0449, LDE225 and HhA were used. This was done due to the fact that 
10 µM GDC-0449, 10 µM HhA or 5 µM cyclopamine were in generally as potent as the 
respective higher concentration (exception was 30 µM HhA plus MK-2206) and that the 
apoptosis induction using 30 µM LDE225 was extremely high (i.e. at that concentration potential 





Figure 17: Regulation of apoptosis by SMO antagonists and/or PI3K/AKT/mTOR inhibitors. RD cells were 
incubated (48 h) with 10 µM or 30 µM GDC-0449 (A), LDE225 (B), HhA (C), 5 µM or 10 µM cyclopamine (D) 
and/or 3 µM PI103, 10 µM GDC-0941, 5 µM MK-2206, 50 nM everolimus (everol), 100 nM rapamycin (rapa). 
Apoptotic cells are illustrated as AnnexinV positive cells in percent. All data represent at least two independent 
experiments and were displayed as mean +/-SEM; *, p<0.05; **, p<0.01; ***, p<0.001 compared to the solvent 







































































































+ 10 µM GDC-0449
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+ 10 µM HhA



































































































+ 5 µM cyclopamine









6.2.2 Effects on PI3K/AKT/mTOR signaling, on AMPK activity and on 
LC3-II protein levels in RD cells 
Protein analysis of RD cells after treatment with low doses of SMO antagonists (10 µM) plus 
PI3K/AKT/mTOR inhibitors revealed that, as expected, single incubation with PI103, 
GDC-0941 and MK-2206 inhibited phosphorylation of AKT (Figure 18). Interestingly, the 
mTOR inhibitors everolimus and rapamycin stimulated phosphorylation of AKT. The activity of 
mTOR was repressed by everolimus and rapamycin as well as by PI103 and GDC-0941 
(revealed by a decrease in pS6). In contrast, MK-2206 did not modulate the pS6 protein level. In 
addition, pAMPK/AMPK levels were not regulated by the compounds. The exception was PI103 
which slightly decreased it. Caspase 3 was activated by PI103 and to a lesser extent by 
GDC-0941 and MK-2206. Induction of LC3-II was observed by all PI3K/AKT/mTOR inhibitors 
however to a variable range. The most pronounced increase in LC3-II was seen with PI103, 
GDC-0941 and MK-2206 (Figure 18).  
 
 
Figure 18: Effects of GDC-0449 and/or PI3K/AKT/mTOR inhibitors on PI3K/AKT/mTOR signaling, 
phosphorylation status of AMPK and LC3-II protein levels. Western blot analysis of RD cells incubated for 48 h 
with 10 µM GDC-0449, 3 µM PI103, 10 µM GDC-0941, 5 µM MK-2206, 50 nM everolimus (everol), 100 nM 
rapamycin (rapa) and with the drug combination as indicated. HSC70 expression levels served as loading control. 






















































































The combination of PI3K/AKT/mTOR inhibitors with GDC-0449 in RD cells (Figure 18) did 
not alter the analyzed protein levels compared to the drugs alone and hence provided no 
improvement over the single drug treatment. It rather seemed that the active caspase 3 levels 
induced by PI103, GDC-0941 and MK-2206 were reduced in combination with GDC-0449.  
 
Incubation with 10 µM LDE225 in combination with PI3K/AKT/mTOR inhibitors did not 
markedly alter the analyzed parameters, i.e. no cooperative effects were observed (Figure 19). 
However, similarly to GDC-0449, caspase 3 activity induced by PI103, GDC-0941 and 
MK-2206 seemed to be slightly decreased in combination with LDE225.  
 
 
Figure 19: Effects of LDE225 and/or PI3K/AKT/mTOR inhibitors on PI3K/AKT/mTOR signaling 
phosphorylation status of AMPK and LC3-II protein levels. Western blot analysis of RD cells incubated for 48 h 
with 10 µM LDE225, 3 µM PI103, 10 µM GDC-0941, 5 µM MK-2206, 50 nM everolimus (everol), 100 nM 
rapamycin (rapa) and with the combination as indicated. HSC70 expression levels served as loading control. The 
data represent the results from one experiment. solv, solvent. 
In contrast to GDC-0449 and LDE225, the combination of HhA plus everolimus and rapamycin 
resulted in reduction of pAKT comparable to solvent levels and a slight decrease of AMPK 
phosphorylation was observed when combining HhA plus PI103, GDC-0941 or MK-2206 



















































































However it strongly enhanced MK-2206 induced caspase 3 activity. These findings correspond 
to the data of the apoptosis assay, in which combination of 10 µM HhA and MK-2206 strongly 
increased the number of AnnexinV positive cells compared to the single drug treatments (Figure 
17 C). HhA also cooperated with all drugs in the induction of LC3-II protein levels, which was 
in contrast to GDC-0449 and LDE225. It should be noted that the latter western blot analyses are 
preliminary. Thus, the respective experiments have to be repeated in the future. 
 
 
Figure 20: Effects of HhA and/or PI3K/AKT/mTOR inhibitors on PI3K/AKT/mTOR signaling, 
phosphorylation status of AMPK and LC3-II protein levels. Western blot analysis of RD cells incubated for 48 h 
with 10 µM HhA, 3 µM PI103, 10 µM GDC-0941, 5 µM MK-2206, 50 nM everolimus (everol), 100 nM rapamycin 
(rapa) and with the drug combination as indicated. HSC70 expression levels served as loading control. The data 
represent the results from one experiment. solv, solvent. 
In conclusion, the data suggest that HhA is the most efficient compound for combination therapy 
with PI3K/AKT/mTOR inhibitors. This assumption is based on its cooperative proapoptotic 
effects with several of the used inhibitors (especially seen for the combination HhA plus 
MK-2206, Figure 17 C, Figure 20). HhA also exerted combination effects that could be of 
relevance in antitumor therapies e.g. it reversed the phosphorylation of AKT mediated by mTOR 
inhibitors and reduced AMPK phosphorylation when combined with PI103, GDC-0941 or 
MK-2206 (Figure 20). In addition as a single drug HhA showed antiproliferative and 

















































































the effects of HhA plus PI3K/AKT/mTOR inhibitors were studied in more detail and in 
additional human RMS cell lines.  
6.2.3 Effects of HhA plus PI3K/AKT/mTOR inhibitors in RD, RUCH-2, 
RMS-13 and Rh41 cells 
The following investigations focused on possible cooperative effects of the SMO antagonist 
HhA in combination with PI3K/AKT/mTOR inhibitors in different RMS cells. Since 30 µM 
HhA showed more potency to reduce cellular proliferation and to induce apoptosis in all RMS 
cell lines than compared to 10 µM HhA, the higher dose was used for the next investigations. 
6.2.3.1 Effects on HH signaling activity, IGF2 expression and muscle differentiation 
markers  
In RD cells 30 µM HhA significantly inhibited HH signaling activity. HH signaling inhibition 
was also seen for all used PI3K/AKT/mTOR inhibitors (Figure 21 A). In combination with 
PI103 or rapamycin HhA showed a cooperative effect on GLI1 expression compared to the 
corresponding single drug treatments. Paradoxically, GLI1 expression was significantly 
increased when HhA was combined with MK-2206.  
In contrast to RD cells, single treatment with HhA did not significantly reduced HH signaling 
activity in RUCH-2 cells. However, similar to RD cells all PI3K/AKT/mTOR inhibitors 
deceased GLI1 expression in RUCH-2 cells (Figure 21 B). The strongest reduction was revealed 
with GDC-0941, which was similar to RD cells. However, cooperative effects on GLI1 
repression were not observed when HhA was combined with PI3K/AKT/mTOR inhibitors 
(Figure 21 B). 
In RMS-13 cells GLI1 transcription was reduced by PI103, GDC-0941, MK-2206 and 
rapamycin, whereas HhA and everolimus had no effect (Figure 21 C). Cooperative effects on 
GLI1 expression were not revealed.  
Analysis of Rh41 cells showed that PI103 and GDC-0941 inhibited HH signaling activity, 
whereas MK-2206 and the mTOR inhibitors did not (Figure 21 D). In this cell line HhA 
paradoxically increased GLI1 expression. Similar to RUCH-2 and RMS-13 cells, cooperative 






Figure 21: Modulation of HH signaling activity by HhA and/or PI3K/AKT/mTOR inhibitors. Relative GLI1 
expression in RD (A), RUCH-2 (B), RMS-13 (C) and Rh41 (D) cells after incubation (24 h) with 30 µM HhA, 3 µM 
PI103 (200 nM for Rh41), 10 µM GDC-0941 (500 nM for Rh41), 5 µM MK-2206 (1 µM for RMS-13, Rh41), 
50 nM everolimus (everol), 100 nM rapamycin (rapa) or in combination as indicated. GLI1 expression was 
normalized to 18S rRNA expression levels. The corresponding solvent controls (solv) were set to 1. The data 
represent three independent experiments for RD, two for RMS-13 and one experiment for RUCH-2 and Rh41 cells. 
The data are displayed as mean +/-SEM; *, p<0.05; **, p<0.01; ***, p<0.001 compared to the solvent; #, p<0.05 
compared to cells treated with either drug alone. Comparisons were made with ANOVA/Tukey’s testing. 
In RD cells IGF2 expression was inhibited upon single drug treatment using HhA, PI103 and 
GDC-0941, whereas MK-2206 had no effect (Figure 22 A). In contrast, the mTOR inhibitors 
everolimus and rapamycin induced the expression of IGF2. Combinations with HhA did not 
significantly enhance these effects compared to single drug incubations, except for the 
























































































































































































































































































































RUCH-2 did not express IGF2, its transcription was not analyzed. In RMS-13 cells IGF2 
expression was inhibited by GDC-0941 and MK-2206 and induced by everolimus (Figure 22 B). 
Cooperative effects were not achieved. In Rh41 cells only PI103 inhibited IGF2 transcription 
(Figure 22 C). Similar to RD cells IGF2 expression was stimulated by rapamycin. Even though 
there were no significant cooperative effects, the combination of HhA with PI3K/AKT/mTOR 
inhibitors seemed to slightly suppress IGF2 expression compared to the single drug treatments. 
 
Figure 22: Modulation of IGF2 transcription by HhA and/or PI3K/AKT/mTOR inhibitors. Relative IGF2 
expression in RD (A), RMS-13 (B) and Rh41 (C) cells after incubation (24 h) with 30 µM HhA, 3 µM PI103 
(200 nM for Rh41), 10 µM GDC-0941 (500 nM for Rh41), 5 µM MK-2206 (1 µM for RMS-13, Rh41), 50 nM 
everolimus (everol), 100 nM rapamycin (rapa) or in combination as indicated. IGF2 expression was normalized to 
18S rRNA expression levels. The corresponding solvent controls (solv) were set to 1. The data represent three 
independent experiments for RD, two for RMS-13 and one experiment for Rh41 cells. The data are displayed as 
mean +/-SEM; *, p<0.05; **, p<0.01; ***, p<0.001 compared to the solvent; #, p<0.05 compared to cells treated 












































































































































































































































Because RUCH-2 cells neither expressed MYOD nor MYH1, expression analyses of these genes 
was not possible.  
The expression of MYOD in RD cells was not altered by MK-2206 and mTOR inhibitors (Figure 
23 A). However, MYOD expression was significantly decreased by single incubation with PI103 
and GDC-0941. The combination with HhA that itself decreased MYOD expression, did not 
further promote these effects compared to single drug treatment. The exception was the 
combination HhA plus GDC-0941, which significantly enhanced MYOD transcription above the 
respective single drug levels (Figure 23 A). In RMS-13 cells no significant effects on MYOD 
transcription were observed for any of the drugs or drug combinations (Figure 23 B). In Rh41 
cells MYOD expression was decreased by everolimus and increased by GDC-0941 and MK-2206 
(Figure 23 C). Again no cooperative effects were determined. 
 
In RD cells the expression of MYH1 was inhibited by all drugs (Figure 24 A). Thus, PI103, 
GDC-0941 and MK-2206 reduced MYH1 expression by approximately 85 % compared to the 
solvent. These effects were not further enhanced upon addition of HhA. In RMS-13 MYH1 
transcription was inhibited by HhA, PI103 and GDC-0941 (Figure 24 B). In contrast, MK-2206 
and everolimus slightly induced MYH1 expression while rapamycin had no effect. Interestingly, 
the combination of HhA plus MK-2206 almost completely blocked MYH1 expression and 
significantly cooperated in this suppression. No other cooperative effects were observed (Figure 
24 B). In Rh41 cells a significant inhibition of MYH1 expression was seen after single treatment 
with HhA or by the combination HhA plus MK-2206 (Figure 24 C), however without any 













Figure 23: Modulation of MYOD transcription by HhA and/or PI3K/AKT/mTOR inhibitors. Relative MYOD 
expression in RD (A), RMS-13 (B) and Rh41 (C) cells after incubation (24 h) with 30 µM HhA, 3 µM PI103 
(200 nM for Rh41), 10 µM GDC-0941 (500 nM for Rh41), 5 µM MK-2206 (1 µM for RMS-13, Rh41), 50 nM 
everolimus (everol), 100 nM rapamycin (rapa) or in combination as indicated. MYOD expression was normalized to 
18S rRNA expression levels. The corresponding solvent controls (solv) were set to 1. The data represent three 
independent experiments for RD, two for RMS-13 and one experiment for Rh41 cells. The data are displayed as 
mean +/-SEM; *, p<0.05; ***, p<0.001 compared to the solvent; #, p<0.05 compared to cells treated with either 












































































































































































































































Figure 24: Modulation of MYH1 transcription by HhA and/or PI3K/AKT/mTOR inhibitors. Relative MYH1 
expression in RD (A), RMS-13 (B) and Rh41 (C) cells after incubation (24 h) with 30 µM HhA, 3 µM PI103 
(200 nM for Rh41), 10 µM GDC-0941 (500 nM for Rh41), 5 µM MK-2206 (1 µM for RMS-13, Rh41), 50 nM 
everolimus (everol), 100 nM rapamycin (rapa) or in combination as indicated. MYH1 expression was normalized to 
18S rRNA expression levels. The corresponding solvent controls (solv) were set to 1. The data represent three 
independent experiments for RD, two for RMS-13 and one experiment for Rh41 cells. The data are displayed as 
mean +/-SEM; *, p<0.05; **, p<0.01; ***, p<0.001 compared to the solvent; #, p<0.05 compared to cells treated 
with either drug alone. Comparisons were made with ANOVA/Tukey’s testing. 
Together, the data show that the PI3K/AKT/mTOR inhibitors can decrease HH signaling 
activity, and that the strongest inhibition of GLI1 expression is mediated by GDC-0941 in almost 
all RMS cell lines (Figure 21). Indeed, GDC-0941 seems to have more potency to block GLI1 
transcription than the HH inhibitor HhA (according to the used concentrations). GDC-0941 also 









































































































































































































































the data demonstrate that mTOR inhibitors can induce IGF2 transcription in all three analyzed 
cell lines (Figure 22). Furthermore, all used inhibitors have the potency to modulate muscle 
differentiation, which however again is depended on the used cell line. Since the respective gene 
expressions in RUCH-2 and Rh41 cells were only measured once, the data should be judged with 
caution and the experiments have to be repeated in the future (see respective figure legends). 
6.2.3.2 Effects on proliferation and apoptosis 
In RD cells single drug treatment with HhA, PI103 and GDC-0941 significantly reduced the 
proliferation rate by 35 %, 20 % and 25 %, respectively (Figure 25 A). In contrast and 
surprisingly, MK-2206 and both mTOR inhibitors significantly increased the proliferation rate of 
RD cells. However, when the latter drugs were combined with HhA, proliferation levels went 
down to HhA induced levels and a cooperative antiproliferative effect was detected for the 
combination of HhA plus MK-2206. Such a cooperative antiproliferative effect was also seen for 
the combination of HhA plus GDC-0941. 
Similar to RD cells single drug treatment using HhA, PI103 or GDC-0941 significantly inhibited 
cellular proliferation of RUCH-2 cells, whereas MK-2206, everolimus and rapamycin did not 
(Figure 25 B). Again the combination HhA plus GDC-0941 or MK-2206 strongly inhibited 
proliferation by 75 % and 80 %, respectively, which was significant compared to the single drug 
treatments. 
In RMS-13 cells significant antiproliferative effects were revealed with HhA, PI103 and 
GDC-0941 (Figure 25 C). In contrast everolimus did not impact on proliferation, whereas 
MK-2206 and rapamycin increased the proliferation rate. When the latter drugs were combined 
with HhA, proliferation rates went down to HhA induced levels. A cooperative antiproliferative 
effect was detected when HhA was combined with PI103. Otherwise no cooperative effects were 
obvious. 
In Rh41 cells HhA, PI103, GDC-0941 and also MK-2206 inhibited proliferation, while mTOR 
inhibitors did not (Figure 25 D). In this cell line cooperative antiproliferative effects were 







Figure 25: Modulation of proliferation by HhA and/or PI3K/AKT/mTOR inhibitors. Measurement of BrdU 
incorporation in RD (A), RUCH-2 (B), RMS-13 (C) and Rh41 (D) cells after incubation (24 h) with 30 µM HhA, 
3 µM PI103 (200 nM for Rh41), 10 µM GDC-0941 (500 nM for Rh41), 5 µM MK-2206 (1 µM for RMS-13, Rh41), 
50 nM everolimus (everol), 100 nM rapamycin (rapa) or in combination as indicated. BrdU incorporation is 
presented as percentage of respective solvent controls (solv) that were set to 100 %. The data shown summarize at 
least three independent experiments and are represented as mean +/-SEM; *, p<0.05; **, p<0.01; ***, p<0.001 
compared to the solvent; #, p<0.05 compared to cells treated with either drug alone. Comparisons were made with 
ANOVA/Tukey’s testing. 
Subsequently the impact of HhA plus PI3K/AKT/mTOR inhibitors was compared concerning 
their potential to induce apoptosis. As already shown in Figure 17 C, in RD cells single drug 
treatment using HhA, PI103 and GDC-0941 significantly increased the number of AnnexinV 
positive cells (Figure 26 A). A significant cooperative proapoptotic effect was observed for HhA 


























































































































































































































































































































whereas MK-2206, everolimus and rapamycin had no proapoptotic effect (Figure 26 B). A 
significant increase in AnnexinV positive cells compared to the single drug treatments was 
revealed by the combinations HhA plus PI103, HhA plus GDC-0941 or plus MK-2206. In Rh41 
cells a stimulation of apoptosis was caused by HhA, PI103, GDC-0941 and MK-2206 (Figure 26 
C). Similar to the other RMS cell lines the mTOR inhibitors did not activate apoptosis. However, 
a significant cooperative proapoptotic effect of HhA with the other drugs was not observed in 
Rh41 cells. 
 
Figure 26: Modulation of apoptosis by HhA and/or PI3K/AKT/mTOR inhibitors. RD (A), RMS-13 (B) and 
Rh41 (C) cells were incubated for 48 h with 30 µM HhA, 3 µM PI103 (200 nM for Rh41), 10 µM GDC-0941 
(500 nM for Rh41), 5 µM MK-2206 (1 µM for RMS-13, Rh41), 50 nM everolimus (everol), 100 nM rapamycin 
(rapa) or in combination as indicated. Apoptotic cells are illustrated as AnnexinV positive cells in percent. All data 
represent at least three independent experiments measured in duplicates and were displayed as mean +/-SEM; *, 
p<0.05; **, p<0.01; ***, p<0.001 compared to the solvent (solv); #, p<0.05 compared to cells treated with either 

































































































































































































































































Together these data demonstrate that a single drug treatment using HhA, PI103 or GDC-0941 
inhibits proliferation of the cell lines used in this study (Figure 25) and induces proapoptotic 
effects (Figure 26). In contrast, mTOR inhibitors increase the proliferation rate of almost all cell 
lines and do not modulate apoptosis. Moreover, substantial cooperative antiproliferative effects 
are induced by the combination of HhA plus PI103, HhA plus GDC-0941 or HhA plus MK-2206 
in almost all cell lines. In addition, the combination HhA plus MK-2206 strongly induces 
apoptosis in RD cells (Figure 26 A) and cooperative proapoptotic effects are observed for HhA 
plus PI103 or GDC-0941 in RMS-13 cells (Figure 26 B). 
6.2.3.3 Effects on PI3K/AKT/mTOR signaling, on AMPK activity and on LC3-II 
expression 
As observed before in RD cells (see 6.2.2) PI103, GDC-0941 and MK-2206 also inhibited 
phosphorylation of AKT in all other RMS cell lines (Figure 28, Figure 29, Figure 30). 
Phosphorylation of S6 was repressed by the mTOR inhibitors everolimus and rapamycin and by 
PI103 and GDC-0941.  
In RD cells single drug treatment with 30 µM HhA increased LC3-II expression (Figure 27). 
This has also been shown for 10 µM HhA (Figure 20 in section 6.2.2). However, the effects of 
30 µM HhA on inhibition of pAKT were more pronounced and 30 µM HhA additionally reduced 
pAMPK and pS6 levels in contrast to 10 µM HhA (Figure 27). Although single treatments with 
everolimus or rapamycin induced pAKT levels, the combination with 30 µM HhA reduced it and 
this effect was stronger than that observed upon combination with 10 µM HhA. Moreover, 
30 µM HhA plus MK-2206 inhibited S6 phosphorylation in contrast to 10 µM HhA. 
Additionally, 30 µM HhA in combination with GDC-0941 or MK-2206 also reduced pAMPK 
levels more potently than 10 µM HhA. Treatment with 30 µM HhA plus MK-2206 resulted in an 
enormous increase of caspase 3 activity, which confirmed the results from the AnnexinV 
experiments (Figure 17 C). This effect was also stronger than upon combination of MK-2206 
with 10 µM HhA (Figure 20 in section 6.2.2). Similar to 10 µM HhA, the combinations of 
30 µM HhA with any drug resulted in an increase in LC3-II levels compared to incubations with 











Figure 27: Effects of HhA and/or PI3K/AKT/mTOR inhibitors on PI3K/AKT/mTOR signaling, 
phosphorylation status of AMPK and LC3-II protein levels in RD cells. Western blot analysis of RD cells 
incubated for 48 h with 30 µM HhA, 3 µM PI103, 10 µM GDC-0941, 5 µM MK-2206, 50 nM everolimus (everol), 
100 nM rapamycin (rapa) and with the drug combination as indicated. HSC70 expression levels served as loading 
control. Representative blots of two independent experiments are shown. solv, solvent. 
In RUCH-2 cells (Figure 28) the effects of the drugs were similar as in RD cells. The exceptions 
were everolimus and rapamycin which did not activate AKT. Moreover phosphorylation of S6 
was not inhibited by HhA in RUCH-2 cells and activation of caspase 3 by PI103 was not 
observed. Furthermore HhA plus MK-2206 did not block phosphorylation of S6. Activation of 
caspase 3 was induced by the combination of HhA plus PI103 or plus GDC-0941. This was in 
contrast to RD cells, in which activation of caspase 3 was revealed only by the combination HhA 
plus MK-2206 (Figure 27). Cooperative effects of HhA plus GDC-0941 or HhA plus MK-2206 
with respect to inhibition of AMPK phosphorylation was not observed in RUCH-2 cells. The 
combinations of HhA with PI103, GDC-0941, everolimus or rapamycin resulted in increased 

























































































Figure 28: Effects of HhA and/or PI3K/AKT/mTOR inhibitors on PI3K/AKT/mTOR signaling, 
phosphorylation status of AMPK and LC3-II protein levels in RUCH-2 cells. Western blot analysis of RUCH-2 
cells incubated for 48 h with 30 µM HhA, 3 µM PI103, 10 µM GDC-0941, 5 µM MK-2206, 50 nM everolimus 
(everol), 100 nM rapamycin (rapa) and with the drug combination as indicated. HSC70 expression levels served as 
loading control. The data represent the results from one experiment. solv, solvent. 
In the ARMS cell line RMS-13 (Figure 29) the effects of the drugs were more heterogeneous 
than in ERMS cells. Main differences to the ERMS cell lines (Figure 27, Figure 28) was the lack 
of inhibition of AKT phosphorylation by HhA and the moderate stimulation of AMPK 
phosphorylation upon treatment with HhA, PI103, GDC-0941, MK-2206 or everolimus (Figure 
29). Furthermore, the incubation with PI103 and GDC-0941 strongly activated caspase 3. Active 
caspase 3 levels induced by PI103 and GDC-0941 were repressed in combination with HhA 
compared to single drug treatments. Another difference was that the combination HhA plus 
MK-2206 repressed pS6/S6 as well as pAMPK/AMPK protein levels. The combination 
treatment of HhA plus mTOR inhibitors slightly increased LC3-II levels compared to the 
respective single drug incubations. Similar to the results in ERMS cells, LC3-II levels were 
enhanced upon treatment with HhA, GDC-0941 and MK-2206. In addition, combination of HhA 





















































































Figure 29: Effects of HhA and/or PI3K/AKT/mTOR inhibitors on PI3K/AKT/mTOR signaling, 
phosphorylation status of AMPK and LC3-II protein levels in RMS-13 cells. Western blot analysis of RMS-13 
cells incubated for 48 h with 30 µM HhA, 3 µM PI103, 10 µM GDC-0941, 1 µM MK-2206, 50 nM everolimus 
(everol), 100 nM rapamycin (rapa) and with the drug combination as indicated. HSC70 expression levels served as 
loading control. The data represent the results from one experiment. solv, solvent. 
In the ARMS cell line Rh41, HhA stimulated phosphorylation of AKT (Figure 30). Similar 
effects were seen with both mTOR inhibitors. Single treatment with MK-2206 decreased S6 
phosphorylation and increased active caspase 3 in contrast to all other RMS cell lines. LC3-II 
was induced only by HhA and MK-2206. As in the other cell lines a reduction of pAKT was 
observed when combining HhA with mTOR inhibitors. In addition, increase in activated 


























































































Figure 30: Effects of HhA and/or PI3K/AKT/mTOR inhibitors on PI3K/AKT/mTOR signaling, 
phosphorylation status of AMPK and LC3-II protein levels Rh41cells. Western blot analysis of Rh41 cells 
incubated for 48 h with 30 µM HhA, 200 nM PI103, 500 nM GDC-0941, 1 µM MK-2206, 50 nM everolimus 
(everol), 100 nM rapamycin (rapa) and with the drug combination as indicated. HSC70 expression levels served as 
loading control. The data represent the results from one experiment. solv, solvent. 
In summary, the data show that the combination of HhA plus PI3K/AKT/mTOR inhibitors 
induces variable effects among the analyzed RMS cell lines. In general the effects of the drugs 
are more heterogeneous in ARMS than in ERMS. Phosphorylation of AKT, which is increased 
or unaffected upon treatment with everolimus or rapamycin alone, is repressed upon combination 
with HhA in all RMS cell lines.  
Furthermore the combinations of HhA plus PI3K/AKT/mTOR inhibitors reduce pAMPK levels 
in RD cells, but induce it in RMS-13 and do not alter it in RUCH-2 cells. Cooperative effects on 
caspase 3 activation are triggered by HhA plus PI103, or HhA plus GDC-0941 in RUCH-2 
(Figure 28) and by HhA plus MK-2206 in RD (Figure 27) and RMS-13 (Figure 29). 
Paradoxically, the combination of HhA plus PI103 or HhA plus GDC-0941 results in a reduction 
of caspase 3 activity in RMS-13 cells (Figure 29), which is also revealed in Rh41 when HhA was 
combined with MK-2206 (Figure 30). Finally, the combination of HhA plus PI3K/AKT/mTOR 
inhibitors further strengthened the increase in LC3-II levels compared to the single drug 
treatments in ERMS. However, it should be emphasized that the latter results in RUCH-2, 


















































































6.3 In vivo effects of the SMO antagonist HhA plus PI3K inhibitor 
GDC-0941  
As described in section 6.2, the combination of HhA plus GDC-0941 intensifies several 
antitumoral effects in human RMS cell lines and results in a cooperative antiproliferative effect 
(Figure 25 A, B, D). In order to investigate whether these effects also occur in vivo, the drugs 
were applied to RMS bearing Ptch
+/–
 mice, which spontaneously develop RMS, that resemble 
the embryonal subtype in humans. Therefore, these mice are a perfect model for the preclinical 
evaluation of HH pathway antagonists and other drugs in the treatment of ERMS.  
6.3.1 Effect of HhA plus GDC-0941 on tumor growth in Ptch+/– mice 
RMS bearing mice were treated orally every day for five weeks with vehicle, 100 mg/kg HhA, 
75 mg/kg GDC-0941 or with the combination of both (as described in section 5.4.6). To 
calculate the tumor growth during treatment, the tumor volume was measured via VCT at the 
day of therapy onset, two weeks after therapy onset and at therapy end. 
As shown in Figure 31, the analysis revealed that in comparison to the control the single drug 
treatments with either HhA or GDC-0941 significantly inhibited the tumor growth at the end of 
the treatment. In addition, the data showed that the PI3K inhibitor GDC-0941 was more potent 
than HhA. Interestingly and similar to the in vitro situation, the combination of both drugs 
induced a cooperative antitumoral effect, which was already seen after two weeks. The tumor 
growth was thereby significantly decreased compared to the vehicle controls and to tumors that 
have been treated with HhA alone (Figure 31).  
In summary, the results suggest that HhA is a potential treatment option in RMS, especially in 














Figure 31: Cooperative antitumoral effect of HhA and/or GDC-0941 on RMS growth in vivo. Ptch+/– mice 
were treated orally for five weeks with a daily dose of 100 mg/kg HhA (n=6) and 75 mg/kg GDC-0941 (n=6) alone 
or in combination (n=9). Vehicle treated animals served as controls (n=6). Tumor size was measured by VCT. 
*, p<0.05; **, p<0.01 compared to tumors of vehicle treated mice; #, p<0.05 compared to tumors of mice treated 
with HhA. Multiple testing was done by the method of Tukey. 
6.3.2 Immunohistochemical analysis of the proliferation marker Ki67 
In order to analyze the proliferative capacity of the tumors from the four cohorts, paraffin 
sections were stained with an anti-Ki67 antibody (Figure 32 A). The calculation of Ki67 positive 
cells revealed that single drug treatment with either HhA or GDC-0941 significantly decreased 
the amount of Ki67 positive cells in the tumors by approximately 75 % compared to the control 
(Figure 32 B). However, the combination of both drugs did not result in a further reduction of 
Ki67 positive tumor cells. Thus, the cooperative effect of the drugs on tumor growth inhibition 
must be due to other antitumoral effects, e.g. possibly by induction of apoptosis (see Figure 28 
for combination effect on caspase 3 activation in RUCH-2). 
 









































Figure 32: Analysis of the proliferation marker Ki67 in tumors derived from in vivo treatment. Analysis of the 
proliferation marker Ki67 in tumors derived from in vivo treatment. (A) Ki67 stained paraffin embedded sections of 
tumors derived from Ptch+/– mice treated orally for five weeks with a daily dose of 100 mg/kg HhA (n=6) and 
75 mg/kg GDC-0941 (n=6) alone or in combination (n=9). Vehicle treated animals served as controls (n=6). (B) 
Calculated amount of Ki67 positive cells (in %) counted on Ki67 stained tumor sections from the in (A) described in 
vivo treatment. (C) Ki67 positive cells (in %) of tumors derived from Ptch+/– mice treated systemically over a period 
of four weeks with a daily dose of 20 mg/kg cyclopamine (cp) (n=3) or vehicle (n=4). The in vivo treatment of the 
tumors in (C) was done by Ines Ecke as described previously (Ecke et al., 2008). The data represented mean +/-
SEM; *, p<0.05 compared to the vehicle treatment. 
A vehicle HhA
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Ki67 stainings were also done on tumor samples of mice that have been treated with 
cyclopamine (Figure 32 C). As described by Ines Ecke from our group (Ecke et al., 2008), tumor 
bearing Ptch
+/–
 mice were treated systemically over four weeks with a daily dose of 20 mg/kg 
cyclopamine or vehicle. However, in this cohort the tumor volume was not reduced by 
cyclopamine treatment. Instead the tumor growth rather seemed to be increased compared to the 
vehicle treated mice (Ecke et al., 2008). These data indicate that in contrast to HhA and/or 
GDC-0941, cyclopamine does not exert any antiproliferative effect in vivo.  
Indeed, the analysis of the proliferation marker Ki67 in the tumor samples revealed, that 
cyclopamine does not reduce the number of Ki67 positive cells (Figure 32 C). This is in line with 
the in vitro data of this thesis, showing that cyclopamine either did not inhibit cellular 
proliferation (Figure 10 A, C) or induced it (Figure 10 B, D).  
 
Because the effective tumor growth inhibition upon HhA and/or GDC-0941 treatment was not 
associated with a decrease in Ki67 positive cells, it was intended to analyze the activity of 
PI3K/Akt/mTOR signaling and of Ampk and the expression of Lc3-II in the tumor samples. 
Unfortunately, the samples that have been treated with HhA and/or GDC-0941 were too small 
for RNA or protein isolation. Hence, in an alternative approach, cultured primary RMS cells 
isolated from Ptch
+/–
 mice were incubated with the substances in vitro. 
The findings revealed that single drug treatment with HhA reduced phosphorylation of Akt and 
slightly induced Lc3-II compared to the control (Figure 33). As expected, GDC-0941 also 
inhibited phosphorylation of Akt. Moreover GDC-0941 decreased phosphorylation of S6 and 
Ampk and slightly activated caspase 3. Furthermore, it increased the Lc3-II protein level, which 
was higher compared to that induced by HhA. When HhA and GDC-0941 were combined, the 
effects on the respective proteins were not different compared to GDC-0941, except for 
caspase 3 activation, which was slightly increased upon combination treatment. However, these 











Figure 33: Effects of HhA and/or GDC-0941 on PI3K/Akt/mTOR signaling, activation of Ampk and Lc3-II 
protein levels in murine primary RMS cells. Western blot analysis of primary cells, which were isolated from 
RMS bearing Ptch+/– mice and incubated for 24 h with 10 µM HhA and/or 10 µM GDC-0941. Hsc70 expression 
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7.1 Effects of four SMO antagonists on RMS cell lines  
The HH signaling pathway regulates cellular proliferation, differentiation and tissue patterning. 
Therefore, it is not surprising that a pathological activation of HH signaling can result in cancer 
development. Types of cancer which show aberrant HH pathway activation include malignancies 
of the skin, brain, prostate, lung, breast and also subgroups of RMS (Pressey et al., 2011; Zibat et 
al., 2010). Thus, the HH pathway is considered to represent a new therapy option and RMS 
might be sensitive towards a targeted therapy using small molecule inhibitors directed against 
components of the HH pathway.  
In the last years, various HH inhibitors - predominantly targeting SMO - have been developed. 
The efficacy of these SMO antagonists has been investigated already in several clinical trials 
(Amakye et al., 2013). GDC-0449 as the frontrunner of these drugs, has already been approved 
in 2012 for advanced and metastasizing BCC (Rudin, 2012) and LDE225, as another potent 
SMO inhibitor from a novel structural class (Pan et al., 2010), was approved 2015 in the USA 
for treatment of advanced BCC. HhA is the forerunner of GDC-0449 and provided convincing 
responses of MB in mouse models (Romer et al., 2004). Cyclopamine represents the natural 
prototype of SMO inhibitors (Taipale et al., 2000).  
In the first part of this thesis, the effects of these four SMO antagonists on RMS cells were 
investigated in order to analyze potential antitumoral effects in vitro. In order to include the most 
common subtypes of RMS, the effects were analyzed in the ERMS cell lines RD and RUCH-2 
and in the ARMS cell lines RMS-13 and Rh41. 
7.1.1 Effects on HH signaling activity 
As already mentioned, the used RMS cell lines express major components of the HH signaling 
pathway, including the main target genes GLI1 and PTCH (Graab et al., 2015; Ridzewski et al., 
2015). Therefore, these cell lines show activation of the HH signaling pathway. In order to 
investigate if GDC-0449, LDE225, HhA and cyclopamine were able to inhibit HH signaling in 
RMS cells, HH pathway activity was analyzed by qRT-PCR of GLI1, because GLI1 mRNA 
expression is the most reliable indicator for active HH signaling (reviewed in (Scales and de 
Sauvage, 2009)). The data revealed that intrinsic HH pathway activation in RMS cell lines was 




applied drug and their respective concentration, and varied from cell line to cell line (Figure 5). 
Against all expectations, an inhibition of GLI1 expression by SMO inhibitors was in general not 
prior-ranking in RMS cell lines and frequently the drugs had no effect on GLI1 expression (e.g. 
1 µM GDC-0449, LDE225 and HhA in RUCH-2 cells). This has also been described for 
GDC-0449 in RMS cells by other groups (Graab et al., 2015). Conversely, GLI1 expression was 
also not modulated in RD cells after treatment with the SMO agonist SAG (Figure 15 B). 
However mutations in SMO, which potentially could impede binding of the drugs to SMO and 
consequently impair their efficacy in the analyzed RMS cell lines were excluded (personal 
communication Javed Khan, National Cancer Institute, Bethesda, USA). These findings indicate 
that canonical HH signaling via the SMO/GLI axis is not the main source of HH pathway 
activation and accordingly of GLI1 expression in RMS cells. Thus, GLI1 expression in RMS 
cells is rather regulated independently of SMO by a noncanonical mechanism. This assumption 
is also supported by data showing that knockdown of SMO has no effect on proliferation of 
ERMS cell lines and that inhibition of GLI1/2 by the GLI inhibitor GANT61 induces apoptosis, 
while cyclopamine does not (Tostar et al., 2010).  
As mentioned in section 2.3.3, noncanonical activation of HH signaling has been described in 
several cancers. One of the pathways that can activate noncanonical HH signaling is 
PI3K/AKT/mTOR signaling (Filbin et al., 2013; Stecca et al., 2007; Wang et al., 2012). 
Activation of the PI3K/AKT/mTOR pathway often appears in RMS (Petricoin et al., 2007; 
Renshaw et al., 2013) and is also observed in the analyzed RMS cell lines (as demonstrated by 
distinct expression of pAKT and pS6 in all RMS cell lines; e.g. see Figure 13 solvent treated 
cells). Indeed, inhibition of this pathway with PI3K/AKT/mTOR inhibitors efficiently decreased 
GLI1 expression in the used RMS cell lines (Figure 21), especially obvious in RD and RUCH-2 
cells (Figure 21 A, B). Inhibition of HH signaling in RMS in vitro and in vivo after treatment 
with PI3K/AKT/mTOR inhibitors has also been shown by other groups. For instance, PI103 
reduces GLI1 transcription in RD cells (Graab et al., 2015) confirming the results of this thesis. 
Furthermore the mTOR inhibitor rapamycin decreases GLI1 mRNA as well as GLI1 protein 
levels in RMS xenografts (Kaylani et al., 2013). These findings strongly suggest that in the 
analyzed RMS cell lines, GLI1 transcription and thus the HH pathway activity can be regulated 
through a noncanonical mechanism independently of SMO, which probably involves 
PI3K/AKT/mTOR signaling. 
On the other hand, it is likely that the PI3K/AKT/mTOR pathway is regulated by SMO. Thus, as 
shown in this thesis, HhA decreases AKT activity in ERMS cells (Figure 13 A, B). Since the 





reported by other groups (Rao et al., 2004; Riobo et al., 2006; Wang et al., 2012)), reduced AKT 
activity subsequently could repress GLI1 expression in these cell lines (Figure 5 RD, RUCH-2). 
This scenario could also explain the induction in GLI1 transcription upon cyclopamine treatment 
in most cases (Figure 5), because (in contrast to HhA) cyclopamine increased AKT activity in all 
cell lines (Figure 13). Notably, the effect on AKT is not regulated by GLI factors themselves 
because GLI1/2 inhibition by GANT61 does not influence pAKT levels in RMS cells (Graab et 
al., 2015). Therefore, interaction between both pathways might be due to a SMO/AKT/GLI1 
axis. However, this is not consistently seen for all settings and therefore needs verification in the 
future. The data also indicate that the noncanonical SMO derived effects on PI3K/AKT/mTOR 
pathway were regulated differently by SMO inhibitors, e.g. HhA inhibited AKT but cyclopamine 
induced AKT activity in most cell lines, whereas GDC-0449 and LDE225 showed no effect on 
AKT activity.  
Besides cyclopamine, also other SMO inhibitors paradoxically can stimulate GLI1 expression 
levels in some settings (e.g. LDE225 in RMS-13 cells). The possibility that the drugs modulate 
other signaling components, which vice versa could activate GLI1 expression, has been 
demonstrated for the SMO agonist SAG. Thus, SAG induced HH signaling activity in a dose 
dependent manner with an EC50 of 3 nM, but it paradoxically inhibited the activity at 
concentrations above 1 μM (Chen et al., 2002b). The authors suggested a model, in which SAG 
may interact not only with SMO, but also with another cellular effector of SMO. According to 
their model, optimal SAG concentrations induce HH pathway activation by enabling the 
association of SMO with the respective cellular effector. Higher SAG concentrations however 
would begin to inhibit this process, as SAG then would independently bind both, SMO and the 
effector (Chen et al., 2002b). Comparable models might apply to the SMO inhibitors used in this 
study and could explain some concentration dependent effects as well as the triphasic GLI1 
expression patterns in RD cells (i.e. a decrease at 10 µM, a re-increase at 30 µM compared to 
10 µM and again a decrease at 50 µM upon GDC-0449, LDE225 or HhA treatment; Figure 5). 
 
Igf2 is another downstream target of Hh signaling and is essential for the formation of Ptch 
associated RMS in Ptch
+/–
 mice (Hahn et al., 2000). Moreover, IGF2 is a very important 
embryonal growth factor and plays a crucial role in RMS pathology (Martins et al., 2011). 
Indeed, most human RMS show high IGF2 gene expression levels (de Souza et al., 2014; El-
Badry et al., 1990; Zhan et al., 1994). Therefore, it was hypothezised that repression of IGF2 
mediated by SMO inhibitors could further strengthen the antitumoral effects of these drugs in 




determined by qRT-PCR. The investigation revealed that SMO inhibitors also modulated IGF2 
transcription in human RMS cell lines. Similar to modulation of GLI1 expression, this differed 
from drug to drug, their concentrations and from cell line to cell line (Figure 6).  
Interestingly, modulation of IGF2 expression was not necessarily correlated with the 
corresponding GLI1 expression (compare Figure 6 with Figure 5). Similar to GLI1, inhibition of 
IGF2 expression by SMO inhibitors was in general not pronounced in RMS cell lines. This 
suggests that the SMO inhibitors regulate IGF2 expression probably by noncanonical 
mechanisms or by regulation of other factors that are involved in regulation of IGF2 mRNA 
transcription. For instance, the transcription factor AP-2, which mediates responses of cyclic 
adenosine monophosphate (cAMP) dependent protein kinase A (PKA) and protein kinase C 
(PKC), can increase IGF2 transcription in RMS cell lines (Zhang et al., 1998b). In addition, p53 
is associated with repression of IGF2 transcription in RMS cell lines (Zhang et al., 1998a). 
However, the precise mechanisms of p53 mediated regulation of IGF2 transcription remained 
not fully elucidated (Martins et al., 2011).  
Remarkably, it has been shown that IGF2 functions as an autocrine growth factor in RMS cells 
(El-Badry et al., 1990; Minniti et al., 1994) and induces phosphorylation of AKT in cerebellar 
granule cell precursors and MB cells (Hartmann et al., 2005). Therefore, it is possible that IGF2 
(via its receptor IGF1R) signals back to the cell in an autocrine manner and activates the 
PI3K/AKT/mTOR pathway. This might be the case e.g. for 5 and 10 µM cyclopamine that 
induced IGF2 expression in RMS-13 cells (Figure 6), which correlated with activation of AKT 
(Figure 13 C). Vice versa 10 and 30 µM HhA repressed IGF2 transcription in RD cells (Figure 
6), which was associated with reduced pAKT levels (Figure 13 A) and also with decreased 
cellular proliferation (Figure 10 A). Moreover, the correlation between IGF2 and AKT was also 
be revealed on protein level. In RD cells 10 µM HhA reduced IGF2 and pAKT protein levels, 
100 nM SAG increased IGF2 and pAKT, and HhA plus SAG decreased IGF2 and pAKT protein 
expression (Figure 15 A). However, the relation between IGF2 levels and pAKT levels was not 
consistently observed, which was probably due to cell line specific differences or heterogeneous 
drug effects. For instance in Rh41 cells, 10 and 30 µM GDC-0449 increased IGF2 expression 
(Figure 6) and stimulated cell proliferation (Figure 10 D), but AKT levels were not modulated 
(Figure 13 D). Because IGF1R stimulation can also activate the RAS/MEK/ERK cascade 
(Pollak, 2008), it is possible that the increase in IGF2 may have activated the RAS/MEK/ERK 
pathway which subsequently stimulated cellular proliferation of Rh41 upon 10 and 30 µM 
GDC-0449 treatment. Thus, similar to GLI1, the data suggest that IGF2 transcription might be 





7.1.2 Effects on muscle differentiation 
It has been demonstrated that HH signaling also regulates the expression of muscle 
differentiation markers. For instance, MYOD expression is suppressed by GLIs in RMS cells 
(Gerber et al., 2006). In addition, HH signaling inhibits terminal muscle differentiation (Bren-
Mattison and Olwin, 2002). Therefore, it was hypothesized that inhibition of HH signaling by 
SMO antagonists should lead to induction of MYOD and MYH1 expression and thus, to a more 
differentiated RMS phenotype.  
However, a negative correlation between GLI1 transcription and expression of muscle 
differentiation markers, as described in the literature, was not continuously observed. The data 
demonstrate that MYOD and MYH1 expression was only induced by some SMO inhibitors at 
certain concentrations in specific cells lines (e.g. GDC-0449 in Rh41 cells; Figure 7, Figure 8), 
whereas other inhibitors rather led to a downregulation of MYOD and MYH1 gene expression 
(e.g. LDE225 and HhA in RD cells; Figure 7, Figure 8). Based on the observation that GLI1 
expression can be regulated in a noncanonical manner in the analyzed RMS cell lines, it is not 
surprising that SMO inhibitors did also not induce MYOD and MYH1 expression in most settings 
(compare Figure 5 with Figure 7 and Figure 8). Furthermore, with the exception of Rh41 cells, 
the MYOD and MYH1 expression patterns did not necessarily correspond to each other (compare 
Figure 7 with Figure 8). 
Nevertheless, the expression of the muscle differentiation markers was sometimes associated 
with IGF2 expression, e.g. HhA treated RD and RMS-13 cells showed a positive correlation 
between MYH1 and IGF2 levels (compare Figure 8 with Figure 6). Moreover, a positive 
correlation between both muscle differentiation markers and IGF2 expression was demonstrated 
also for GDC-0449 and LDE225 in Rh41 cells for mainly all concentrations (compare Figure 7 
and Figure 8 with Figure 6). A similar correlation has also been described by other groups. Thus, 
MyoD induced myocyte differentiation goes along with Igf2 transcription that is followed by 
autocrine signaling leading to activation of Akt (Wilson et al., 2003). Even if increased levels of 
AKT upon treatment with GDC-0449 and LDE225 in Rh41 were not observed (Figure 13 D), a 
general consequence of autocrine activation of IGF1R signaling by IGF2, i.e. the induction of 
proliferation, was indeed revealed for GDC-0449 and 10 µM LDE225 in this cell line (Figure 10 
D). 
Heterogeneous effects of SMO modulators on muscle differentiation independently of GLI1 have 
also been described by others. For instance, the classical SMO agonist SAG induced GLI1 




novel SMO agonist GSA-10 stimulated SMO to induce differentiation but in contrast decreased 
GLI1 expression (Gorojankina et al., 2013). Moreover, the same authors demonstrated that 
GDC-0449 and LDE225 blocked GSA-10 induced differentiation. This is similar to data 
presented in this thesis showing that LDE225 and HhA inhibited expression of myogenic 
markers in RD cells (Figure 7, Figure 8). Finally, Gorojankina et al. confirmed heterogeneous 
effects of SMO inhibitors on differentiation, in which LDE225 potentially inhibited GSA-10 
induced differentiation, whereas GDC-0449 was less effective and cyclopamine did not impact 
on differentiation at all (Gorojankina et al., 2013). 
7.1.3 Effects on cellular proliferation and apoptosis 
Antiproliferative and proapoptotic effects were mainly triggered by LDE225 and HhA in most of 
the RMS cell lines (Figure 10, Figure 12). The decrease of the proliferation rate obtained by 10 
and 30 µM HhA in RD and RUCH-2 cells (Figure 10 A, B) and the increase of apoptosis by 
30 µM HhA in RD cells (Figure 12 A) was additionally associated with the repression of GLI1 
and IGF2 expression (Figure 5, Figure 6) and with reduction of AKT activity (Figure 13 A, B). 
However, a similar association was not seen for most of the other inhibitors and cell lines.  
As described in 2.3.3 noncanonical HH signaling derived from SMO can control different 
cellular processes independently of GLI transcription factors (reviewed in (Robbins et al., 
2012)). This noncanonical activity of SMO could explain the observed antitumoral effects of 
SMO antagonists (e.g. decrease of proliferation and induction of apoptosis) and that this was not 
necessarily correlated with GLI1 inhibition. For instance, 30 μM LDE225 and HhA induced 
antiproliferative and proapoptotic effects in RMS-13 cells, but did not alter GLI1 expression or 
moderately induced it, respectively (compare Figure 10 C and Figure 12 B with Figure 5). 
Conversely inhibition of HH signaling was detected for 10 µM GDC-0449 in RD cells (Figure 
5), but resulted in a stimulation of proliferation (Figure 10 A). Similar to that inhibition of IGF2 
expression did not necessarily correlate with decreased proliferation. The lack of correlation 
between growth inhibition and decreased HH pathway activity (measured by GLI1 and PTCH 
expression) is also described in the literature and was detected in a large panel of human cancer 
cell lines upon treatment with HhA and cyclopamine (Yauch et al., 2008). 
GDC-0449 and cyclopamine induced proliferation in some RMS cells at certain concentrations 
(e.g. 10 μM GDC-0449, 5 μM cyclopamine in RUCH-2 and Rh41 cells; Figure 10 B, D). 
Moreover, they did not induce apoptosis in most of the cell lines (Figure 12), which has been 





2010). In general, the increase in BrdU incorporation upon GDC-0449 and cyclopamine 
treatment was neither correlated with induction of GLI1 expression nor IGF2 overexpression. 
However, in some settings increased proliferation and lack of apoptosis was accompanied by 
increased pAKT levels. This was e.g. seen after cyclopamine treatment of RUCH-2 and Rh41 
cells (Figure 10 B, D). Thus, activation of AKT could be the underlying mechanism responsible 
for increased cellular proliferation and lack of apoptosis. Indeed, previous work from our lab 
showed that treatment of RMS bearing Ptch
+/–
 mice with cyclopamine did not inhibit tumor 
growth but rather increased it (Ecke et al., 2008). Whether this growth induction by cyclopamine 
is also associated with increased AKT phosphorylation remains to be established in the future.  
Of course it is possible that off-target effects, which could be derived from the varying molecular 
structure of the drugs, could account for their heterogeneous effects on proliferation and 
apoptosis. Such effects have to be excluded in future experiments (see section 7.3).  
However despite all these puzzling results, the data presented here suggest that LDE225 and 
HhA are the most potent drugs with respect to their antiproliferative and proapoptotic capacity. 
This is very important when using the drugs in RMS therapy knowing that SMO inhibitors can 
rapidly lead to resistance (see 2.5.4). For instance, GDC-0449 resistance occurred in MB through 
a mutation in SMO that impedes GDC-0449 binding while keeping HH signaling active (Rudin 
et al., 2009; Yauch et al., 2009). Similar resistance mechanisms have been described for LDE225 
(Buonamici et al., 2010). Due to these facts, the selection of appropriate SMO inhibitors that 
instantly and very potently inhibit proliferation and/or induce apoptosis is of uttermost 
importance for the clinics. 
7.1.4 Effects on PI3K/AKT/mTOR signaling, on AMPK activity and on 
LC3-II expression 
As already mentioned, HH signaling can modulate the activation status of PI3K/AKT/mTOR 
signaling and vice versa AKT can stabilize and thus activate GLI transcription factors (Fu et al., 
2006; Morton et al., 2007; Riobo et al., 2006; Wang et al., 2012). Our data demonstrate that HhA 
inhibits phosphorylation of AKT in both ERMS cell lines (Figure 13 A, B), whereas the other 
SMO antagonists do not (Figure 13). In contrast, cyclopamine rather enhances pAKT levels 
(Figure 13). Effects on S6 phosphorylation were not observed. This suggests indeed a crosstalk 
between HH and AKT signaling. However, as with many of the parameters described before, this 




and/or was cell line dependent. In the case of HhA it is likely that the reduction of pAKT levels 
contributed to the very effective antitumoral properties of this drug. 
 
SMO antagonists can also activate a noncanonical SMO/Ca
2+
/AMPK cascade, which triggers a 
Warburg like effect (Teperino et al., 2012). This has been demonstrated for GDC-0449 and 
cyclopamine, but not for LDE225 in cell culture. Furthermore, the physiological outcome of 
Ca
2+
 influx and AMPK mediated catabolism may be responsible for the two major side effects of 
SMO inhibitors, such as muscle cramping and weight loss (Teperino et al., 2012). Indeed, 
pAMPK levels were upregulated in e.g. Rh41 cells by all SMO inhibitors (Figure 13 D). This 
suggests that also HhA and LDE225 can induce a Warburg like effect. However, the regulation 
of pAMPK strongly depended on the drug concentration and the cellular context. Hence, it is 
difficult to draw valid conclusions about the modulation of pAMPK by SMO antagonists in 
RMS.  
 
Because HH signaling can inhibit autophagosome synthesis (Jimenez-Sanchez et al., 2012), it 
was also investigated whether the applied drugs were able to induce autophagy in RMS cells. 
Indeed LDE225, HhA and cyclopamine strongly increased the levels of LC3-II in nearly all 
settings (Figure 13). In contrast, GDC-0449 was not able to induce autophagy in any of the used 
cell lines, which is in line with data from hepatocellular carcinoma cells (Wang et al., 2013). 
Induction of autophagy upon inhibition of the HH pathway has been shown in a variety of other 
cancer cells. In pancreatic carcinoma cells, that were treated with GLI inhibitor GANT61, the 
induced autophagy was accompanied with reduced cell viability and increased apoptosis in vivo 
and in vitro (Wang et al., 2013; Xu et al., 2014). This is different from the data presented here, 
which showed that induction of autophagy by SMO inhibitors is not necessarily accompanied by 
antiproliferative or proapoptotic effects. For instance cyclopamine treatment of Rh41 cells 
increased LC3-II levels but induced proliferation without affecting apoptosis (compare Figure 13 
D with Figure 10 D and Figure 12 C). Furthermore, induction of autophagy by LDE225, HhA 
and cyclopamine was independent from GLI1 expression (compare Figure 13 with Figure 5). 
Similar observations have been made by other groups, e.g. LC3-II levels were increased by 
cyclopamine in Gli2 null mouse embryonic fibroblasts (Jimenez-Sanchez et al., 2012). 
Moreover, the SMO agonist SAG (1 µM) induced LC3-II levels instead of blocking it (Figure 15 
A). SAG also did not modulate GLI1 expression (Figure 15 B) confirming GLI independent 
modulation of autophagy. These findings suggest that SMO probably regulates autophagy 





7.1.5 Overview on diverse and noncanonical effects of SMO inhibitors in 
RMS cells 
The efficacy of SMO inhibitors in cancer have been investigated in many preclinical studies. In 
tumors that show canonical HH signaling activity due to activating mutations of the HH pathway 
(e.g. BCC and MB), SMO inhibitors are effective in inhibition of HH signaling, repression of 
proliferation and induction of apoptosis (Amakye et al., 2013; Ng and Curran, 2011). 
However, this might be different in RMS in which the HH pathway apparently is activated in a 
noncanonical manner, i.e. by a SMO independent GLI1 regulation, which is demonstrated in this 
work and also by other groups (Graab et al., 2015; Tostar et al., 2010). As shown in this thesis, 
noncanonical regulation of GLI1 expression in RMS involves the PI3K/AKT/mTOR pathway. 
Therefore it is not astonishing, that some of the used SMO inhibitors had no antitumoral effects 
on RMS cell lines or that they were less effective. Similar results have been obtained by other 
groups who targeted SMO and GLI factors in RMS cell lines. Thus, it has been shown that 
genetic silencing of GLI1/2 or treatment with GANT61 was more efficient in RMS cell lines 
than genetic silencing of SMO or treatment with GDC-0449 or cyclopamine (Graab et al., 2015; 
Tostar et al., 2010).  
Nevertheless, the results of this thesis clearly demonstrate that some SMO inhibitors i.e. HhA 
and LDE225 had excellent antitumoral properties on RMS cell lines, although this was 
sometimes independent from GLI1 expression and therefore from canonical HH signaling. 
Indeed, SMO can regulate several cellular pathways independently of GLI (reviewed in (Robbins 
et al., 2012)). SMO is a functional G-protein-coupled receptor (GPCR) with selectivity toward 
heterotrimeric Gi proteins and has been shown to mediate noncanonical HH signaling through 
the activation of small GTPases (reviewed in (Brennan et al., 2012)). For instance, SMO 
dependent cell tubulogenesis in endothelial cells was mediated by the small GTPase RhoA, but 
was not associated with Gli1 transcription (Chinchilla et al., 2010). Another example for 
noncanonical signaling of SMO is the observation that Smo promoted fibroblast migration via a 
downstream Gi/PI3K/Akt axis, which was also independent of Gli1 transcription (Polizio et al., 
2011). The latter findings also confirm the data of this thesis that SMO can regulate PI3K/AKT 
signaling. Thus, the antitumoral effects of SMO inhibitors in RMS might be due to the 
mentioned mechanisms or could be due to other - still unidentified - cellular targets or interaction 
partners of SMO. Indeed, the results of this thesis indicate that at least HhA inhibits AKT 





However, off-target effects of the inhibitors can generally not be excluded and together with cell 
context specific findings might reflect some inconsistency in the results.  
A second important observation is that the four SMO inhibitors used in this thesis had highly 
different and heterogeneous effects on the analyzed parameters. Similar variances in action of 
SMO inhibitors have been demonstrated by other groups (Chinchilla et al., 2010; Gorojankina et 
al., 2013; Teperino et al., 2012; Yam et al., 2009) and indicate that pharmacological modulation 
of SMO seems to exert complex cellular effects. 
This could be due to the fact that SMO inhibitors can stabilize multiple conformations of SMO 
which confer different SMO activation states and subcellular localizations (reviewed in (Ruat et 
al., 2014)). In detail, activation of SMO requires two steps: the initial translocation of SMO to 
the primary cilia followed by a still unidentified activation step of SMO, which allows SMO to 
trigger the downstream HH signaling cascade (Rohatgi et al., 2009). Therefore SMO can exist in 
various inactive and active conformations and several SMO antagonists induce these different 
conformations and favor specific subcellular localizations. Whereas GDC-0449, LDE225 and 
HhA bind to an inactive form of SMO and prevent its translocation to the cilia, cyclopamine 
promotes the enrichment of an inactive SMO conformation in the primary cilia (Dijkgraaf et al., 
2011; Rohatgi et al., 2009; Wilson et al., 2009; Wu et al., 2012). All this different mode of action 
at SMO could explain some of the diverse effects of the inhibitors used in this study.  
Another explanation for the different actions of the drugs could be due to their different binding 
modes inside the binding pocket of the SMO transmembrane domain. This could subsequently 
cause different conformations of SMO and hence diverse cellular effects. They can bind to the 
same cavity but interacting with different or overlapping residues, e.g. GDC-0449 and 
cyclopamine mostly bind to the extracellular loops and others like SANT-1 primarily contact the 
transmembrane residues deeply in the binding pocket (reviewed in (Ruat et al., 2014)). Notably 
cyclopamine, SANT-1, GDC-0449 and SAG bind to the same binding pocket in the 
transmembrane domain of SMO (Chen et al., 2002a; Chen et al., 2002b; Wang et al., 2014), but 
have different cellular functions, i.e. whereas SAG is a SMO agonist, the other drugs are all 
SMO antagonists. Another possibility might be a binding of the drugs to additional specific 
molecules that cooperate with SMO in canonical or noncanonical signal transduction.  
 
In summary, the HH pathway in human RMS cell lines is apparently activated in a noncanonical 
manner, probably by the PI3K/AKT/mTOR pathway. Nevertheless, the SMO antagonists HhA 
and LDE225 showed excellent antitumoral effects on most of the used RMS cell lines, making 





involved inhibition of AKT. Due to the highly heterogeneous effects of SMO inhibitors in 
different RMS cell lines, the use of these drugs in the clinics certainly will require a thorough 
pretesting before applying them to RMS patients.  
7.2 Effects of combining SMO antagonists with PI3K/AKT/mTOR 
inhibitors in RMS  
The PI3K/AKT/mTOR pathway is often activated in human RMS (Petricoin et al., 2007; 
Renshaw et al., 2013). Due to the potential interaction between the HH pathway and the 
PI3K/AKT/mTOR signaling cascade in RMS and concerning that some SMO inhibitors i.e. HhA 
inhibited at least activation of AKT (see Figure 13 A, B), SMO antagonists were combined with 
PI3K/AKT/mTOR inhibitors and potential cooperative antitumoral effects were investigated. In 
order to block PI3K/AKT/mTOR signaling the dual PI3K/mTOR inhibitor PI103, the specific 
PI3K inhibitor GDC-0941, the pure AKT inhibitor MK-2206 and the mTOR inhibitors 
everolimus and rapamycin were applied (see Figure 4). 
It was hypothesized that the combination of SMO inhibitors with inhibitors of the 
PI3K/AKT/mTOR pathway not only improve the anticancer effects, but also may help to 
potentially lower the dose of each drug and subsequently to avoid side effects. Indeed, SMO 
inhibitors are known to cause chronic side effects such as weight loss and anorexia in humans as 
well as bone defects in young mice (Kimura et al., 2008), which may hamper their use especially 
in children. Additionally, the occurrence of acquired resistance to SMO antagonists further 
impairs their application. Mechanisms of resistance include secondary mutations in SMO, 
downstream amplification of GLI2 and also aberrant activation of PI3K/AKT/mTOR signaling 
(Buonamici et al., 2010; Dijkgraaf et al., 2011; Rudin et al., 2009; Yauch et al., 2009).  
7.2.1 Comparison of cooperative antitumor effects of SMO antagonists in 
combination with PI3K/AKT/mTOR inhibitors in RD cells 
The data in this thesis demonstrate that HhA was the only SMO antagonists with an inhibitory 
effect on PI3K/AKT/mTOR signaling. Therefore, HhA was the best candidate for combination 
with PI3K/AKT/mTOR inhibitors. Nevertheless, in several initial experiments the anticancer 
effects of GDC-0449, LDE225, HhA and cyclopamine in combination with the latter drugs were 




cells and the impact on phosphorylation of AKT, S6 and AMPK and on other proteins was 
examined by western blot. 
Concerning AnnexinV positivity, RD cells were more sensitive to 3 µM PI103 and 10 µM 
GDC-0941 than to treatment with the SMO inhibitors (except for 30 µM LDE225 and HhA; 
Figure 17). This again indicated a strong dependency of RMS cells on PI3K/AKT/mTOR 
signaling. The observation that MK-2206 or both mTOR inhibitors alone induced marginal or 
even no proapoptotic effects was astonishing. Lack of proapoptotic effects upon treatment of 
RMS cell lines with everolimus has also been shown by other groups, even at a concentration of 
1 µM (Preuss et al., 2013). It is possible that for efficient apoptosis induction, the cells require a 
combined inhibition of pAKT and mTOR (indicated by decreased pS6 levels), which was 
observed for PI103 and GDC-0941, but not for MK-2206, everolimus or rapamycin (see e.g. 
Figure 18). However, this cannot explain the strong apoptosis induction resulting from the 
combination of 10 µM HhA plus MK-2206 (Figure 17 C) because this treatment did not lead to a 
decrease in pS6 (Figure 20). In this case it is rather possible that HhA or MK-2206 modulate 
additional factors that are responsible for this effect.  
The specific PI3K inhibitor GDC-0941 blocked phosphorylation of AKT as well as of S6 in all 
RMS cell lines (Figure 27 - Figure 30). Because PI3K activates PDK1 (Cantley, 2002), which 
can also control mTORC1 activity (Finlay et al., 2012), inhibition of PI3K/PDK1 upon 
GDC-0941 could possibly reduce pS6 levels in addition to pAKT. Nevertheless since the 
catalytic subunit of PI3K and mTOR are structurally similar, GDC-0941 probably exerts 
inhibitory effects on both proteins.  
HhA was the most efficient compound when combined with PI3K/AKT/mTOR inhibitors. 
Combination effects were not that convincing when GDC-0449, LDE225 or cyclopamine were 
used. This is similar to a report by Graab et al., who also demonstrated that the combination of 
GDC-0449 plus PI103 failed to induce cooperative effects on apoptosis in RMS cell lines (Graab 
et al., 2015). In contrast to the other SMO antagonists, HhA induced cooperative effects, e.g. it 
reversed the increase of pAKT levels caused by mTOR inhibitors and reduced AMPK 
phosphorylation when combined with PI103, GDC-0941 or MK-2206 (Figure 20). Moreover, 
HhA showed cooperative proapoptotic effects with several of the used PI3K/AKT/mTOR 
inhibitors as determined by AnnexinV positive cells (Figure 17 C).  
Indeed HhA increased number of AnnexinV positive RD cells (Figure 17 C) but without 
stimulating caspase 3 activity (Figure 20). This indicated a caspase 3 independent proapoptotic 
mechanism. This was similar for PI103 and GDC-0941 in combination with 10 µM GDC-0449 





whereas caspase 3 activity was rather repressed by these combinations (Figure 18, Figure 20). 
Similar results were observed in RMS-13 cells for HhA plus PI103 or GDC-0941 (compare 
Figure 26 B with Figure 29). These findings suggest that besides caspase 3 activation other 
mechanisms could contribute to apoptosis induction by the respective drugs and their 
combinations. One possibility is that the cells undergo apoptosis due to activation of other 
effector caspases such as caspase 6 or 7. Moreover, several other groups demonstrated that also 
caspase 3 independent pathways could contribute to apoptosis (Alvarez et al., 2011; Bai et al., 
2015). Furthermore complex interactions between apoptosis and autophagy are known, in which 
both pathways either cooperate, assist or antagonize each other (reviewed in (Nikoletopoulou et 
al., 2013)). Therefore, it is possible that autophagy may have contributed to caspase 3 
independent apoptosis. This is supported by the observation that apoptosis was accompanied by 
autophagy in nearly all experimental settings. 
 
Together the data showed that HhA was the most promising compound for combination with 
PI3K/AKT/mTOR inhibitors. Moreover and as already described, single drug treatment with 
HhA resulted in antiproliferative and proapoptotic effects, inhibited pAKT and induced LC3-II. 
Therefore, the impact of HhA plus PI3K/AKT/mTOR inhibitors was studied in more detail and 
in additional human RMS cell lines.  
7.2.2 Detailed analyses of cooperative antitumoral effects of HhA plus 
PI3K/AKT/mTOR inhibitors 
As already described in section 7.1.1, nearly all PI3K/AKT/mTOR inhibitors efficiently blocked 
HH signaling activity in almost all RMS cell lines (Figure 21). Similar results were obtained by 
other groups (Graab et al., 2015; Kaylani et al., 2013). Interestingly, the strongest GLI1 
inhibition was revealed with GDC-0941, which had more potency than the SMO inhibitor HhA 
(Figure 21). This may indicate that PI3K (that is targeted by GDC-0941) has an enormous 
influence on GLI transcription. The phosphorylation of PIP2 to PIP3, catalyzed by PI3K, leads to 
activation of various kinases including PDK1 (Cantley, 2002). PDK1 activates AKT, but it has 
also other targets e.g. PKCδ (Le Good et al., 1998), which is involved in GLI activation (Lauth et 
al., 2007). Therefore it is possible that inhibition of PI3K and consequently PDK1/PKCδ 
(together with AKT inhibition) is responsible for the strong repression of GLI transcription. 
Since RMS-13 cells harbor a GLI1 amplification (Roberts et al., 1989), but GLI1 expression was 




PI3K/AKT/mTOR pathway stabilize GLI transcription factors and maintain their transcriptional 
activity as already described by others (Riobo et al., 2006; Wang et al., 2012).  
Interestingly, when 30 µM HhA was combined with MK-2206 in RD cells GLI1 expression was 
slightly increased compared to the single drug treatments (Figure 21 A). This went along with an 
enormous apoptosis induction (Figure 17 C, Figure 27) probably caused by complete blocking of 
AKT. Since this combination inhibited the activity of AKT together with that of mTOR (Figure 
27), it is possible that PI3K was strongly activated due to loss of negative feedback by the 
S6K/IRS/PI3K axis (see section 2.6). Therefore, overactivated PI3K via PDK1/PKCδ may have 
induced GLI1 transcription despite inactivation of AKT.  
Nevertheless, combination treatment of RMS cells with HhA plus PI3K/AKT/mTOR inhibitors 
rarely showed cooperative effects on GLI1 suppression. The lack of cooperative effects on GLI1 
transcription was not very surprising, because HhA was in most cell lines not able to reduce 
GLI1 expression (Figure 21). These data again support the assumption that GLI1 expression in 
the analyzed RMS cell lines is regulated in a noncanonical manner by the PI3K/AKT/mTOR 
pathway. 
 
The analysis of IGF2 expression revealed no cooperative effects of the combinations in all RMS 
cell lines (Figure 22). In contrast to mTOR inhibitors, which rather enhanced IGF2 transcription, 
PI103, GDC-0941 and MK-2206 reduced IGF2 expression in most settings. One possibility for 
these results is that PI103, GDC-0941 and MK-2206 inhibited AKT (Figure 27, Figure 29, 
Figure 30). Since AKT represses p53 via MDM2 (see section 2.6), inhibition of AKT may led to 
induction of p53 action and finally to repression of IGF2 transcription, because IGF2 expression 
is suppressed by p53 in multiple cell lines including RMS cell lines (Zhang et al., 1996; Zhang et 
al., 1998a). In contrast to that, mTOR inhibitors lead to an overactivation of AKT in RD and 
Rh41 cells (Figure 27, Figure 30) which in turn may have blocked p53 and consequently induced 
IGF2 transcription. Because IGF2 can act as an autocrine growth factor in RMS cells (El-Badry 
et al., 1990; Minniti et al., 1994) and induces phosphorylation of AKT (Hartmann et al., 2005), 
this could have additionally strengthened the activation of AKT upon mTOR inhibition.  
 
Expression of the muscle differentiation markers MYOD and MYH1 was in most cases 
unaffected upon single drug treatment with MK-2206 and mTOR inhibitors, whereas PI103 and 
GDC-0941 rather decreased their expression (Figure 23, Figure 24). However, these effects were 
cell line dependent. As already described in chapter 7.1.2, the expression pattern of the muscle 





showed co-regulation of MYOD and IGF2 levels (compare Figure 23 A, B with Figure 22 A, B). 
A similar correlation has been described by Wilson and colleagues who showed that Igf2 
inhibition resulted in decreased MyoD expression and that vice versa MyoD increased Igf2 
transcription (Wilson et al., 2003; Wilson and Rotwein, 2006).  
Similar to GLI1, the data on IGF2, MYOD and MYH1 expression suggest that combination 
treatment of HhA plus PI3K/AKT/mTOR inhibitors did not strengthen the effects of the single 
drug treatments in most settings. These findings indicate that concerning the latter factors, 
combination of HhA plus inhibitors of the PI3K/AKT/mTOR pathway do not represent an 
improvement over single drug treatment. 
 
In general, the analysis of the combination effects on the PI3K/AKT/mTOR pathway, activation 
of AMPK and on LC3-II levels revealed that HhA plus PI3K/AKT/mTOR inhibitors induced 
variable outcomes among the analyzed RMS cell lines, which were more heterogeneous in 
ARMS than in ERMS.  
For instance the combinations of HhA plus PI3K/AKT/mTOR inhibitors reduced pAMPK levels 
in RD cells, but mostly induced them in RMS-13 and did not modulate them in RUCH-2 cells. 
Although these results are preliminary, it is tempting to speculate that inhibition of pAMPK upon 
combination of HhA with PI103, GDC-0941 or MK-2206 (as an example see RD cells, Figure 
27) would be beneficial for RMS therapy, because the pAMPK level is positively correlated with 
the induction of a Warburg like effect. The Warburg effect describes the metabolic shift from 
mitochondrial oxidative phosphorylation towards aerobic glycolysis, which is observed in cancer 
cells. This leads to several proliferative and survival advantages of the cancer cells, e.g. a 
decreased dependence on oxygen (reviewed in (Hsu and Sabatini, 2008)). Hence, a reduction of 
pAMPK levels (indicating the repression of Warburg like metabolism) by the mentioned drug 
combinations might decrease the viability of RMS cells. Furthermore, the physiological outcome 
of AMPK mediated catabolism may be responsible for side effects upon therapy with SMO 
inhibitors i.e. muscle cramping and weight loss (Teperino et al., 2012). Therefore, an inhibition 
of AMPK by the mentioned combination treatment could avoid these side effects. 
 
LC3-II as a marker for autophagy was examined. Other groups have demonstrated that active 
HH signaling inhibits autophagy and vice versa inactivation of HH signaling using the GLI 
inhibitor GANT61 induces autophagy (Jimenez-Sanchez et al., 2012; Wang et al., 2013; Xu et 
al., 2014). Indeed, PI3K/AKT/mTOR inhibitors efficiently inhibited GLI1 transcription (e.g. 




increased LC3-II levels observed by most of the PI3K/AKT/mTOR inhibitors (Figure 27 - Figure 
30). However these findings were again strongly dependent on the cell line and a clear 
correlation between GLI1 inhibition and LC3-II induction was not always seen, e.g. PI103 or 
GDC-0941 decreased GLI1 expression in Rh41 cells, but LC3-II levels were not modulated 
(compare Figure 21 D with Figure 30). 
Nevertheless, inhibition of PI3K/AKT/mTOR signaling is well known to result in autophagy 
because this pathway (and mainly mTOR) regulates autophagy (reviewed in (Chen and Karantza, 
2011). In our settings everolimus and rapamycin did not enhance LC3-II expression as strong as 
observed for PI103, GDC-0941 or MK-2206 (e.g. in RD and RUCH-2 cells; Figure 18, Figure 
28) or they did not induce LC3-II expression at all (e.g. in Rh41, Figure 30). When everolimus 
and rapamycin were combined with HhA, LC3-II expression was increased up to HhA induced 
levels in most of the cell lines. Cooperative effects on LC3-II were e.g. observed in RUCH-2 
cells, when HhA was combined with PI103, GDC-0941 or mTOR inhibitors (Figure 28).  
Because the role of autophagy in cancer is controversial and complex and because it could 
function as a tumor suppressor or act as a protector of cancer cell survival (reviewed in (White 
and DiPaola, 2009)), it was tried to correlate the increase in LC3-II with antiproliferative or 
proapoptotic effects of HhA and/or PI3K/AKT/mTOR inhibitors. However, the increase in 
LC3-II was not unequivocally positively or negatively related to the anticancer effects, probably 
due to drug and combination specific effects and because of the cellular context. Therefore it 
cannot be judged whether the observed increase of LC3-II levels are beneficial or 
disadvantageous for RMS treatment with the respective drugs. 
 
In contrast to HhA, PI103 and GDC-0941, the mTOR inhibitors everolimus and rapamycin 
increased the proliferation rate of some cells (Figure 25) and did not modulate apoptosis (they 
neither increased the number of AnnexinV positive cells nor activated caspase 3; Figure 26, 
Figure 27 - Figure 30). As already mentioned, this can be explained by induction of IGF2 
expression (Figure 22) and by activation of AKT (Figure 27, Figure 30) in some settings. 
Overactivation of AKT due to treatment with mTOR inhibitors has been frequently demonstrated 
by others in various cell lines including RMS (O'Reilly et al., 2006; Tamburini et al., 2008; Wan 
et al., 2007). The reason for the increased AKT activation is that inhibition of mTORC1 releases 
the negative feedback by the S6K/IRS/PI3K axis, which in turn can paradoxically overactivate 
AKT. These effects might limit their application for RMS therapy. Indeed, rapamycin treatment 
of RMS xenografts generated from six different RMS cell lines showed only in two cases 





relatively low (Houghton et al., 2008). Although the combination with HhA mostly abrogated 
these unwanted effects, the use of everolimus and rapamycin in RMS therapy should be carefully 
reconsidered. 
 
Growth inhibition and apoptosis induction are the most important parameters of an efficient 
antitumor treatment. The data here show that single drug treatment with HhA, PI103 and 
GDC-0941 inhibited proliferation (Figure 25) and induced proapoptotic effects (Figure 26) in all 
RMS cell lines. Importantly, cooperative antiproliferative and proapoptotic effects were detected 
for the combination of HhA plus PI103, HhA plus GDC-0941 and HhA plus MK-2206 in most 
of the cell lines (Figure 25, Figure 26). Therefore, the cell culture experiments suggested that 
these combinations might be promising treatment options for both, ERMS and ARMS, and could 
be further employed for RMS therapy. 
Since GDC-0941 is used in clinical trials (in contrast to PI103) and showed the most convincing 
effects on growth inhibition in all RMS cell lines (in contrast to MK-2206, which induced 
proliferation of some cell lines; Figure 25 A, C), HhA plus GDC-0941 were applied to RMS 
bearing Ptch
+/–
 mice. As single substances both HhA and GDC-0941 were able to efficiently 
stop the growth of the tumors, whereas GDC-0941 showed more potency than HhA (Figure 31). 
These findings again suggest that besides Hh signaling pathway, the PI3K/Akt/mTor cascade 
plays an important role in RMS. In addition, this also implies that the PI3K/Akt/mTor pathway is 
also crucial for those RMS, in which Hh signaling is activated due to Ptch mutations, as it is the 
case for RMS of Ptch
+/–
 mice. In these mice Hh signaling is most likely activated in a SMO 
dependent (i.e. canonical) manner due to the Ptch mutation. However, the tumors of these 
animals also show activation of the PI3K/Akt/mTor pathway (Kappler et al., 2003) and tumor 
growth is decreased upon GDC-0941 treatment (Figure 31). Thus, RMS of Ptch
+/–
 mice 
resemble human RMS cell lines and represent a suitable model for the preclinical evaluation of 
both HH and PI3K/AKT/mTOR inhibitors. 
Similar to the in vitro data, the combination of HhA plus GDC-0941 induced a cooperative 
growth inhibitory effect on murine RMS (compared to the control and to single treatment with 
HhA). This is comparable to studies that combined LDE225 with the dual PI3K/mTOR inhibitor 
NVP-BEZ235 in murine Ptch mutant MB (Buonamici et al., 2010) or with the PI3K inhibitor 
NVP-BKM120 in PTEN deficient glioblastomas (Filbin et al., 2013). Interestingly, the 
cooperative effect on RMS growth inhibition was not reflected by a further decrease in Ki67 
positive cells compared to either drug alone (Figure 32 B). Accordingly, cooperative RMS 




proliferation and might be additionally associated with other antitumoral effects (e.g. induction 
of apoptosis or autophagic cell death).  
Cyclopamine enhanced RMS tumor growth in vivo (Ecke et al., 2008) and did not decrease the 
amount of Ki67 positive cells of the respective tumors (Figure 32 C). This confirmed the in vitro 
effects of cyclopamine in this thesis in which cyclopamine did not decreased proliferation or 
rather induced it (Figure 10). Moreover, these contrary outcomes of HhA and cyclopamine on 
RMS growth in Ptch
+/–
 mice, confirmed again the heterogeneous effects of SMO antagonists on 
RMS found in this thesis. 
 
In conclusion, the data strongly suggest that combined inhibition of the HH and the 
PI3K/AKT/mTOR signaling pathways could be a treatment strategy to improve therapy of RMS. 
Single drug treatment with some PI3K/AKT/mTOR inhibitors alone already showed antitumoral 
effects in human RMS cell lines (e.g. inhibition of proliferation and induction of apoptosis), 
which was not seen with everolimus and rapamycin. Combination of the SMO antagonists HhA 
with PI103, GDC-0941 or MK-2206 enhanced anticancer effects, which demonstrates a more 
effective treatment option than the corresponding single drug treatments. Particularly the 
combination of HhA plus the pure PI3K inhibitor GDC-0941 intensifies numerous antitumoral 
effects in the analyzed human RMS cell lines and hence represented the most promising drug 
combination. Indeed, cooperative growth inhibitory effects of this combination have been 
observed in both, human RMS cell lines and in RMS of Ptch
+/–
 mice. Unfortunately, the 
experiments performed in the frame of this thesis cannot explain the underlying mechanisms. 
However, the response of RMS cell lines highly depends on the used SMO antagonist and is also 
influenced by the used PI3K/AKT/mTOR inhibitor and thus by the respective combinations. Due 
to this heterogeneous response of RMS, it will be necessary to conduct thorough pretesting of the 
substances and combinations before applying these drugs to RMS patients. This could be done 
either in patient derived short term RMS cultures or in patient derived xenograft mouse models. 
7.3 Outlook  
In the future, preliminary findings have to be validated and therefore repeated. This includes the 
analysis of the effects upon SAG treatment on AKT and GLI1 expression. Moreover, the western 
blot analyses of the comparison of the SMO antagonists plus PI3K/AKT/mTOR inhibitors in RD 





RUCH-2, RMS-13 and Rh41 cells. Finally, the gene expression studies of HhA plus 
PI3K/AKT/mTOR inhibitors in RUCH-2 and Rh41 cells have to be replicated.  
 
In order to unravel the molecular mechanisms contributing to the observed effects of SMO 
antagonists and/or PI3K/AKT/mTOR inhibitors, the following experiments should be performed. 
 
To exclude that the effects of the SMO antagonists are off-target effects, loss-of-function 
experiments on SMO should be performed e.g. by SMO knockdown.  
In order to verify that the HH pathway is indeed activated in a noncanonical manner by 
PI3K/AKT/mTOR signaling, e.g. PI3K or AKT could be activated by transfection of the RMS 
cells with constitutively active AKT or PI3K isoforms. Conversely, the respective proteins could 
be blocked either by overexpression of respective dominant negative proteins or by knockdown. 
In order to prove that the effects induced by SMO inhibitors are indeed independent of canonical 
HH signaling, all three GLI transcription factors should be silenced by mean of siRNA 
technology.  
Moreover, it will be interesting to compare the gene expression profiles within one RMS cell 
line, which has been treated with different SMO inhibitors with various outcomes. This could 
give some information about the individual properties of the specific drugs. Vice versa it would 
be interesting to compare the gene expression profiles between different cell lines that were 
treated with the same SMO inhibitor with different responsiveness. 
Another interesting observation is the HhA mediated increase in AnnexinV positive cells, 
accompanied by either absent or reduced caspase 3 activity, which was also seen upon some 
drug combinations. In order to show that apoptosis is indeed caspase independent, caspase 3 or 
pan caspase inhibitors could be applied. 
While autophagy was often found to be induced upon specific drug treatments, it was not clearly 
defined whether this would be beneficial or unfavorable. Applying autophagy inhibitors together 
with the drugs would distinguish between a tumor suppressor and a tumor survival function of 
autophagy during the treatment with the drug and define their role in RMS therapy. 
It would also be important to unravel the mechanisms underlying the tumor response after the in 
vivo treatment with HhA and/or GDC-0941. The same parameters as in the human RMS cell 
lines could be investigated (i.e. analysis of pAkt, pS6, Lc3-II, pAmpk, Igf2 via 
immunohistochemistry and western blot, as well as Gli1 expression and muscle differentiation 




Finally, it also would be worth analyzing the in vivo response of RMS towards GDC-0449 and 
LDE225 alone or in combination with a PI3K and/or AKT inhibitor. Although these drugs did 
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ARMS    alveolar rhabdomyosarcoma 
BAD    Bcl-2-associated death promoter 
BAX    Bcl-2-associated X protein 
BCA    bicinchoninic acid 
BCC    basal cell carcinoma 
Bcl2    B-cell lymphoma 2 
bp    base pairs 
BrdU    5-bromo-2-deoxyuridine 
BSA    bovine serum albumin 
cDNA    complementary deoxyribonucleic acid 
CRC    colorectal cancer 
ddH2O    double distilled water 
DMEM    Dulbecco’s Modified Eagle Medium 
DMSO   dimethyl sulfoxide 
DNA    deoxyribonucleic acid 
dNTP    deoxyribonucleotide triphosphate 
DOX     doxorubicin 
DTT    dithiothreitol 
EAC    esophageal adenocarcinoma 
EDTA    ethylenediaminetetraacetic acid 
EGFR     epidermal growth factor receptor 
ERMS    embryonal rhabdomyosarcoma 
EtOH    ethanol 
FCS    fetal calf serum  
FITC    fluorescein isothiocyanate 
FOXO    forkhead transcription factor  
gDNA    genomic deoxyribonucleic acid 




GLI    glioma-associated oncogene 
GPCR     G-protein-coupled-receptor 
GSK3    glycogen synthase kinase 3 
GTPase    guanosine triphosphate hydrolase 
HE    haematoxylin eosin 
HH    hedgehog 
HRP    horseradish peroxidase 
HSC70    heat shock protein 70 
IGF1/2R   insulin-like growth factor 1/2 receptor 
IGF2    insulin-like growth factor 2 
IHC    immunohistochemistry 
IRS    insulin receptor substrate 
LOH    loss of heterozygosity 
MB    medulloblastoma 
MCT    methyl cellulose tween 
MDM2   murine double minute 2 
mRNA   messenger ribonucleic acid 
mTOR    mammalian target of rapamycin 
Myc    myelocytomatosis oncogene 
MYH1    myosin heavy chain 1 
neo     neomycin resistance 
PBS    phosphate buffered saline 
PBST    phosphate buffered saline -tween 
PCR    polymerase chain reaction 
PDK1    phosphoinositide-dependent kinase 1 
PFA    paraformaldehyde 
PI    propidium iodide 
PI3K    phosphatidylinositol-3-kinase 
PIP2    phosphatidylinositol 4,5-bisphosphate 
PIP3    phosphatidylinositol 3,4,5-trisphosphate 
PKA    protein kinase A 
PKC    protein kinase C 
PMSF    phenylmethanesulfonylfluoride 




PTCH    patched 
PTEN     phosphatase and tensin homolog deleted on chromosome 10 
p53    transformation related protein 53 
P/S    penicillin/streptomycin 
qRT-PCR    quantitative real-time polymerase chain reaction 
RCC     renal cell carcinoma  
RhoA    ras homolog family member A 
RMS    rhabdomyosarcoma 
RT    room temperature 
RTK    receptor tyrosine kinases 
S6    ribosomal S6 protein 
S6K    S6 kinase 
SAG    smoothened agonist 
SEM    standard error of the mean 
SDS    sodiumdodecylsulfate 
SHH    sonic hedgehog 
SMO    smoothened 
SUFU     suppressor of fused 
TBE    tris-boric acid-EDTA 
TBS    tris-buffered saline 
TBST     tris-buffered saline-Triton X-100 
VCT    volumetric computer tomography 
v/v     volume/volume 
WST    water soluble tetrazolium salt 1 
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